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1 GENERAL INTRODUCTION 
 
1.1 The ABC superfamily 
 
Traditionally, it was believed that the physicochemical properties such as molecular weight, 
charge and lipophilicity and the metabolic processes were the major determinants of the 
bioavailability of most drugs [1]. However, recent progress has led us to understand why the 
minimal effective concentrations of certain drugs are not attained and why chemotherapy and 
the treatment of several brain disorders, immunosuppressive diseases and infectious diseases 
fail. Often, this mechanism is mediated by a large list of efflux transporters, most of which 
belong to the ATP-binding cassette (ABC) transporters super family [2, 3]. ABC transporters 
are transmembrane proteins that use the energy from the ATP hydrolysis to drive the efflux of 
lipids, peptides, amino acids, carbohydrates, vitamins, glucuronide and glutathione conjugates 
and xenobiotics across cellular membranes. Some members of the ABC superfamily show 
specificity for one substrate whereas others can transport a broad variety of structurally 
unrelated hydrophobic compounds [4].  
 
The basic functional unit of an ABC transporter contains minimally four domains, two 
transmembrane domains (TMDs) and two cytoplasmic nucleotide binding domains (NBDs) 
(Fig1). These four domains form two symmetric halves. The TMDs form the pathway through 
which the substrates cross the membrane and the NBDs, also known as ABC domains, 
provide the nucleotide dependent engine that drives the transport. At the sequence level, the 
superfamily of ABC transporters is identified by a characteristic set of highly conserved 
motifs present in the NBDs. In contrast, the sequences and architectures of the TMDs are 
quite variable, reflecting the chemical diversity of the translocated substrates [5, 6] (Table 1).  
Various studies identified 49 human ABC proteins that can be grouped into seven subclasses 
or families (ABCA to ABCG) based on the organization of their domains and amino acid 
homology [7]. Among the ABC transporters, P-glycoprotein (P-gp), multidrug resistance-
associated proteins (MRPs) and breast cancer resistance protein (BCRP) are the most critical 
efflux proteins due to their significant roles in restricting the permeability of several 
pharmacological agents [8, 9].  
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Table 1: Therapeutic key ABC transporters and their principal characteristics. 
 
Transporter 
name 
Size (aa) Topology 
Polarized cell 
localization 
Location 
MDR1/P-gp 1280 
TMD1-NBD1- 
TMD2-NBD2 
Apical 
GIT, lungs, stem cells, BBB, 
BCSFB, BTB, placenta, 
liver and kidney 
BSEP/SPGP 1321 
TMD1-NBD1- 
TMD2-NBD2 
Apical Liver 
MRP1 1531 
TMD0-L0- 
TMD1-NBD1- 
TMD2-NBD2 
Basolateral, apical 
(in brain 
endothealial cells) 
Lungs, placenta 
and kidney 
MRP2 1545 
TMD0-L0- 
TMD1-NBD1- 
TMD2-NBD2 
Apical GIT, placenta, liver and kidney 
MRP3 1527 
TMD0-L0- 
TMD1-NBD1- 
TMD2-NBD2 
Basolateral GIT, placenta, liver and kidney 
MRP4 1325 
TMD1-NBD1- 
TMD2-NBD2 
Apical, basolateral BBB, BCSFB, liver and kidney 
MRP5 1437 
TMD1-NBD1- 
TMD2-NBD2 
Basolateral, apical BBB and liver 
BCRP/MXR 655 
TMD-NBD 
(homodimer) 
Apical 
GIT, stem cells, BBB, placenta, 
mammary glands, liver and kidney 
 
Gastrointestinal tract (GIT), blood- brain barrier (BBB), blood-cerebrospinal fluid barrier (BCSFB) and blood-
testis barrier (BTB). 
 
 
1.2 P-glycoprotein 
 
Since its discovery in 1976 [10], P-glycoprotein is the most extensively studied ABC 
transporter and is often regarded as the prototype to understand the biochemical mechanism of 
all ABC transport proteins. Two factors make P-gp the most critical efflux transporter: (1) its 
broad substrate specificity eliciting multidrug resistance (MDR) [11] and (2) the prominent 
presence of P-gp in most excretory and barrier function tissues [3]. As a result of these 
aspects, P-gp is a major obstacle for the treatment of cancer and several brain disorders, as 
well as immunosuppressive and infectious diseases.  
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Human P-gp is encoded by two multidrug resistance genes, MDR1 and MDR2 (also called 
MDR3) situated on chromosome 7q21.12. MDR1 is associated with a multidrug resistance 
phenotype, while the MDR2 isoform inefficiently mediates the efflux of MDR1 substrates; 
however, MDR2 also functions as a phosphatidylcholine translocase [10, 12, 13].  
In rodents, P-gp is encoded by three genes, mdr1a, mdr1b and mdr2. The substrate specificity 
of P-gp encoded by mdr1a and mdr1b is different but partly overlapping. Together, these two 
rodent genes are expressed in roughly the same manner as the single human MDR1 gene, 
suggesting that they perform the same set of functions in rodents as the MDR1 P-gp in 
humans. The rodent mdr2 gene is more homologous to human MDR2. [3]. According to the 
Human Genome Nomenclature Committee, the approved symbols for the human MDR1 gene 
is ABCB1 and for the mouse and rat mdr1a and mdr1b genes are Abcb1a and Abcb1b, 
respectively.  
Comparison between the rodent P-gp homologues and human P-gp over the equivalent 
nucleotide range (2866 base pairs) showed that mouse Abcb1a and Abcb1b shares an identity 
with human ABCB1 of 89.4 % and 82.7 %, respectively and that rat Abcb1a and Abcb1b 
shares an identity with human ABCB1 of 89.5 % and 83.3 %, respectively [14]. This high 
sequence identity makes the rodent models promising tools to predict P-gp-drugs interactions 
at the human BBB. 
  
1.2.1 Structure of P-glycoprotein 
 
In humans, P-gp is a 170-kDa polypeptide which consists of 1280 amino acids organized in 
two tandem repeats of 610 amino acids joined by a linker region of about 60 amino acids. P-
gp appears to be encoded by a gene duplication event fusing two related half molecules, each 
consisting of one NBD and one TMD which is made up of six transmembrane domain 
segments (α helices) [15]. 
In 2001, Loo and Clarke have succeeded in measuring the size of the drug-binding pocket 
(Fig. 1) by using thiol-specific methanethiosulfonate cross-linkers which were also P-gp 
substrates. These authors found that the substrate binding pocket is funnel shaped and narrow 
at the cytoplasmic side, with a diameter between 9 and 25 Å in the central region and 50 Å at 
its widest [16].  
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Figure 1. Structure of P-gp showing its four domains and its substrate-binding pocket. 
 
Recently, Aller et al. has described the crystal structure of mouse P-gp at a 3.8 Å resolution 
(Fig. 2) [17]. This P-gp structure represent the inward-facing conformation arranged as two 
“halves” spanning ∼136 Å length and ∼70 Å width with a 30 Å separation of the two NBDs. 
The inward-facing conformation formed from two bundles of six helices, results in a large 
internal cavity of approximately 6000 Å3 open to both, the cytoplasm and the inner leaflet of 
the membrane. The entry of the hydrophobic substrates from the membrane to the internal 
cavity involves the presence of two gates formed by two pairs of transmembrane segments 
which are localized in each TMD unit. This internal cavity comprises mostly hydrophobic and 
aromatic residues and could accommodate at least two compounds simultaneously. Moreover 
P-gp is able to distinguish between the stereo-isomers of cyclic peptides, resulting in different 
binding locations, orientation and stoichiometry. This last one has validated earlier studies, 
where it was stated that P-gp presents at least four and possibly several overlapping substrate 
binding sites. Some research teams even suggest that substrate binding sites can be classified 
as both transport and modulating sites [18] and have the ability to switch between high and 
low affinity states to accommodate substrates and/or modulators [19].  
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Figure 2. Front cristal structure of P-gp at a 3.8 Å resolution [17]. 
 
1.2.2 The transport cycle of P-glycoprotein 
 
Currently, it is well known that the P-gp mediated transport mechanism is saturable, 
osmotically sensitive and ATP dependent [20]. Nevertheless, insights into how P-gp couples 
the hydrolysis of ATP to the movement of substrates across the plasma membrane are still 
controversial. The substrate transport presumes two interconnected cycles. First, the catalytic 
cycle of ATP hydrolysis which drives the transport and second, the substrates transport cycle, 
whereby the substrate is moved from the cytoplasmic side to the extracellular side of the 
membrane. Some models have been proposed to help in the understanding of these two 
cycles. 
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1.2.2.1 P-glycoprotein models of the catalytic cycle 
 
Two potential models have been proposed in order to explain the sequence of events in the 
catalytic cycle. The most significant difference between these two models is the nature of the 
power stroke that drives the drug from a high affinity site to a low affinity site.  
In the ATP switch model (proposed for all ABC proteins) (Fig. 3), the drug binding to the 
high affinity binding in the TMDs induces ATP binding and dimerization of the two NBDs. 
This in turn, results in conformational changes that are communicated to the TMDs. In this 
new conformation, the substrate binding sites are exposed to the extracellular environment 
and the substrate is released due to a reduction in the binding affinity. Then, two sequential 
ATP hydrolysis events provide the energy to break the dimerization, inorganic phosphate and 
ADP are released and P-gp finally returns to its original conformation [21, 22].  
 
 
Figure 3. Model proposing the dimerization of the ATP sites as the power stroke. Step I: The substrate binds to a 
high affinity site in the TDM domain. Step II: Binding of the substrate reduces the activation energy and 
increases the affinity for ATP. This, results in the dimerization of the two NBD and ATP is tightly bound at the 
interface. Steps III and IV: Two sequential ATP hydrolysis events provide the energy to break apart the 
nucleotide dimer-ATP sandwich. Steps V and VI: Inorganic phosphate and two ADPs are released and P-gp is 
reset to its ground state. 
 
Nonetheless, the data proposed by Al-Shawi et al. and Omote et al. demonstrated that P-gp 
substrates are not absolutely required for the dimerization of the NBDs and ATP hydrolysis 
rather than ATP binding causes the conformational changes in the drug binding sites [23, 24]. 
Then an alternate model was proposed (Fig. 4). In this model, the ATP binding and the 
substrate binding, which are independent on each other, initiate the cycle. The asymmetric 
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occlusion of ATP at site I causes conformational changes that decrease the affinity of the drug 
binding sites, thus releasing the substrate. The occluded ATP is hydrolyzed and inorganic 
phosphate and ADP are released but the efflux protein is still in a low affinity state. After the 
second occlusion and hydrolysis of the second ATP at site II, inorganic phosphate and ADP 
are once more released and P-gp returns to its initial conformation [25, 26].  
 
 
Figure 4. Model proposing the ATP hydrolysis as the power stroke. Step I: Binding of ATP and substrate 
initiates the cycle. Step II: Occlusion of one ATP at site I of the two NBDs results in the release of the substrate. 
Step III and IV: Hydrolysis of ATP and the sequential release of inorganic phosphate and ADP make the NBDs 
accessible to the second ATP but the drug binding sites are still in their low-affinity conformation. Steps V and 
VI: The binding and hydrolysis of a second ATP at site II result in the release of inorganic phosphate and ADP. 
This, resets the protein to its ground state, where the P-gp can bind substrates. 
 
Is the binding energy of the nucleotide sandwich that generates the closed dimer or is the ATP 
hydrolysis? Remaining a challenge, the harmonization of the aforementioned models could 
help us to understand the coupling between the ATP hydrolysis and drug transport. Further 
studies using high resolution structures of intact P-gp at different stages of the catalytic cycle 
could help to increase the understanding of this cycle. 
1.2.2.2 P-glycoprotein models of substrates transport cycle 
 
The original model of membrane transport was that of a classic pump which moves its polar 
substrates from the internal aqueous phase, through its hydrophilic interior directly to the 
external aqueous phase. However, since hydrophobic compounds were discovered to be P-gp 
substrates, the hydrophobic vacuum cleaner and flippase models were proposed. Both models 
assume that the substrate partition into the lipid membrane is prior to the interaction with the 
8 
 
substrate binding sites. However, given the  rapid partitioning of the substrate between the 
aqueous phase and the membrane, it is difficult to distinguish between these two models  [15].  
In the hydrophobic vacuum cleaner model (Fig. 5), the hydrophobic substrate is extracted 
from the inner leaf of the plasma membrane where it is embedded and is then pumped directly 
to the external aqueous medium [27, 28]. This model supposes that substrates gain their 
access to their binding sites through gates formed in the TMDs, which becomes evident by the 
crystal structure of the P-gp at a 3.8 Å resolution [17]. 
 
 
Figure 5. Hydrophobic vacuum cleaner model. 
 
Alternatively, in the flippase model (Fig 6), the lipid-like substrate is extruded from the inner 
(cytosolic) leaflet to the outer (extracellular) leaflet of the plasma membrane, from where the 
substrate will diffuse to the external aqueous medium by simple diffusion [29]. This model 
agrees with some studies where fluorescent lipids such as phosphatidylcholine, 
phosphatidylethanolamine, phosphatidylserine, and and sphingomyelin are flipped between 
the inner and the outer leaflets of the lipid membrane [30]. 
 
 
Figure 6. Flippase model  
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Although earlier studies favored one or another model, recent data indicates that both models 
are not exclusive. The partition of the substrate into the plasma membrane and its migration to 
the extracellular environment exposed by the vacuum cleaner and flippase models strongly 
confirms that P-gp is a unidirectional efflux pump [17, 31] 
 
1.2.3 P-glycoprotein substrates 
 
P-gp substrates are molecules actively transported by the efflux protein and therefore have a 
higher concentration outside the cell than in the cytosol [32]. As a result of the broad substrate 
specificity of P-gp, efforts have been made to find similarities among the P-gp substrates. 
Hence, Didziapetris and co-workers introduced the “rule of fours” which can roughly estimate 
whether a compound is a P-gp substrate or not. This rule states that if a compound has: (1) a 
total of at least eight nitrogen and oxygen atoms, (2) a molecular weight (MW) of more than 
400 daltons and an acid with a pKa greater than four, it is more likely to be a P-gp substrate. 
In contrast, if a compound has: (1) a total of no more than four nitrogen and oxygen atoms, 
(2) a molecular weight less than 400 daltons and a base with a pKa lower than than eight, it is 
likely to be non-substrate [33].  
 
(N + O) ≥ 8, MW > 400 and acid pKa > 4 = P-gp substrate 
(N + O) ≤ 4, MW < 400 and base pKa < 8= P-gp non-substrate 
 
Recently, several computational models have been developed in order to predict if a 
compound is a P-gp substrate or not. To date, the most accurate model (accuracy > 90%) 
proposed for prediction of P-gp substrates uses a Particle Swarm (PS) algorithm and a 
Support Vector Machine (SVM) approach. [34]. However, in March 2010 the International 
Transporter Consortium (ITC) has stated that in general P-gp substrates are organic cations or 
a neutral molecules, relatively hydrophobic with a molecular mass ranging from 200 to 
greater than 1000 daltons [8].  
In fact, the large list of substrates that undergo P-gp translocation (Table 2) support the 
hypothesis of the presence of several binding sites [18]. 
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Table 2: The most clinically representative P-gp substrates 
Anticancer drugs: 
Doxorubicin, daunorubicin, docetaxel, epirubicin, etoposide, idarubicin, 
methotrexate, mitoxantrone, paclitaxel, teniposide, vinblastine and vincristine 
HIV protease inhibitors: Amprenavir, indinavir, nelfinavir, ritonavir and saquinavir  
Analgesics: Fentanyl, morphine and methadone 
Antibiotics:    Erythromycin, fluoroquinolines, valinomycin and tretracyclines 
Antiepileptic drugs:  
Carbamazepine, felbamate, gabapentin, lamotrigine, phenytoin, phenobarbital 
and topiramate 
Antidepressants:  Amitryptiline,  doxepin, nortryptiline, paroxetine and venlafaxine 
Antidiarrheal agents: Loperamide 
Antiemetics:  Domperidone and ondansetron 
Anthelminthic agents: Abamectin and ivermectin 
Antigout agents:  Colchicine 
Antipsychotic agents: Amisulpride and olanzapine 
β-Adrenoceptor antagonists: Bunitrolol, carvedilol, celiprolol and talinolol 
Cytokines:    IL-2, IL-4 and IFN-y 
Corticoids: 
Aldosterone, corticosterone, cortisol, dexamethasone, hydrocortisone and 
prednisolone 
Histamine H1-receptor 
antagonists: 
Cetirizine, fexofenadine and terfenadine 
Histamine H2-receptor 
antagonists: 
Cimetidine 
Immunosuppressive agents: Cyclosporin A and tacrolimus 
Lipid-lowering agents: Atorvastatin, cerivastatin and lovastatin 
Diagnostic (fluorescent) dyes: Calcein-AM, Hoechst 33342/33258 and Rhodamine-123 
Ref [3] 
 
 
1.2.4 Multidrug resistance (MDR) 
 
Multidrug resistance is a phenomenon by which tumor cells simultaneously exhibit intrinsic 
(inherent) or acquired cross-resistance to diverse anticancer drugs, thereby causing cancer 
treatment failure [11]. Treatment with high doses or multiple cytotoxic drugs with different 
mechanisms of action (chemotherapy) are not sufficient to overcome MDR. Furthermore, 
these treatments are often associated with toxic side effects in patients because most 
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anticancer drugs do not have specificity towards cancer cells. Different mechanism can 
mediate the development of MDR. These mechanisms of drug resistance are grouped into (1) 
increased drug efflux, (2) decreased drug uptake, (3) DNA repair activation, (4) detoxifying 
systems activation and (5) blockage of drug-induced apoptosis [35].  
Some members of the ABC superfamily such as P-gp, MRP1 and BCRP have been implicated 
in the efflux of anticancer drugs and the subsequent MDR phenomenon [35, 36]. However, 
the overexpression of P-gp on resistant malignant cells was first recognized in 1976 and is 
considered to be a major cause of MDR [10]. Because of its association with colchicines 
permeability it was called P-glycoprotein. In 1981, Tsuruo et al. demonstrated that the 
calcium-influx blocker, verapamil, could reverse MDR, suggesting thus the possibility of 
clinically useful reversing agents for MDR [37]. In 1983, Kartner et al. using Western blots 
indicated for the first time the presence of P-gp in a variety of MDR cell lines [38]. Since 
then, several studies have led us to confirm that P-gp is a major contributor of the 
phenomenon of MDR (Table 3).  
 
 
Table 3: Timeline of important discoveries related to P-gp 
 
 
Date Discovery Ref. 
1973 Demonstration of increased efflux in MDR cell lines causing decreased drug accumulation. [39] 
1976 Demonstration of P-gp expression in MDR cell lines (Chinese hamster ovary cells). [10] 
1981 Demonstration that verapamil could reverse MDR [37] 
1983 First indication that P-gp is commonly expressed in a variety of MDR cell lines.  [38] 
1986 Detection of ABCB1 and ABCB2 genes amplified in human cancer cells.  
Cloning of the first human mdr sequences. 
[40] 
[41] 
1989 Mice expressing MDR1 in bone marrow are drug resistant. [42] 
1990 Hormone progesterone regulates expression of P-gp. [43] 
1993 Epigenetic induction of MDR1 expression exposure to different chemotherapeutic drugs. [44] 
1997 P-g is a major factor in reducing the oral availability of amphipathic drugs as Taxol. [45] 
2001 Classical trials showing survival advantage for patients with AML treated with MDR 
inhibitors and chemotherapy. 
[46] 
2004 Global prediction of MDR1 substrates and inhibitors. [47] 
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To date, P-gp is found to be expressed in acute myelogenous leukemia in 1/3 of the patients at 
the time of the first diagnosis and in more than 50% of the patients at the first relapse. The 
level of expression of  P-gp at the presentation of the cancer is sufficient to confer resistance 
[26]. MDR1 is also expressed at high levels in many other tumors under three different 
circumstances [26]:  
- Cancers derived from epithelial tissues that normally express P-gp including kidney, 
liver, and colon cancer. 
- Cancers in which P-gp levels are low, but after chemotherapy cancers recur and 
express higher levels of P-gp such as leukemias, lymphomas, and multiple myeloma. 
- Cancers in which the development of the tumor appears to be associated with the 
turning on of expression of P-gp, including chronic myelogenous leukemia in blast 
crisis and neuroblastoma.  
 
1.2.5 Location and physiological functions of P-glycoprotein  
 
The strategic localization of P-gp (Fig. 7), suggests that its main physiological role is to 
protect sensitive organs and the fetus from a variety of endogenous and exogenous molecules. 
Consequently, P-gp also plays a prominent role in the absorption, distribution and excretion of 
clinically administered drugs. 
P-gp is highly expressed on the apical surface of the superficial columnar epithelial cells of 
the ileum and the colon. The expression levels of P-gp are lower in the jejunum, duodenum 
and stomach. Therefore the P-gp in these locations acts as a first natural line of defense 
against toxins such as Listeria monocytogenes [48]. However, the extrusion of substrates from 
the intestinal epithelium into the intestinal lumen limits the oral drug bioavailability [49]. 
In the liver, P-gp is exclusively localized on the apical (canalicular) membrane of hepatocytes, 
where it plays a major role in the hepatic excretion of toxins, many drugs and metabolites into 
the bile. High levels of P-gp are also found on the apical surfaces of epithelial cells of small 
biliary ductules [50, 51]. P-gp is observed on the apical surface of epithelial cells of small 
pancreatic ductules [50]. In the kidney, P-gp is found on the apical surface of epithelial cells 
of the proximal tubules where the efflux protein is supposed to pump the substrates from the 
blood into the urine [50, 52]. In normal human and rat lung tissue, P-gp is localized on the 
luminal membrane of the alveolar epithelium [53]. 
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In addition to the expression of P-gp in human tissues with excretory function, high levels of 
P-glycoprotein are also found at the blood-tissue barriers, such as the blood-brain barrier, the 
blood-testis barrier and the placenta, suggesting that it has a generalized barrier function [3, 
15]. The function of P-gp in the placenta is the protection of the highly sensitive developing 
fetus from xenotoxins and drugs present in the maternal circulation by active back transport 
[52]. The presence of P-gp in hematopoietic progenitor cells protects the bone marrow from 
the toxicity of chemotherapeutic drugs [54]. 
As seen, P-gp is one of the major components of a well developed “chemo immunity system” 
which dynamically protects the body and its more vulnerable structures against the 
accumulation of foreign chemical agents. Although the size, hydrophobicity, charge or the 
amphipathic character of a drug may allow a rapid penetration through the membrane lipid 
layers, P-gp selectively does modulate the entry and exit of the drug through cellular barriers.  
 
Figure 7. Direction of the P-gp-mediated transport in the human body [55]. The bold solid arrows indicate the 
known direction of transport and the dotted arrow indicates unclear direction of transport. The thick black line 
indicates the location of P-gp in the lipid bilayer that forms blood-barriers.   
 
1.2.6 P-glycoprotein, a critical element of the blood brain barrier 
 
The blood-brain barrier (BBB) (Fig. 8) is a selective barrier formed by the endothelial cells 
that line cerebral microvessels. The combined surface area of these microvessels constitutes 
by far the largest interface for the blood–brain exchange [56]. The BBB endothelial cells 
differ from the endothelial cells in the rest of the body by the absence of fenestrations, sparse 
pinocytic vesicular transport and more extensive tight junctions which cover the walls of the 
vessels as a continuous sheath, leaving no space between cells. In addition to endothelial cells, 
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the BBB is also composed by an extracellular matrix (basal membrane), pericytes which are 
embedded within the basal membrane and astrocyte foot processes [3, 56]. 
As a result of this configuration, most molecular traffic take a transcellular route across the 
BBB, rather than moving paracellularly through the junctions, as in most endothelia. Small 
gaseous molecules such as O2 and CO2 can diffuse freely through the lipid membranes, and 
this is also a route of entry for small lipophilic agents, including drugs such as barbiturates 
and ethanol [57]. The presence of specific transport systems on the luminal and abluminal 
membranes regulates the influx or efflux of various essential substrates such as electrolytes, 
nucleosides, amino acids and glucose [58]. It was originally supposed that these membrane 
transporters at the BBB were solely responsible for the transport of such endogenous 
compounds and that drugs transport across the BBB was dependent on their physicochemical 
properties such as lipophilicity, molecular weight and ionic state. Nonetheless, it is the 
presence of drug efflux transporters at the BBB which limit the brain uptake of a variety of 
therapeutic compounds, including compounds that are relatively lipophilic and would be 
predicted to permeate the endothealial lining of the brain microvasculature [59]. 
 
 
Figure 8. The Blood-Brain barrier 
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The presence of various efflux transporters at the BBB acts as a gatekeeper in the entry of 
many therapeutic drugs into the brain. Based on three critical defining criteria: (1) multi-
specificity, (2) location and (3) energetic; P-glycoprotein (P-gp) is considered to be the most 
important efflux transport at the BBB [60]. The expression of P-gp on the endothelial cells at 
the human BBB was first described in 1989 by Cordon-Cardo et al. and Theibaut et al [61, 
62]. Since these studies have been published, P-gp has been found to be localized at the 
luminal membrane of the endothelial cells lining the capillaries of the brain [56, 63], in 
neurons [64] and in astrocytes [65]. Other studies have demonstrated the presence of P-gp at 
the apical surfaces of the epithelial cells that constitute the ventricular exposed surface of the 
human choroid plexus [66]. Consequently, the relevant distribution of P-gp at the BBB offers 
a mechanism of detoxification to remove harmful endogenous and exogenous compounds 
from the brain. Thus, the penetration of therapeutic compounds into the brain tissue is equally 
decreased leading to the failure of various clinical treatments for brain diseases such as 
epilepsy, depression and brain cancer [3]. Additionally, it is known that Alzheimer’s, 
Parkinson’s and Huntington’s diseases are related to the expression and function of P-gp at 
the BBB [3]. The replication of the human immunodeficiency virus (HIV) in its primary 
stages takes place in the central nervous system (CNS), which causes neurological 
complications in HIV patients [67]. Unfortunately, many of the anti-HIV drugs are known P-
gp substrates, inhibitors, or inducers, which results in toxicity or drug resistance and the 
subsequent failure of the treatment [68].  
 
The in vivo impact of Pgp at the BBB has been properly illustrated in knockout mice lacking 
the Pgp isoform mdr1a (mdr1a (-/-) mice) or the isoforms, mdr1a and mdr1b (mdr1a/1b (-/-) 
mice). The mdr1a (-/-) mice were healthy and fertile and appeared phenotypically normal, but 
they accumulate much higher levels of P-gp substrates in the brain. A clear example was the 
increased sensitivity to the centrally neurotoxic pesticide ivermectin [69]. Knockout mice 
treated with ivermectin developed a severe intoxication and nearly all of the animals died 
because they were 100-fold more sensitive to the neurotoxic adverse effects of this 
compound. This enhanced sensitivity was due to the 100-higher accumulation of ivermectin in 
the brain as compared to wildtype mice. Based on this impressive proof, pharmacokinetic 
studies in knockout mice were rapidly extended to other drugs. The absence of mdr1a led to 
highly increased levels of vinblastine, digoxin, and cyclosporin A in the brain. Some drugs 
such as loperamide, domperidone, and ondansetron also demonstrated to be substrates for P-
gp, while phenytoin demonstrated to be a relatively weaker substrate. Haloperidol, clozapine, 
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and flunitrazepam are transported hardly or not at all by P-gp [70]. Tissue distribution studies 
demonstrated that the relative brain penetration of radiolabeled ondansetron and loperamide is 
increased 4- and almost 14-fold, respectively in mdr1a (-/-) mice. Moreover, a pilot toxicity 
study showed that the oral administration of loperamide gains potent opiate-like activity in the 
CNS of mdr1a (-/-) mice. Oral domperidone also showed neuroleptic-like side effects in 
mdr1a (-/-) mice [70]. These results have certified the prominent role of P-gp in the clinical 
use of many drugs that could eventually target the CNS. 
 
1.2.7 Techniques to measure the drug transport across the blood-brain 
barrier 
 
A number of techniques have been developed to study the disposition of drugs in the brain, 
after P-gp overcoming. The following techniques give evidence of the bi-directional 
(influx/efflux) transport of the drug across the BBB. 
 
1.2.7.1 In vitro models 
 
Early in vitro models of the BBB used cells from non-cerebral origin such as human umbilical 
endothelial cells (HUEVCs), epithelial Madin-Darby canine kidney (MDCK) or human colon 
carcinoma cells (Caco-2) [71, 72]. The high technical skills to isolate HUEVCs and their 
rapid senescence, made their use quite expensive and time consuming [72]. MDCK and Caco-
2 are easy to grow up and retain differentiating properties after repetitive passages [72], 
however their variable P-gp expression promoted the transfection of MDCK with human 
MDR1 gene and the treatment of Caco-2 with vinblastine to enhance and standardize the P-gp 
expression [73]. Hence, both cell lines are currently considered useful predictors of the BBB 
permeability (Table 4). 
The isolation of brain capillaries led to the first primary cerebral endothelial cultures and cell 
lines. One of the best characterized is the rat brain endothelial cell line (RBE4), which is able 
to retain many BBB characteristics like high alkaline phosphatase, gamma-glutamyl 
transpepetidase activity and P-gp expression [71]. The hCMEC/D3 is another reliable human 
brain endothelial cell line that was proposed as a model system for drug transport 
investigations given the expression of tight junction proteins and efflux transporters [71]. Due 
to the presence of other cell types that play important regulatory roles at the BBB, several 
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research groups initiated the co-culture of endothelial cells with glial cells or pericytes or even 
with neurons to mimic the BBB. To cut down the distance between in vitro and in vivo 
models even more, a triple co-culture system was opportunely proposed. It is based on the 
culture of endothelial cells, pericytes and astrocytes (Table 4) [71].  
 
Table 4: Correlation coefficient (r2) between in vitro and in vivo BBB models 
 
In vivo mouse brain 
distribution model 
In vivo rat microdialysis 
MDCK-MDR1 0.78 0.85 
Caco-2 0.60 0.91 
VB-Caco-2 0.72 --- 
BBMECs --- 0.99 
Triple culture (BCECs 
+ pericytes + astrocytes) 
0.80 --- 
Ref [73] [74] 
Madin-Darby canine kidney (MDCK) transfected with human MDR1 (MDCK-MDR1), human colon carcinoma 
cells (Caco-2), Vinblastine-treated Caco-2 (VB-Caco-2), bovine brain microvessel endothelial cells (BBMEC) 
and brain capillary endothelial cells (BCECs) 
 
Mimicking the functional properties of the BBB is critical to succeed the development of 
novel CNS pharmacotherapies. Hence, in vitro models have to accomplish the following 
characteristics [73]: 
 A low penetrability for paracellular transport of low molecular size tracer. 
 A transepithelial electric resistance (TEER) greater or equal to 150 – 200 Ω cm2. 
 The expression and activity of transporters, most importantly that of P-gp  
Because in vitro models cannot provide information on drug distribution into the brain once 
the drug passes the BBB, in vivo BBB models may predict the clinical fate of drugs more 
accurately.    
 
1.2.7.2 In vivo quantitative models 
 
The study of the BBB and brain uptake has been expedited by the use of techniques that 
quantify the influx and efflux of various molecules across the BBB in the living animal. The 
most common techniques used in the latest studies are described herein. 
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1.2.7.2.1 Intravenous pharmacokinetics and brain distribution studies 
 
The aim of a pharmacokinetic study is to assess the fraction of the administered dose that is 
distributed to the brain or is excreted from the body. The intravenous technique remains the 
reference for brain uptake studies because it represents fully physiological conditions. 
Additionally, it offers the potentially highest sensitivity, as brain uptake in intravenous 
experiments can be measured over long periods [75]. In this method, blood (plasma) and brain 
are sampled at several time points and drug concentrations are measured in both 
compartments. From these measurements, the area under the concentration-time curve (AUC) 
can be obtained for blood and brain. Pharmacokinetic models quantify the rate and extent of 
the distribution by mathematically analyzing these data. Thus, several pharmacokinetic 
parameters such the peak concentration (Cmax), time to reach peak concentration (Tmax), half-
life (t1/2) and mean residence time (MRT) can be determined for both, blood and brain. Other 
organs can be also included in the pharmacokinetic study [76]. It is important to keep in mind 
that the analytical method to be applied must be validated in order to avoid potential pitfalls. 
 
1.2.7.2.2 Microdialysis  
 
The use of microdialysis techniques is gaining popularity in the study of P-gp at the BBB. 
This technique involves the surgical implantation of a microdialysis probe in the brain of mice 
or rats. Once the probe is implanted it allows the in vivo measurement of drug transport into 
specific brain region(s) and monitoring of the time course of drug-drug interactions in freely 
moving animals. Furthermore, more than one compound can be assessed simultaneously using 
dual/triple-probe approaches. Sziráki and co-workers used a dual/triple-probe system with 
simultaneous sampling of blood and brain in mice for testing P-gp modulation by valspodar, a 
second-generation P-gp modulator using quinidine as P-gp probe substrate [77]. 
 
1.2.7.2.3 External detection  
 
The non-invasive character of external detection methods make them applicable in humans 
and allow to measure individually the time course of uptake together with plasma 
pharmacokinetics. Special resolution of single photon computed tomography (SPECT) is in 
the centimeter range, whereas positron emission tomography (PET) approaches the 
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autoradiographic resolution [75]. Recent efforts were directed to the development of 
radiotracers to study drug-drug and drug-P-gp interactions at the BBB. The most common 
radiotracers for P-gp studies are (R)-[11C]verapamil and [11C]loperamide [78]. However, 
[11C]elacridar and [11C]tariquidar are currently available [79]. 
Each of the previous techniques has its own advantages and disadvantages (Table 5), which 
should be cautiously considered before starting the experiments. Parameters like expertise, 
equipments and treatment of the data should be taken into account to ensure the success of the 
experiment. 
1.2.7.3 In vivo behavioral models 
 
Behavioral tests are in general used to reveal the pharmacodynamics of drugs  that have the 
ability to interfere with the brain signaling and induce specific behavioral effects (opioid 
analgesics) [76]. Early in vivo studies characterized behavioral abnormalities when mice 
received morphine, an opiate that does enter the CNS. Mice displayed a typical crouched 
appearance and the Straub reaction, which is characterized by the rigidity and erection in an 
S-shaped curve of the tail across the back of the animal [80]. In addition animals exhibited a 
compulsive circling behavior interspersed with periods of immobility [81]. This opiate-
induced behavior pattern was used to evaluate the brain uptake of loperamide, a µ-opioid 
agonist without central effects that could become a drug that produces substantial 
antinociception in P-gp-deficient animals or after P-gp inhibition in wild-type animals [82, 
83]. 
Behavioral tests of nociception are also widely used to assess the brain uptake of opioids. The 
term nociceptive refers to the potential of a stimulus to produce a tissue lesion and a reaction 
(response) from the organism. Among the short-duration stimuli, three basic tests have been 
developed based on thermal stimuli: The tail-flick test, the paw withdrawal test and the hot 
plate test. The tests based on long-duration stimuli involve the use of irritant chemical agents 
as the nociceptive stimulus. The administration of the irritant undergoes intradermal 
(Formalin test) or intraperitoneal (Writhing test) injections [84]. These tests are convenient 
because they apply to healthy wild-type mice or rats, requiring no disease induction or 
transgenic animals. More exhaustive literature and protocols about these methods and some 
other models of nociception have been properly described by Le Bars et al. [84]. 
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Table 5: Comparison between in vitro and in vivo BBB models  
 
 
  Advantages Disadvantages 
In 
vitro 
 
Molecular mechanisms 
Cell isolation 
Cell manipulation 
Drug permeability 
No brain imaging 
No histology 
No drug distribution 
No drug efficacy and safety 
No clinical outcome 
Cells of non-cerebral 
origin 
Not laborious 
Differentiating properties even after 
repetitive passages 
Differences in tight junction 
proteins and transporters compared 
to the BBB 
Cerebral endothelial 
cells 
Expression of tight junction proteins, 
transporters and drug-metabolizing 
enzymes 
Lack of interactions between the 
CNS cells 
Co-culture systems 
Most approximate representation of the 
BBB 
Laborious 
Variable permeability for repeated 
tests 
In 
vivo 
 
Brain imaging 
Histology 
Molecular mechanisms 
Drug distribution 
Drug efficacy and safety 
Physiological conditions 
Clinical outcome 
Laborious cell isolation 
Limited cell manipulation 
Limited drug permeability 
IV pharmacokinetic 
and brain distribution 
Highest sensitivity 
Low technical difficulty 
Laborious and good analytical tools 
Careful pharmacokinetic analysis 
Microdyalisis 
Time-course measurements 
Samples well suited for analytical 
procedures 
Probe calibration 
Possible damage of the BBB 
External detection 
Non-invasive 
Applicable in humans 
Time-course measurements 
Expensive equipment and tracers 
Poor spatial resolution for small 
animals (SPECT) 
Availability of labeled tracers 
(PET) 
Behavioral observation Rapidity and not laborious 
No quantitative information of the 
drug uptake 
Response may be influenced by the 
animal handling 
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The extent to which a drug in the bloodstream gains access to the CNS needs to be determined 
to improve existing CNS pharmacotherapies as well as to study drug candidates with primary 
targets in the CNS. This concern pushed researches to develop various in vitro BBB models. 
Despite all the progress, there is no an in vitro BBB model able to replace the in vivo human 
BBB. Hence, the different available models and methods (Table 5) should complement each 
other and should be chosen depending on whether we want to obtain (uptake values, visualize 
the uptake mechanism or test the drug effects). 
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2 DELIVERY OF P-GLYCOPROTEIN SUBSTRATES USING 
CHEMOSENSITIZERS AND NANOTECHNOLOGY FOR SELECTIVE AND 
EFFICIENT THERAPEUTIC OUTCOMES 
 
Abstract 
As a result of its broad substrate specificity and critical localization in excretory and barrier 
function tissues, P-glycoprotein (P-gp) plays major roles in the pharmacokinetics, safety and 
efficacy profiles of numerous drugs. P-gp is often responsible for the failure of many 
chemical treatments against cancer, immunosuppressive, infectious and neurodegenerative 
diseases. Among the therapeutic approaches to circumvent P-gp function, advances in the 
design of new chemical P-gp modulators to interact specifically with P-gp have yielded few 
clinical successful reports. Members of a class of components that were initially developed as 
surface active agents showed promising results with regard to the modulation of P-gp. These 
components include surfactants and amphiphilic co-polymers. Alternatively, colloidal systems 
were developed to facilitate drug uptake in resistant cells. This approach is based on the 
encapsulation of drugs, which masks them from the biological environment and prevents their 
transport by P-gp using the surfactants released from the nanocarrier. Likewise, a novel and 
synergistic strategy is currently being explored and involves nanocarrier-mediated transport 
and controlled release of both P-gp substrates and P-gp modulators. In this review, we discuss 
recent results obtained by direct modulation with chemosensitizers and the available 
nanotechnology to modulate P-gp function. In this manuscript, we also discuss unexplored 
pathways for future therapies. 
 
Keywords: P-glycoprotein, drug efflux, P-gp modulators, nanocarriers, drug delivery 
strategies   
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2.1 Introduction 
 
Over the last several years, a large body of literature has confirmed that drug efflux 
transporters play prominent roles in the pharmacological behavior of most clinically used 
drugs, thereby affecting drug absorption, disposition and elimination. Often this efflux of 
therapeutic compounds is mediated by the family of ATP-binding cassette (ABC) 
transporters. Among the ABC transporters, P-glycoprotein (P-gp), multidrug resistance-
associated proteins (MRPs) and breast cancer resistance protein (BCRP) play significant roles 
in restricting the permeability of several pharmacological agents, including anti-cancer and 
anti-HIV agents [1, 2].  
Because P-gp was the first member of the ABC transporter family to be described [3], it is 
currently the most recognized efflux protein. Two factors make P-gp the most critical efflux 
transporter: (1) its broad substrate specificity eliciting multidrug resistance (MDR) [4] and (2) 
the prominent presence of P-gp in most excretory and barrier function tissues [2]. As a result 
of these aspects, P-gp is a major obstacle for the treatment of cancer and several brain 
disorders, as well as immunosuppressive and infectious diseases.  
Screening studies to identify P-gp substrates indicated that some of the substrates also have 
the ability to block P-gp efflux, which led to a new strategy to identify successful therapeutic 
treatments. Unfortunately, the association of these compounds, known as first- and second-
generation P-gp modulators, with cytotoxic drugs failed in clinical trials due to toxic profiles. 
These limitations prompted the development of third-generation P-gp modulators that 
specifically and potently inhibit P-gp function without interfering with other ABC transporters 
[5].  
In addition, members of a diverse group of structurally and functionally excipients, such as 
surfactants and amphiphilic polymers, which are used for the preparation of drug delivery 
systems (DDSs), have clearly demonstrated their abilities to modulate the P-gp-mediated 
efflux mechanisms [6, 7]. DDSs, also known as nanocarriers, range in size from 1 to 200 nm, 
thus allowing parenteral administration. Their major advantages reside in their ability to mask 
drugs from the host environment, especially the reticuloendothelial system and in the 
recognition of target tissues by passive or active pathways. A few promising DDSs, such as 
doxorubicin-loaded pluronic® micelles (SP1049C), were tested in clinical trials. This micellar 
nanocarrier has shown promising results in terms of efficiency and safety in a phase II clinical 
trial in patients with advanced adenocarcinoma of the esophagus and gastroesophageal 
junction [8].   
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To ensure selective delivery of P-gp substrates and P-gp modulators, a relevant strategy 
would be to utilize nanocarriers to target both compound types to cells affected by the disease 
and thereby improving the therapeutic effectiveness and safety profile.  
The present review is focused on the emerging strategies to modulate P-gp function. The main 
results and obstacles obtained by direct modulation of chemosensitizers will be described. We 
will also outline the characteristics of pharmaceutical excipients, with a focus on the most 
sophisticated DDSs. Modulation of P-gp is becoming a high imperative for the research 
medical community and the pharmaceutical industry. Thus, this manuscript will highlight a 
novel and synergistic strategy that engages the association of chemosensitizers and DDSs to 
provide unexplored pathways for selective and efficient therapeutic outcomes. 
 
2.2 Role of P-glycoprotein in efflux mechanisms 
 
The discovery of efflux transporters has helped to explain why the minimal effective 
concentrations of certain drugs are not attained and why chemotherapy and the treatment of 
several brain disorders, immunosuppressive and infectious diseases fail. This mechanism  is 
mediated by a large list of efflux transporters, most of which belong to the ABC transporter 
family [2, 9].  
ABC transporters are transmembrane proteins that use ATP hydrolysis to drive the efflux of 
endogenous substrates and also xenobiotics. Some members of this family show specificity 
for one substrate, whereas others can transport a broad variety of structurally unrelated 
hydrophobic compounds. Previous studies identified 49 human ABC proteins that can be 
grouped into 7 subclasses or families (ABCA to ABCG) based on the organization of their 
domains and their amino acid homology [10-12]. 35 years after its discovery, P-gp is still the 
most-relevant member and serves as a model for the study of all ABC transport proteins (Fig. 
1).   
In humans, P-gp is a 170-kDa polypeptide encoded by two multidrug resistance genes, MDR 
1 and MDR 2 (also called MDR 3). MDR 1 is associated with a multidrug resistance 
phenotype, while the MDR 2 isoform inefficiently mediates the efflux of MDR 1 substrates; 
however, MDR 2 also functions as a phosphatidylcholine translocase [3, 13-15].  
Little is known about the complex mechanism by which P-gp recognizes an unlimited number 
of molecules that differ in chemical structure and pharmacological action. However, it is clear 
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that today we dispose of several documents where the P-gp structure and its mechanism of 
translocation have been properly described [16-18].  
The overexpression of P-gp on resistant malignant cells was first recognized in 1976 and is 
considered to be a major cause of MDR, a phenomenon by which tumor cells simultaneously 
exhibit intrinsic (inherent) or acquired cross-resistance to diverse anti-cancer drugs, thereby 
causing cancer treatment failure [16, 19, 20]. Treatment with high doses or combination 
treatments with anti-cancer drugs (chemotherapy) are not sufficient to inhibit the function of 
P-gp; furthermore, these treatments are often associated with toxic side effects in patients 
because most anti-cancer drugs do not have specificity towards cancer cells. 
In addition to the expression of P-gp in human tissues with excretory function, such as liver 
and kidney, P-gp is highly expressed on the apical surfaces of the superficial columnar 
epithelial cells of the ileum and the colon, which results in limited oral drug bioavailability. 
The expression levels of P-gp is lower in the jejunum, duodenum and stomach [21].   
Moreover, P-gp is highly expressed at the blood-tissue barriers, such as the blood-brain 
barrier (BBB), the blood-testis barrier and the placenta, suggesting that it has a generalized 
barrier function [2, 18]. The expression of P-gp on the endothelial cells at the human BBB 
was first described in 1989 by Cordon-Cardo et al. and Theibaut et al. [22, 23]. Since these 
studies have been published, P-gp has been found to be localized at the luminal membrane of 
the endothelial cells lining the capillaries of the brain [24, 25] and in primary brain tumors 
[26, 27] and astrocytes [27, 28]. Other studies have demonstrated the presence of P-gp at the 
apical surfaces of the epithelial cells that constitute the ventricular exposed surface of the 
human choroid plexus [29]. Consequently, the relevant distribution of P-gp at the BBB offers 
a mechanism of detoxification to remove harmful endogenous and exogenous compounds 
from the brain. Thus, the penetration of therapeutic compounds into the brain tissue is equally 
decreased [2], leading to the failure of various clinical treatments for brain diseases, such as 
epilepsy [2, 30] and depression [31, 32]. Additionally, it is known that Alzheimer’s, 
Parkinson’s and Huntington’s diseases are related to the expression and function of P-gp at 
the BBB [2, 33]. The replication of the human immunodeficiency virus (HIV) in its primary 
stages takes place in the central nervous system (CNS), which causes neurological 
complications in HIV patients [34]. Unfortunately, many of the anti-HIV drugs are known P-
gp substrates, inhibitors, or inducers, which results in toxicity or drug resistance and the 
subsequent failure of the treatment [35, 36].  
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Figure 1. Structural and functional insights into P-glycoprotein, a transmembrane efflux protein that uses ATP 
hydrolysis to transport drugs out of the cell. 
 
Because of the meaningful role of P-gp, it has become an important target for the successful 
treatments of various diseases. Some strategies that have been proposed to modulate P-gp 
include the use of: 
- Chemosensitizers to achieve direct modulation of the efflux activity of P-gp. 
- Nanocarriers to encapsulate P-gp substrates and therefore overcome the P-gp-mediated 
efflux system 
- Both nanocarriers and chemosensitizers to emphasize P-gp inhibition. 
 
2.3 Therapeutic approaches using P-gp modulators 
 
The modulation of P-gp is complex and involves competition at the P-gp substrate-binding 
sites, as well as the blockage of the ATP hydrolysis necessary for efflux transport function 
[37]. Over the last two decades, several P-gp modulators have been thoroughly studied to 
achieve effective inhibition of P-gp with the fewest possible interactions. Early in the 1980s, 
the calcium channel blocker verapamil was recognized for its ability to module P-gp efflux 
activity [38]. This property was quickly studied in other pharmacological compounds, from 
immunosuppressive drugs, such as cyclosporine A [39], to anti-steroidal compounds, such as 
tamoxifen [40]. Having obtained similar results, these agents were classified as first 
generation P-gp modulators or chemosensitizers (Table 1). Nevertheless, a few years later, 
phase I clinical trials showed that these compounds were not specific enough to ensure 
pharmacological intracellular concentrations of P-gp substrates [41-46]. Because most of 
these P-gp modulators are also P-gp substrates, the usage of higher doses to compete with 
cytotoxic drugs resulted in toxic profiles. Additionally, many of these drugs are substrates for 
34 
 
other efflux proteins and enzymes, which increases the risk of undesirable pharmacokinetic 
profiles [4, 5].  
 
Table 1| P-gp modulators and pharmaceutical excipients with P-gp inhibitory activity 
 
 
In view of these limitations and based on quantitative structure-activity relationships (SARs) 
of the first-generation P-gp modulators, a few laboratories have synthesized second-
generation P-gp modulators [48-50, 67]. Unfortunately, these compounds presented affinity 
for P-gp and also for cytochrome P450 3A4, thus minimizing the clearance of P-gp substrates, 
                                                   Drug Analog Ref 
P-gp modulators 
 
First 
generation 
Verapamil 
Cyclosporin A 
Anthranilamide 
Nifedipine 
Pipecolinate 
Quinidine 
Quinine 
Quinoline 
Amiodarone 
Chlorpromazine 
Promethazine 
Azidopine 
Ketoconazole 
Tamoxifen 
Reserpine 
Cephalosporines 
Propranolol 
 
 
 
 
 
 
 
 
 
[2, 
47] 
Second 
generation 
PSC-833 (valspodar) 
VX-710 (biricodar) 
Dexverapamil 
Dexniguldipine 
Cyclosporin D 
Pipecolinate 
Verapamil 
Niguldipine 
[48] 
[49] 
[50] 
[51] 
Third 
generation 
GF120918 (elacridar) 
XR9576 (tariquidar) 
LY335979 (zosuquidar) 
OC144-093 (ONT-093) 
MS-209 
R101933 (laniquidar) 
      --- 
Anthranilamide 
Cyclopropyldibenzo suberane 
Diarylimidazole 
Quinoline 
      --- 
[52] 
[53] 
[54] 
[55] 
[56] 
[57] 
Pharmaceutical 
excipients with 
P-gp inhibitory 
activity 
Surfactants 
Brij® 30 
Brij® 78 
Cremophor® EL 
Myrj® 52 
Solutol® HS 15 
Tween® 20/Tween® 80 
Vitamin E TPGS 
[58] 
[59]  
[60] 
[58] 
[61] 
[62] 
[63] 
Synthetic 
polymers 
methoxypolyethylene glycol-block-polycaprolactone (MePEG-b-PCL) 
poly(ethylene oxide)-block-poly(e-caprolactone) (PEO-b-PCL) 
polyethylene-glycol-phosphatidylethanolamine (PEG-PE) 
Pluronic® P85 
[64] 
[65] 
[63] 
[66] 
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such as anti-cancer drugs, until they reached toxic levels. The reduction in P-gp substrate 
dosages resulted in a reduction in therapeutic efficacy [68, 69].  
Because of its disappointing level of interaction with P-gp substrates, PSC-833 (valspodar or 
Amdray®), a non-immunosuppressive derivative of cyclosporine D and the most-studied 
second-generation P-gp modulator, was discontinued by Novartis [70]. Later, phase III studies 
corroborated the hypothesis that valspodar, administered together with vincristine, 
doxorubicin, dexamethasone, paclitaxel or carboplatin, did not improve treatment outcomes 
but did increase toxicity [71, 72]. In spite of these results, Binkhathlan et al. showed in a 
recent in vivo study that methoxy-poly(ethylene oxide)-block-poly(e-caprolactone) (PEO-b-
PCL) micelles are a good alternative to improve valspodar solubility and its subsequent 
intravenous administration. The PEO-b-PCL formulation displayed significantly higher 
plasma area under the curve (AUC) and lower volume of distribution (Vdss) and clearance 
(CL) than a formulation similar to the earlier clinical product, Amdray® [65].  The 
composition of Amdray® included ethanol and Cremophor® EL [65]. This latter excipient 
could increase pharmacokinetics interactions of valspodar due to its ability to inhibit P-gp by 
itself [60]. Moreover, Cremophor® EL has also been associated with acute hypersensitivity 
reactions and neurological toxicity, depending on the dosage used [73]. Hence, the study of 
Binkhathlan et al. suggests that the association of a DDS and a P-gp modulator could 
significantly improve the pharmacokinetics of the P-gp modulator and reduce the 
pharmacokinetic interactions with P-gp substrates and possible toxic profiles caused by 
Cremophor® EL. 
Although no interactions between VX-710 (biricodar) and cytochrome P450 3A4 were 
reported, clinical studies with this second-generation P-gp modulator were not successful [74, 
75].   
To avoid the limitations of the first- and second-generation P-gp modulators, third-generation 
P-gp modulators have been developed using the power of combinational chemistry and SARs. 
These compounds are non-competitive inhibitors that induce changes in protein conformation, 
thereby modulating the transport of P-gp substrates [52-56].  
GlaxoSmithKline developed GF120918 (elacridar), an acridonecarboxamide derivative, 
which has high affinity for P-gp [52]. Interestingly, their assays have shown that elacridar 
mediates the efflux of several P-gp substrates in various in vitro and in vivo models [76-78] 
and these data led to the assessment of this P-gp modulator in cancer patients. Oral 
administration of elacridar allowed the appropriate plasma concentrations of doxorubicin and 
paclitaxel to reverse MDR without the harmful pharmacokinetic interactions [79-81]. Other 
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studies, including a phase I trial, reported that elacridar is a modulator of breast cancer 
resistance protein (BCRP) [82, 83].  
In agreement with earlier assays [84, 85], recent clinical studies examining XR9576 
(tariquidar), an anthranilic acid derivative, demonstrated that it is a well-tolerated and 
selective P-gp modulator with fewer pharmacokinetic interactions and a high duration of 
inhibition but without significant systemic side effects [86, 87]. In contrast, intravenous 
tariquidar in 5% dextrose failed to produce significant central nervous effects caused by 
loperamide in humans [88]. The authors justified this finding in a previous in vivo study, in 
which high doses of tariquidar in propylene glycol, 5% dextrose and ethanol (4:5:1) were 
needed to inhibit P-gp function at the BBB [89].  
LY335979 (zosuquidar), is another third-generation modulator that, similar to tariquidar, is 
not a P-gp substrate and according to clinical trials does not significantly affect the 
pharmacokinetics of true P-gp substrates [90-92]. In addition, zosuquidar achieved P-gp 
inhibition in patients with acute myeloid leukemia in clinical trials [93, 94]. Unfortunately, in 
vivo model studies reported that P-gp at the BBB is only partially inhibited by zosuquidar, in 
spite of the presence of mannitol (inducer of BBB disruption) in the sterile saline vehicle [95, 
96].  
Other third-generation P-gp modulators include R101933 (laniquidar) and OC144-093 (ONT-
093), which in combination with anti-cancer drugs result in good safety profiles [57, 97, 98].  
The development of P-gp modulating agents and SAR studies were well described by 
Colabufo et al. and McDevitt et al [37, 99]. 
As reviewed above, much remains to be clarified. Phases II and III clinical trials are still 
ongoing to assess the lack of pharmacokinetic interaction between third-generation P-gp 
modulators and anti-cancer drugs, as well as the inhibition of P-gp in malignant cancer cells 
to elicit a better clinical prognosis. Inhibition of P-gp at the BBB requires higher doses of P-
gp modulators. However, these doses might approach the maximum tolerated doses in 
patients, thus limiting the use of these agents. Another relevant factor that strongly influences 
the bioavailability and therefore the efficacy of third-generation P-gp modulators is their 
limited solubility in aqueous solutions. As demonstrated in the study of Binkhathlan et al., the 
association between a P-gp modulator or a P-gp substrate with a DDS could reduce the 
effective doses and improve the solubility and the consequent release and bioavailability of 
these agents at the pharmacological sites of action. Moreover, this strategy would utilize the 
properties of certain colloidal systems to bypass and modulate the P-gp efflux system.  
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2.4 Therapeutic approaches with drug-loaded nanocarriers 
 
Many studies emphasize the promising potential of nanocarriers to overcome drug efflux 
mechanisms [7]. These colloidal systems include polymeric micelles [100], nanoparticles 
(NPs) [101], lipid nanocapsules (LNCs) [102], liposomes [103] and microemulsions [104]. 
These DDSs have many advantages. First, they promote the partial solubilization of 
hydrophobic drugs. Second, the presence of high molecular weight hydrophilic polymers, 
including polyethylene glycol (PEG) or dextran, on the surface confers stealth properties by 
drastically reducing mononuclear phagocyte system uptake. This prolongs the vascular 
residence time of the encapsulated drug [105]. Third, various DDSs have clearly 
demonstrated their ability to modulate the P-gp efflux pump.  The IC50 of doxorubicin-loaded 
lipid NPs was 8-fold lower in a P-gp-overexpressing human melanoma cell line compared 
with free doxorubicin [59]. In contrast, the nanocarriers had no effects on the sensitive cells, 
demonstrating a selective interaction with the MDR system.  Colloidal systems facilitate the 
accumulation of P-gp substrates in drug-resistant cells by modulating both their 
physicochemical properties and their compositions. After encapsulation, the biological fates 
of the drugs are dependent on the nanocarrier properties, not on the structures of the drugs. 
Additionally, some additives, such as surfactants or certain polymers located in the 
nanocarrier structure, could be responsible for P-gp inhibition, especially if they have 
amphiphilic properties. P-gp modulation strategies based on the use of surfactants and 
amphiphilic copolymers will be described further, as well as the mechanisms involved. Active 
targeting strategies will be also mentioned. These approaches involve the conjugation of 
ligands onto the nanocarrier surface, which promotes the recognition of specific receptors 
overexpressed on drug-resistant cells. The aim of these approaches is to facilitate drug uptake 
by receptor-mediated endocytosis.  An alternative strategy was reported with doxorubicin-
laden polyalkylcyanoacrylate (PACA) NPs. De Verdière et al. showed that the enhanced 
uptake of doxorubicin in resistant murine leukemia (P388/ADR) cell lines using PACA NPs 
was due to the degradation products of the polymer, in particular polyalkylcyanoacrylic acid. 
Intracellular diffusion of the drug was then facilitated by the accumulation of doxorubicin-
polyalkylcyanoacrylic acid ion pairs formed during the degradation step [106].  
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2.4.1 Surfactant-based strategies 
 
Surfactants are required for both the preparation and stabilization of NPs. Due to their 
interfacial activity, they facilitate the emulsification step [107] or allow the formation of 
microemulsion precursors [108, 109]. They are located at the surface of colloidal systems and 
govern the surface properties. Due to their nature, they can confer to the NPs steric and/or 
electrostatic barriers. Numerous authors have shown that the efficiency of surfactants as P-gp 
inhibitors is dependent on their chemical structure. Most of the MDR-reversing surfactants, 
such as Solutol® HS15, Cremophor® EL and Tween® 80, contain PEG in their hydrophilic 
portion [110]. Lo et al. showed that intracellular accumulation of epirubicin in human 
colorectal adenocarcinoma (Caco-2) cells was enhanced after pre-treatment with surfactants 
composed of PEG and fatty acids or fatty alcohols. Additionally, the authors reported a 
relevant relationship between the hydrophilic-lipophilic balance (HLB) values of surfactants 
and drug uptake in resistant cells. Optimal values ranged from 10 to 17 [62]. Tween® 20, 
Tween® 80, Myrj® 52 and Brij® 30 decreased the apical efflux of epirubicin across Caco-2 
monolayers in the same range as verapamil.  Similar results were observed with surfactant-
coated colloidal systems. De Juan et al. showed that Tween® 80 significantly enhanced the 
cytotoxic effects of doxorubicin-loaded polybutylcyanoacrylate NPs in rat glioma cell lines 
[58]. Recently, Dong et al. showed that doxorubicin uptake was 7-fold higher than free 
doxorubicin in resistant human ovarian carcinoma (NCI/ADR-RES) cell lines that were pre-
treated with blank lipid NPs [59]. Lipid nanocarriers were obtained from a warm 
microemulsion composed of emulsifying wax, D-alpha-tocopheryl polyethylene glycol 
succinate (Vitamin E TPGS). Additionally, the same uptake enhancement was obtained by 
pre-treatment with Brij® 78, thus confirming the role of surfactants as P-gp modulators. 
Furthermore, promising results were also obtained with an anionic surfactant, dioctylsodium 
sulfosuccinate (AOT). AOT was used for the preparation of alginate NPs [111]. Blank AOT-
alginate NPs facilitated the accumulation of the P-gp substrate rhodamine 123 in drug-
resistant cells [112],  whereas no effect was observed with fluorescein, a non-P-gp substrate. 
The efficiency of the NPs was in the same range as Verapamil. However, this strategy can be 
limited by the potential toxicity of the surfactants. Lamprecht et al. showed that toxicity levels 
were dependent on both the chemical structure of the surfactants and their surface activities. 
Due to their amphiphilic structure, surfactants insert themselves into the lipid bilayer, thereby 
altering cellular viability. This effect was inversely proportional to the length of the 
hydrophilic chain [113].   
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2.4.2 Amphiphilic copolymer-based strategy 
 
Similar to low-molecular weight surfactants, amphiphilic polymers have shown promising 
potential for the inhibition of the P-gp efflux system. One of the most well-known polymers is 
Pluronic® P85 (P85), a poloxamer composed of a central hydrophobic chain (polypropylene 
glycol) and two hydrophilic chains of PEG [114]. Other polymers are more seldom used, 
including methoxypolyethylene glycol-block-polycaprolactone (MePEG-b-PCL) [64] and 
polyethylene-glycol-phosphatidylethanolamine (PEG-PE) [63].   The polymers are organized 
in micelles from a threshold concentration termed the critical micelle concentration (CMC).  
The micellar structure allows the entrapment of poorly soluble drugs within a hydrophobic 
core. Kabanov et al. have shown that the internalization of P-gp substrates in resistant cells 
was drastically increased with Pluronic® copolymers [66]. This enhancement correlated with 
the level of P-gp expression, while Pluronic® had no effect on sensitive cells. P-gp substrates 
solubilized in mixed PEG-PE/vitamin E TPGS were successfully internalized in Caco-2 
resistant cells [63]. Recently, the uptake of doxorubicin in P-gp-overexpressing breast cancer 
cells was greatly enhanced by PEG-PE micelles compared with free drug [115].  
 
2.4.3 Mechanisms of P-gp modulation using amphiphilic excipients and/or 
nanocarriers  
 
Amphiphilic structure appears to be a preponderant condition for the modulation of the P-gp 
efflux pump. The components are then able to insert themselves into the lipid bilayers of cells, 
leading to a fluidization of the lipid membrane [116]. This mechanism is closely linked to the 
interfacial activity of amphiphilic structures and therefore the HLB. The fluidity modulation 
of the lipid bilayer is generally evaluated by measuring the 1,6-diphenyl-1,3,5-hexatriene 
(DPH) fluorescent anisotropy. Numerous authors have hypothesized that the fluidization of 
lipid membrane directly correlates with P-gp inhibition [110, 117, 118].  However, this 
correlation has not been clearly demonstrated and was not supported by the study of Rege et 
al. [119]. These authors showed that the vitamin E TPGS was able to inhibit rhodamine 123 
efflux across a Caco-2 monolayer and to rigidify the lipid bilayer. Additionally, cholesterol 
and benzylalcohol, which are well-known membrane modulators, do not modify the efflux 
transport of rhodamine 123 across a Caco 2 monolayer. Thus, other mechanisms are 
hypothesized to be involved in P-gp inhibition that could then interact in a synergistic manner. 
P-gp inhibition by Cremophor® EL was demonstrated to be specific. Cremophor® EL binds to 
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the hydrophobic sites of the efflux protein, leading to a modification of the conformation of P-
gp and subsequently a reduction in the efflux activity [60] .   
Another mechanism involves the ATP-dependent transport mediated by P-gp.  P85, after 
internalization in MDR cells, reaches the mitochondria and alters the respiratory chain [120]. 
This leads to the inhibition of the ATPase and subsequently to ATP depletion. Then, the 
efflux activity of P-gp is tremendously reduced.  Verapamil-stimulated P-gp ATPase activity 
was also partially inhibited by polyoxyethylene (40) stearate [118].  
All the mechanisms described above are significant for free surfactants or for unimers. When 
surfactants are used for the preparation of nanocarriers, they are immobilized on the 
nanoparticle surface. To solubilize hydrophobic drugs, amphiphilic polymers self-assemble 
into micelles. These arrangements can drastically limit the interaction between hydrophilic 
and hydrophobic groups and thus the ability of the surfactants to inhibit P-gp [62]. Koziara et 
al. showed that lipid nanoparticles (LNPs) prepared with Brij® 78 facilitated paclitaxel 
delivery to the brain and drug uptake in resistant human colon adenocarcinoma cells (HCT-
15). After comparison with Taxol, a commercial formulation of paclitaxel and Cremophor® 
EL, the authors suggested that the efficiency of the NPs was not due to the presence of Brij® 
78, despite its ability to inhibit P-gp. The study showed that the cytotoxic effects of paclitaxel-
loaded NPs were much higher than the toxicity from Taxol® alone [108]. These results do not 
support the P-gp inhibition mechanism mediated by Brij® 78 considering both the high 
potential of Cremophor® EL to circumvent P-gp [110] and the 2-fold lower concentration of 
Brij® 78. Additionally, a high proportion of Brij® 78 is embedded in the nanoparticle structure 
due to the preparation process using warm microemulsion precursors, whereas a high amount 
of Cremophor® EL is free. The authors suggested that the encapsulation of the drug strongly 
reduces the interactions between the drug and P-gp. After encapsulation, the fate of the drug is 
mainly dependent on the physicochemical properties of the carrier. A similar study was 
performed with paclitaxel-loaded LNPs [59]. The IC50 value of paclitaxel-NP was 9-fold 
higher than that of Taxol® in resistant cells. In contrast with the study of Koziara et al. [108], 
the authors demonstrated that lipid NPs were able to inhibit P-gp due to the presence of Brij® 
78, which was used for the preparation of microemulsion precursors [109]. A transient and 
reversible depletion of ATP was observed with blank NPs and free Brij® 78. Thus, the high 
accumulation of P-gp substrates was explained by a synergistic combination of NP with Brij® 
78. NPs increase drug uptake by partially bypassing P-gp and the drug efflux is limited by the 
release of Brij® 78 from NPs (Fig. 2).  
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Figure 2. Fate of nanocarriers after uptake in resistant cells. 1: intracellular uptake of nanocarriers; 2: surfactant 
release and migration to mitochondria; 3: ATP depletion and P-gp modulation. 
 
This mechanism was also supported by the study by Lamprecht et al. [61]. Etoposide-laden 
lipid nanocapsules (LNCs) were taken up by glioma cell lines and then the Solutol® HS15 
surfactant was released from the LNCs, leading to P-gp inhibition (Fig. 3).  
 
 
Figure 3. Release profiles of different etoposide-loaded LNC formulations in a phosphate buffer release medium 
at pH 7.4 and 37 °C where etoposide release is given in percent of the entrapped drug and PEG-HS as total 
amount released. The percentages of PEG-HS released after 120 h versus total surfactant amount used for the 
LNC preparation were similar for all preparations LNC25: 37.8 ± 1.8%; LNC50: 38.9 ± 2.6%; LNC100: 35.1 ± 
0.8%. 
Reprinted from Journal of Control Release 112, Lamprecht, A. and J.P. Benoit, Etoposide nanocarriers suppress 
glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition, p. 208-213 (2006) 
with permission from Elsevier. 
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Batrakova et al. studied the effects of P85 on drug transport across Caco-2 or bovine brain 
microvessel endothelial cell (BBMEC) monolayers. The authors showed that drugs 
encapsulated in micelles utilize a different transport route compared with unimers [121]. 
Whereas P-gp inhibition is involved in the drug permeability with P85 unimers, drug-loaded 
micelles are endocytosed and subsequently, the drug is shuttled out of the cells. Similarly, 
polyoxyethylene (40) stearate unimers exhibited a concentration-dependent inhibition of P-gp 
up to the CMC value; however, the effect was not observed for high concentrations above the 
CMC [118]. Generally, the inhibition of P-gp induced by unimers was much more efficient 
than the micelle-mediated transport, which allows a transient accumulation of the drug. Drug 
permeability or cellular uptake generally reaches levels close to controls for high 
concentrations above the CMC [122-124]. The internalization of drug-loaded mixed PEG-
PE/Vitamin E TPGS micelles in Caco-2 cells was not influenced by verapamil hydrochloride, 
thus confirming a P-gp independent transport process [63]. In contrast to the NPs mechanism, 
it appears that micelle internalization does not subsequently lead to a release of unimers, 
which are responsible for P-gp inhibition. The cellular concentration of amphiphilic 
molecules likely stays above the CMC, thereby preserving the micellar structure. However, 
the work of Zastre et al. [64] was not in agreement with these findings.  The authors reported 
that accumulation of a P-gp substrate in Caco-2 cells was enhanced with MePEG-b-PCL for 
concentrations above the CMC. Only a small effect was noted for concentrations below the 
CMC [64]. Despite the presence of micelles, the drugs were transported by P-gp and not via 
an endocytic process [125]. It was hypothesized that below the CMC, MePEG-b-PCL could 
not modulate P-gp due to its low surface properties. Above the CMC, the micelles could act 
as “depots” for free unimers, thereby maintaining a high concentration of the unimers in 
equilibrium with the micelles. Surprisingly, membrane fluidization and significant increases 
in ATPase activity were not observed as P-gp was inhibited [126]. 
In addition to the passive nanocarriers previously described, several DDSs actively target the 
resistant cells using recognition ligands located on the nanocarrier surface. Promising results 
were obtained with these surface-modified systems. The cytotoxicity of transferrin receptor-
targeted liposomal doxorubicin was 3.5-fold higher than free doxorubicin in the resistant 
human small cell lung cancer cells SBC3/ADM [127]. The effect was only observed with 
targeted liposomes with a fluid bilayer, which allows a rapid release of the drug. Additionally, 
folate conjugated to liposomes allowed increased doxorubicin uptake in multidrug-resistant 
tumor cells compared with free drug [128]. The cytotoxic effect of folate-liposomes was 10-
fold higher than untargeted liposomes. The enhanced accumulation observed with folate and 
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transferrin-conjugated liposomes was explained by an overexpression of transferrin and folate 
receptors on cancer cells [127-129]. Moreover, the transport of rhodamine 123 in insulin-
conjugated P85 micelles across a BBMEC monolayer was increased by 2- to 3-fold compared 
with insulin-free micelles or micelles incubated with unconjugated insulin. This effect was 
inhibited after the addition of free insulin and was not observed using a Caco-2 monolayer, 
thus confirming the specific interaction with insulin receptors overexpressed on BBMECs 
[121]. 
 
2.5 Synergistic combination of P-gp modulators with nanocarriers  
 
As previously discussed, DDSs may overcome MDR in many tumor types.  However, 
effective therapeutic P-gp modulation is often limited to cells with high resistance levels 
[130]. Additionally, some nanocarriers that allow high drug loading can exhibit a reduced 
ability to modulate P-gp due to the type of surfactant used, the surfactant concentration and 
the amount of anchorage on the surface. Thus, an alternative approach is to associate 
nanocarriers with chemosensitizers to benefit from both of the following strategies: P-gp 
bypassing and P-gp modulation.  With such strategy, pharmacokinetic interactions either 
between chemosensitizers and P-gp substrates or between chemosensitizers and other protein 
efflux transporters or enzymes could be avoided while improving the selectivity and efficacy 
of P-gp modulation. Additionally, the solubility, bioavailability and half-lives of encapsulated 
compounds could further be improved. This promising approach has been explored over the 
last few years; however, the studies showed a non-uniformity of the strategy. 
In one example, the P-gp modulator was encapsulated in nanocarriers. Lo et al. demonstrated 
that cyclosporin A and valspodar loaded in liposomes, compared with intralipid (o/w 
emulsion) and free valspodar could further achieve the highest level of epirubicin uptake at all 
studied concentrations in Caco-2 cells. In line with these results, the highest absorption of 
epirubicin in the everted sacs of a rat jejunum and ileum model was obtained using 
cyclosporine and valspodar liposomes [131, 132].  
In contrast, Krishna et al. showed in several publications that the encapsulation of P-gp 
substrates and the subsequent use with the free form of the P-gp modulator was also effective. 
First, in BDF1 mice bearing lymphocytic leukemia solid tumors (P388/ADR), no significant 
effect on tumor growth was observed when free doxorubicin was administered with or 
without free valspodar. In contrast, the addition of free valspodar to 1,2 distearoyl-sn-glycero-
3-phosphocholine/cholesterol (DSPC/Chol) liposomal doxorubicin provided complete 
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chemosensitization, thereby inhibiting tumor growth. Furthermore, using pharmacokinetic and 
biodistribution studies in the same tumor model, liposomal doxorubicin exhibited similar 
pharmacokinetic profiles in the presence and absence of valspodar, while decreased plasma 
elimination rates and altered tissue distribution was observed for free doxorubicin in the 
presence of valspodar [133]. All of these results were supported by a rat model with 
implanted jugular vein and bile duct catheters. The co-administration of valspodar with free 
doxorubicin caused significant decreases in renal and biliary clearance, while negligible 
changes were observed for egg phosphatidylcholine/cholesterol (EPC/Chol) liposomal 
doxorubicin and no effects were observed for doxorubicin excretion after administration of 
polyethylene glycol 2000-distearoylglycerophosphatidylethanolamine/1,2-distearoyl-sn-
glycero-3-phosphocholine/cholesterol (PEG2000-DSPE/DSPC/Chol) liposomal doxorubicin.  
Hence, these previous results suggest that the use of a nanocarrier and its composition play 
major roles in the pharmacokinetic properties of the encapsulated drug. Besides the minimal 
pharmacokinetic interactions between PEGylated liposomal doxorubicin and valspodar, this 
liposomal sterically stabilized formulation displayed superiority at suppressing tumor growth, 
particularly in the presence of valspodar [134, 135].  
As a result of the above in vivo data, a phase I clinical study in patients with resistant or 
recurrent malignancies evaluated the effects of valspodar on liposomal doxorubicin (Doxil®) 
toxicity and pharmacokinetics. PEGylated liposomal doxorubicin at a maximal dose of 25 
mg/m2 every two weeks co-administered with valspodar was safely administered by 
intravenous infusion. In agreement with all previous reports in animals, valspodar moderately 
increased the plasma levels and half-life of doxorubicin and decreased the clearance of total 
doxorubicin, indicating that there is a weak interaction between PEGylated liposomal 
doxorubicin (Doxil®) and valspodar [136]. 
As cited by Song et al., many questions arose with the advance of this synergistic strategy. It 
remained unclear which agent should be encapsulated and what is the optimal sequence of 
administration to obtain the highest P-gp inhibition, fewest pharmacokinetic interactions and 
lowest normal tissue toxicity [137]. Subsequent investigations were not limited to the 
encapsulation of a P-gp substrate or P-gp modulator; in fact, they went further and co-
encapsulated both compounds.  
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2.5.1 Co-encapsulation of P-gp substrates and P-gp modulators in 
liposomes and liposomal derivatives 
 
Based on the information presented above and to enhance the reversion efflux of doxorubicin, 
J. C. Wang et al. tested the in vitro cytotoxicity of a series of doxorubicin formulations in the 
multidrug-resistant rat prostate adenocarcinoma Mat-LyLu-B2 (MLLB2) cell line, in which 
the most prodigious formulation was a stealth liposomal co-encapsulation of doxorubicin and 
verapamil (DARSLs). The IC50 of DARSLs was 0.079 µM, which was slightly lower than the 
value obtained with a mixture of liposomal doxorubicin and liposomal verapamil (0.099 µM) 
but 13-fold lower than the IC50 of a mixture of liposomal doxorubicin and free verapamil 
(0.96 µM). Furthermore, the authors reported that the most significant finding was that stealth 
liposomes encapsulating doxorubicin alone was not sufficient to reverse doxorubicin 
resistance in two resistant cell lines, MLLB2 and doxorubicin-resistant human uterus sarcoma 
(MES-SA/Dx5) cells [130]. Additionally, the same research team explored the in vivo 
pharmacokinetics and cardiotoxicity of all previous formulations administered intravenously 
in order to discard reported toxicity of free doxorubicin and free verapamil co-administered in 
neoplastic patients. In accordance with previous reports, verapamil interferes with the 
pharmacokinetics of doxorubicin when both molecules are administered in their non-
encapsulated form. Encapsulation of doxorubicin and its co-administration with verapamil, 
whether free or co-encapsulated, has a major impact on reducing the clearance of doxorubicin, 
resulting in a significant increase of its AUC. This fact could be due to the P-gp inhibition, 
which results in a reduction in doxorubicin transport across the biliary canaliculi. Moreover, 
the co-encapsulation of doxorubicin and verapamil in DARSLs decreased bradycardia 
produced by free verapamil and resulted in the lowest doxorubicin distribution in the heart, as 
well as in other organs, such as the liver, kidneys and lungs [138]. 
One of the most recent studies aimed to develop a system to co-encapsulate a third-generation 
P-gp modulator, tariquidar and paclitaxel in long circulating liposomes. This formulation 
caused high cytotoxicity of a paclitaxel-resistant human ovarian adenocarcinoma (SK-OV-
3TR) cell line at a dose that was ineffective in the absence of tariquidar. Co-loaded long 
circulating liposomes resulted in a about 100-fold lower IC50 than paclitaxel long circulating 
liposomes [139].  
Another approach combined doxorubicin and verapamil co-encapsulated in liposomes 
actively targeted with transferrin (Tf-L-DOX/VER). Human transferrin is an iron-binding 
glycoprotein with high affinity for the Tf receptor, which is overexpressed in tumor and 
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chronic human leukemia (K562) cells. Through cytotoxicity studies in doxorubicin-resistant 
K562/DOX cells, Tf-L-DOX/VER displayed a 3-fold lower IC50 than the value obtained with 
transferrin liposomes loaded with doxorubicin alone (Tf-L-DOX) (4.18 µM vs 11.4 µM). 
These values suggest that the presence of verapamil in the formulation results in a stronger 
reversal of drug resistance in K562 cells [140]. 
Based on its active targeting mechanism of receptor-mediated endocytosis and its high 
affinity for the cerebral capillary endothelium, wheat germ agglutinin (WGA) has been shown 
to be a good candidate for drug carrier targeting. WGA conjugated to the surface could help 
transfer topotecan-tamoxifen-loaded liposomes across the BBB and then target brain tumors. 
Among the four types of topotecan liposomes with or without the P-gp modulator tamoxifen 
and/or WGA, the one modified with tamoxifen and WGA exhibited the strongest cytotoxic 
effect against murine glial tumor (C6) cells. Likewise, this formulation achieved the highest 
inhibitory effect against C6 cells after crossing an in vitro BBB (brain microvascular 
endothelial cells/rat astrocytes) model, with only a 65.8% survival rate. The percent survival 
for topotecan liposomes with WGA was 75.6%, for topotecan liposomes with tamoxifen it 
was 76.1%, for topotecan liposomes it was 86.5% and for free topotecan it was 88.0%. In 
addition, after one week of treatment with the different formulations, the mean survival time 
of an in vivo brain C6 glioma-bearing model was 26 days for topotecan liposomes modified 
with tamoxifen and WGA, 20 days for topotecan liposomes, 19 days for free topotecan and 15 
days for saline. A mean survival time of 31 days was achieved with two weeks of treatment 
with topotecan liposomes modified with tamoxifen and WGA [141].  
Synthetic liposomes, or polymersomes, were recently developed from amphiphilic polymers. 
Because of their similar properties to self-assembled phospholipids, polymersomes are being 
engineered to improve their performance as DDSs [142]. Taking this information into 
account, Pang et al. have recently worked on the formulation of biodegradable polymersomes 
as carriers for the simultaneous co-administration of doxorubicin and tetrandrine (PO-
Dox/Tet). Additionally, these vesicles were actively targeted with lactoferrin (Lf-PO-
Dox/Tet). Tetrandrine is a bis-benzylisoquinoline alkaloid isolated from the roots of Radix 
stephania tetrandrae. In vitro and in vivo studies showed that tetrandrine is not a P-gp 
substrate, but through direct binding, it acts as a P-gp modulator. A clear example is the 
enhancement of doxorubicin plasma levels by co-administration of tetrandrine, with no 
apparent effects on doxorubicin pharmacokinetics [143, 144]. Lactoferrin is a multifunctional 
glycoprotein with high potential to overcome the BBB and to increase the targeting 
interactions with glioma cells. As predicted after the active targeting, a cytotoxicity evaluation 
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against a murine C6 glioma cell line showed that the IC50 of Lf-PO-Dox/Tet was about 2-fold 
lower than the IC50 of PO-Dox/Tet and about 4-fold lower than the IC50 of polymersomes 
containing doxorubicin alone (PO-Dox). Moreover, in an in vivo brain C6 glioma-bearing 
model, treatment with Lf-PO-Dox/Tet resulted in significantly smaller tumor volumes and 
longer median survival time compared with animals treated with Lf-PO-Dox [145].  
 
2.5.2 Co-encapsulation of P-gp substrates and P-gp modulators in 
nanoparticles 
 
Early doxorubicin-targeting strategies included NPs co-loaded with doxorubicin and a 
chemosensitizer compound. A clear example was co-encapsulation of doxorubicin with 
cyclosporine A in polyalkylcyanoacrylate (PACA) NPs. As expected, using cytotoxicity 
assays in a doxorubicin-resistant murine leukemia (P388/ADR) cell line, co-encapsulation of 
both compounds proved to be significantly more efficient than doxorubicin PACA NPs with 
or without free cyclosporine A [146]. 
Y. Patil and co-workers have been studying simultaneous encapsulation and targeted delivery 
of paclitaxel with the P-gp inhibitor, tariquidar, in poly-(lactic-co-glycolic acid) (PLGA) NPs. 
The two P-gp-overexpressing cell lines used in their cytotoxic study were murine mammary 
adenocarcinoma (JC) and human ovarian adenocarcinoma (NCI/ADR-RES) cells, both of 
which are resistant to different anti-cancer drugs. Paclitaxel in solution or encapsulated in NPs 
did not significantly alter the viability of these cells; however, the addition of tariquidar 
restored the cytotoxicity. These results are supported by the amount of paclitaxel accumulated 
in each cell line. Dual-agent NPs displayed almost a 2-fold higher paclitaxel accumulation 
than a mixture of the anti-cancer drug and the P-gp modulator in solution and almost an 8-fold 
higher accumulation than paclitaxel alone in NPs or in solution. Because previous studies 
have shown that cancer cells overexpress biotin receptors and with the purpose of treating a 
JC tumor-bearing animal model, paclitaxel-tariquidar PLGA NPs were functionalized with 
biotin. This formulation led to a significant increase in tumor cell accumulation of NPs and 
the slowest tumor growth, as well as the least ulceration and tumor-induced mortality. In 
contrast, paclitaxel, either encapsulated in NPs or in solution, was not effective and the 
inclusion of tariquidar only showed slightly better tumor growth inhibition [147]. 
The co-encapsulation of doxorubicin and the chemosensitizer elacridar using polymer-lipid 
hybrid nanoparticles (PLNs) was reported for the first time by H.L. Wong et al. This new 
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lipid-based system is a modification of the previously described solid lipid NPs by 
incorporation of anionic polymers to complex cationic drugs, thereby increasing its partition 
in lipids. Among the different formulations, co-encapsulation of doxorubicin and elacridar in 
PLNs resulted in the highest uptake of doxorubicin and the strongest anti-cancer effect in a P-
gp-overexpressing human breast carcinoma (MDA435/LCC6/MDR1) cell line. The IC50 
obtained by this co-encapsulation was 3-fold lower than the value obtained by single 
doxorubicin PLNs and 2-fold lower than the value obtained by doxorubicin PLNs with free 
elacridar [148]. 
In Adriamycin®-resistant human leukemic (K562/A02) cells, treatment with tetrandrine co-
loaded with Adriamycin in Fe3O4 magnetic NPs using a polymerization process resulted in the 
highest growth inhibition among all the polymerized conjugations or single drug forms. These 
results were corroborated by measuring fluorescence intensity of intracellular Adriamycin 
[149].   
In line with previous results, other research teams showed that the simultaneous 
administration of a P-gp substrate and a P-gp modulator co-loaded in nanocarriers achieved 
the highest reversal efficacy and caused minimal tissue drug toxicity and dramatically fewer 
drug-drug interactions (Table 2).   
Promising early preclinical studies certified that P-gp modulation by this synergistic and 
novel strategy is feasible and the results from these studies are encouraging. Among all the 
examples using this approach, the dual-loaded drug delivery system always resulted in the 
highest acute cytotoxicity and uptake of the P-gp substrate by P-gp-overexpressing cell lines. 
Additionally, these co-loaded formulations always achieved the most improved 
pharmacokinetic profiles and the highest long-term suppression of cancerous tumors. More 
encouraging results were only obtained with the actively targeted forms of the co-loaded 
nanocarriers. 
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Table 2: Characteristics and results of in vitro and in vivo studies using the novel combination of nanocarriers 
and P-gp modulators 
 
 
Year P-gp 
modulator 
P-gp 
substrate 
DDS In vitro model In vivo model Results Refs 
1999 Cyclosporin 
A 
Doxorubicin Polyalkylcyanoa-
crylate (PACA) 
nanoparticles 
Doxorubicin-resistant  
leukemia 
(P388/ADR) cells 
--- Improved 
cytotoxicity 
[146] 
2005 Verapamil Doxorubicin Stealth liposomes Multidrug-resistant 
rat prostate 
adenocarcinoma Mat-
LyLu-B2 (MLLB2) 
cells 
--- 
 
 
 
 
Pharmacokinetics 
in Sprague 
Dawley rats 
Improved 
cytotoxicity 
 
 
 
Improved 
pharmacokinetic 
profile 
[130] 
 
 
 
 
[138] 
2006 Elacridar Doxorubicin Polymer-lipid 
hybrid 
nanoparticles 
(PLN) 
Human breast 
carcinoma 
(MDA435/LCC6/M
DR1) cells 
Clonogenic assay in  
MDA435/LCC6/MD
R1 cells 
--- Improved 
doxorubicin 
uptake  
 
Long-term 
cancer growth 
suppression 
[148] 
2007 Verapamil Doxorubicin Transferrin-
conjugated 
liposomes 
Chronic 
myelogenous 
leukemia  
(K562/DOX) cells 
--- Improved 
cytotoxicity 
[140] 
2009 Tamoxifen Topotecan Wheat germ 
agglutinin-
conjugated 
liposomes 
Murine glial tumor 
(C6) cells  
Transport across 
BBB (brain 
microvascular 
endothelial cells / rat 
astrocytes) – 
(BMVECs/RAs) 
 
 
 
 
 
 
 
 
C6 tumor-bearing 
Sprague Dawley 
rats 
Improved 
cytotoxicity 
Improved 
transport and 
targeting of C6 
cells 
 
 
Longer survival 
of animals 
[141] 
2009 Tariquidar Paclitaxel Poly(D,L-lactide-
co-glycolide acid) 
(PLGA) 
nanoparticles 
 
 
Biotin- poly(D,L-
lactide-co-
glycolide acid) 
(PLGA) 
nanoparticles 
Murine mammary 
adenocarcinoma (JC) 
and human ovarian 
adenocarcinoma 
(NCI/ADR-RES) 
cells 
 
 
 
 
 
 
JC tumor-bearing 
female BALB/c 
mice 
Improved 
cytotoxicity 
 
 
 
 
Improved tumor 
growth 
inhibition 
[147] 
2009 
 
 
 
2010 
Verapamil Vincristine Poly(D,L-lactide-
co-glycolide acid) 
(PLGA) 
nanoparticles 
 
Human breast cancer  
(MCF-7/ADR) cells 
 
 
Human 
hepatocellular 
carcinoma 
(BEL7402/5-FU)  
cells 
--- 
 
 
 
--- 
Improved 
cytotoxicity 
 
 
Improved 
cytotoxicity 
[137] 
 
 
 
 
[150] 
2011 Tariquidar Paclitaxel Stealth liposomes Paclitaxel-resistant 
human ovarian 
adenocarcinoma (SK-
OV-3TR) cells 
--- Improved 
cytotoxicity 
[139] 
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2.6 Conclusion 
 
In spite of exponential improvements and progress with the various strategies to circumvent 
P-gp, the efficacy and safety of these strategies in clinical trials are still a challenge for drug 
development programs. The attainment of the ideal modulator is not yet a reality. Although 
third-generation modulators have demonstrated high selectivity and efficacy in preclinical 
studies, the clinical trial results were more conflicting. The poor solubility of 
chemosensitizers and sometimes their short half-lives could limit their use as P-gp 
modulators. These drawbacks can be reduced by the use of DDSs that additionally exhibit a 
high potential to bypass and/or to modulate the P-gp efflux protein. The mechanisms of 
nanocarriers involved in P-gp modulation have not yet been clearly demonstrated. 
Nevertheless, an enhanced intracellular uptake compared with free drug followed by a 
simultaneous release of P-gp substrate and amphiphilic excipients was hypothesized.  
Rather than develop other strategies, some laboratories suggest a synergistic association 
between the unique properties of DDSs and the selectivity and potency of P-gp modulators. In 
this manuscript, we have highlighted a dual strategy where a prominent number of 
nanocarriers containing both P-gp substrates and P-gp modulators are currently being 
explored. In general, the first results in this direction were already obtained with in vitro and 
in vivo studies. To our knowledge, most of these studies succeeded in their goal opening 
outcoming windows to clinical trials. These examples apply to cytotoxic drugs but many other 
P-gp substrates with different therapeutic activities remain to be studied.  Particular attention 
should be given to P-gp substrates, such as HIV protease inhibitors, anti-epileptic or anti-
depressants drugs, which are not able to reach the brain due to the overexpression of P-gp at 
the BBB. First-generation P-gp modulators have been tested most frequently in the studies 
mentioned above. However, the usage of the latest generation of modulators is a factor that 
independently predicts the further decrease of any residual interaction with other ABC 
transporters or enzymes and thereby improves the safety profiles. Among nanocarriers, 
liposomes and nanoparticles have been extensively used for such combinations; however, 
other nanocarriers such as polymersomes or niosomes would also be suitable for this aim. The 
data suggest that future challenges involve taking advantage of the modified, stealth or 
actively targeted nanocarriers and also exploiting the best combinations. Although this 
approach is still probably some years away from the marketplace, more detailed in vivo 
pharmacodynamics, safety pharmacology, pharmacokinetic and toxicology studies could 
maximize the efficacy of this synergistic strategy for the success of future clinical trials.  
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Moreover, some important aspects should be considered when working in vitro models. 
Numerous in vitro models to study P-gp modulation utilize immortalized cells with a different 
phenotype compared to normal primary cells. These phenotypic variations could alter cell 
internalization routes and induce a higher membrane turnover. In addition, culture conditions 
such as the composition of culture media could also result in a poor representation of uptake 
pathways in cells found in intact tissues and thus explaining significant differences observed   
between in vitro and preclinical studies. 
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3 OBJECTIVES OF THE WORK 
 
Although P-gp represents an obstacle to tackle in order to succeed several central nervous 
system pharmacotherapies, it is irrefutable that the main role of P-gp is to protect the brain 
from intoxication by endogenous and exogenous harmful lipophilic compounds that otherwise 
could penetrate the BBB by simple diffusion. Therefore, any modulation of the efflux 
transporter has to consider the potential neurotoxicity of such modulation. 
Elacridar and tariquidar are two potent third-generation P-gp modulators that proved to 
increase the distribution of several P-gp substrates into the brain in various in vivo studies. 
Unfortunately, elacridar also demonstrated a high plasma protein binding in rat and human 
species, which means that high doses of elacridar are required to saturate the protein binding 
and modulate the P-gp-mediated efflux at the BBB. However, at relative high doses, elacridar 
not only increases the P-gp substrates levels in the brain but also in other vital organs, such as 
the liver. Moreover, the bound portion of elacridar may act as a depot from which the P-gp 
modulator would be slowly released, lengthening its pharmacological effects. Similarly, 
because tariquidar failed to produce significant central nervous effects caused by loperamide, 
recent studies suggest the use of high doses of this P-gp modulator to efficiently modulate the 
P-gp at the BBB. Nevertheless, when co-administered with P-gp substrates, these high doses 
may be associated with pharmacokinetic interactions and toxic profiles, thus limiting the use 
of these compounds.  
The general aim of this thesis was then to engineer a different strategy to attain a transient but 
efficient modulation of the P-gp-mediated efflux at the BBB using elacridar and tariquidar but 
avoiding the use of large doses of these compounds. As seen in various diseases, the use of 
multiple drugs with different binding sites or targets increases the efficacy of the therapy via 
synergistic effects, while enables dose reduction and avoids drug resistance and toxicity. A 
specific goal was hence to evaluate the concomitant administration of low but therapeutic 
doses of elacridar and tariquidar and its impact on the pharmacokinetics and brain distribution 
of a P-gp substrate probe, loperamide. For this purpose an analytical method for the 
appropriate measurement of these three compounds in biological fluids was firstly required. 
Immunocarriers have been widely recognized as a promising tool for specific delivery across 
the BBB due to their increased permeability against the brain. Therefore another specific goal 
was to develop an immunonanocarrier to improve the pharmacokinetics and brain distribution 
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of elacridar and tariquidar and consequently enhance the brain uptake of loperamide. 
Although the aforementioned strategies represent steps forward to improve the efficacy of 
central nervous system pharmacotherapies, they do not counteract the possible neurotoxicity 
caused by large doses of elacridar and tariquidar to modulate the P-gp at the BBB. The 
administration of empty nanocarriers that can extract the P-gp modulators from the circulation 
and brain could avoid a long exposure and a long-lasting P-gp modulation. To this extent the 
goal was to investigate the potential of nanocarriers as bio-detoxifying agents for elacridar 
and tariquidar. 
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4 SIMULTANEOUS DETERMINATION OF LOPERAMIDE, ELACRIDAR AND 
TARIQUIDAR IN RAT PLASMA AND TISSUES BY LIQUID 
CHROMATOGRAPHY-MASS SPECTROMETRY: DEVELOPMENT AND 
VALIDATION 
 
Abstract 
 
A rapid, sensitive, precise and accurate liquid chromatography-mass spectrometry (LC-MS) 
method was developed and validated for the simultaneous determination of loperamide, 
elacridar and tariquidar in rat plasma, brain, liver and kidneys. The sample preparation 
method used acetonitrile and tert-butyl methyl ether. Ketoconazole was used as internal 
standard for loperamide and chlorpromazine for elacridar and tariquidar. Analytes were 
separated on a Zorbax Eclipse XDB-C18 column with isocratic elution of ammonium acetate 
(pH 5.5; 10 mM)-methanol-acetonitrile (37.5:40.0:22.5 v/v/v) at 0.4 mL/min. Detection was 
performed using positive electrospray ionization in an octapole quadrupole mass spectrometer 
operating in single ion monitoring mode. The developed LC-MS method presented a run time 
of 12 minutes and was used to construct linear calibration curves over the concentration range 
5.0 ng/mL – 1000 ng/mL for loperamide, elacridar and tariquidar (r2 ≥ 0.9990). Using 100 µL 
of rat plasma or tissue homogenate, the validated lower limit of quantification (LLOQ) for 
each compound was the lowest concentration of standard on the calibration curves, 5.0 
ng/mL. Intra- and inter-day accuracy and precision were within 15% for the three analytes. 
The specificity of the method was confirmed by the absence of interferences from endogenous 
compounds. The applicability of the current method was assessed utilizing plasma and tissues 
samples obtained during the pharmacokinetic and tissue distribution studies of loperamide, 
elacridar and tariquidar in Sprague Dawley rats.  
 
Keywords: Loperamide, elacridar, tariquidar, LC-MS, rat plasma, rat tissues and validation. 
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4.1 Introduction 
 
The presence of various efflux transporters at the blood-brain barrier (BBB) acts as a 
gatekeeper in the entry of many therapeutic drugs into the brain. Based on three critical 
defining criteria (multi-specificity, location and energetics), P-glycoprotein (P-gp) is 
considered to be the most important efflux transport at the BBB [1].  
Clinical studies have revealed that over-expression of P-gp at the human BBB can exert a 
profound effect on the ability of HIV protease inhibitors, anticancer drugs, opioids, some 
psychotropics and other drugs leading to the failure of various clinical treatments for brain 
diseases [2-4]. The inhibition of P-gp could enhance the distribution of these substrates into 
the brain and therefore improve central nervous system (CNS) pharmacotherapies.  
Interesting studies have demonstrated that elacridar and tariquidar are able to mediate the 
efflux of numerous P-gp substrates in different BBB in vitro and in vivo models [5, 6]. These 
third-generation P-gp modulators are non-competitive, well-tolerated, without significant side 
effects and much less pharmacokinetics interactions. Based on an anti-nociceptive response 
model, Choo et al. showed that loperamide, a µ-opioid agonist without central effects could 
become a drug that produces substantial anti-nociception in the presence of elacridar or 
tariquidar [7].   
To further investigate the pre-clinical pharmacokinetic interaction after concurrent 
intravenous administration of loperamide and elacridar and/or tariquidar, a simultaneous 
determination of the three molecules is therefore highly desirable. Liquid chromatography 
methods using ultraviolet, fluorescence or tandem mass spectrometric detection for the 
separately determination of loperamide [8-12], elacridar [13, 14] and tariquidar [15] in 
biological fluids have been fully described. Nevertheless, an extensive literature survey 
revealed a lack of methods for the simultaneous estimation of these three compounds.  
The present study aims to develop a new LC-MS method using electrospray ionization for the 
simultaneous quantitation of loperamide, elacridar and tariquidar in small volumes of rat 
plasma and brain, liver and kidneys homogenates. The present method has been fully 
validated for specificity, lower limit of quantification (LLOQ), calibration curve, accuracy, 
precision, recovery and stability according to the FDA guidance for bioanalytical method 
validation [16]. Matrix factor and dilution integrity were also assessed. In the case of plasma, 
the influence of hemolyzed plasma was also investigated. The applicability of the 
bioanalytical method was evaluated by monitoring pharmacokinetic and biodistribution data 
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after intravenous administration of loperamide alone or concurrently administered with 
elacridar and/or tariquidar to Sprague Dawley rats. 
 
4.2 Materials and methods 
 
4.2.1 Chemicals and reagents 
 
Loperamide hydrochloride, ketoconazole and chlorpromazine hydrochloride were obtained 
from Sigma Aldrich (France). Elacridar was synthesized at the Laboratory of Pharmaceutical 
Chemistry, University of Bonn (Germany) and tariquidar was purchased from API Services 
Inc. (USA). tert-Butyl methyl ether was obtained from Sigma Aldrich (France) and 
polyethylene glycol 600 (PEG 600) from Interchimie (France). 
HPLC grade methanol and acetonitrile were purchased from Carlo Erba (France). Analytical 
grade ammonium acetate and glacial acetic acid were purchased from Sigma Aldrich 
(France). Ultrapure water was freshly obtained before use from a Purelab Prima 7/15/20 - 
Purelab Ultra Mk 2 from Elga (France). Drug-free plasma or tissues homogenates were 
obtained from healthy Sprague Dawley rats (230 – 280 g weight) provided by Janvier 
(France). Trisodium citrate solution was purchased from BD Vacutainer®. 
 
4.2.2 Stock solutions, calibration standards (CS), quality control samples 
(QCS) and internal standards (IS) 
 
Stock solutions of loperamide, elacridar and tariquidar for CS and QCS were prepared 
separately in the mobile phase at a concentration of 1000 µg/mL on each validation day. 
Intermediate solutions were prepared by successive dilutions of the stock solutions in the 
mobile phase. Six calibration standards were prepared by spiking the intermediate solutions 
containing loperamide, elacridar and tariquidar into rat plasma or tissue homogenate to yield 
final concentrations of 1000, 500, 100, 50, 10 and 5 ng/mL. QCS were prepared at 
concentrations of 800, 80 and 8 ng/mL. 
On each day of validation, stock solutions of IS, ketoconazole and chlorpromazine 
hydrochloride were prepared in the mobile phase at 1000 µg/mL and successively diluted in a 
mixture of acetonitrile and tert-butyl methyl ether (1:1). 
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4.2.3 Sample preparation 
 
Prior to chromatographic analysis, 25 µL of the IS solution containing ketoconazole and 
chlorpromazine hydrochloride was added to 100 µL of each plasma or tissue sample. After 
deproteinization with the addition of 800 µL of a mixture of acetonitrile and tert-butyl methyl 
ether (1:1), samples were vortexed for 3 minutes and centrifuged at 5000 g for 10 minutes. 
The upper organic layer was decanted and evaporated to dryness and the residue was 
reconstituted in 100 µL of mobile phase. A volume of 20 µL was injected onto the analytical 
column. The final concentrations of ketoconazole and chlorpromazine hydrochloride were 
100 ng/mL and 25 ng/mL, respectively. All CS, QCS and samples from the pharmacokinetic 
and tissue distribution studies were processed following this same procedure. 
 
4.2.4 Instrumentation: Chromatographic and mass spectrometer 
conditions 
 
Chromatographic analyses were carried out on a Shimadzu High Performance Liquid 
Chromatography/Mass Spectrometer (LCMS-2010EV) equipped with a LC-20AD solvent 
delivery system. Analytes were well separated on a Zorbax Eclipse XDB-C18 (2.1 x 150 mm, 
5.0 µm) column from Agilent Technologies at 50°C using a Millipore Waters oven. The 
mobile phase consisting of ammonium acetate (pH 5.5; 10 mM)-methanol-acetonitrile 
(37.5:40.0:22.5 v/v/v) was delivered in isocratic mode at 0.4 mL/min. An autosampler 360 
from Kontrons Instruments was set to deliver 20 µL.  
Compounds were quantitated using positive electrospray ionization (ESI) in an octapole 
quadrupole mass analyzer with single ion monitoring (SIM) mode at m/z 477 for loperamide, 
m/z 531 for ketoconazole, m/z 564 for elacridar, m/z 647 for tariquidar and m/z 319 for 
chlorpromazine. Nitrogen was used as the nebulizing gas at 1.5 L/min. The curved 
desolvation line (CDL) and heat block temperatures were set at 250°C and 300°C, 
respectively. The detector voltage was 1.5 kV, the interface voltage was -3.5 kV and the CDL 
voltage was 15.0 V. 
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4.2.5 Validation procedure 
 
The current analytical method was validated according to the Guidance for Industry, 
Bioanalytical Method Validation, Food and Drug Administration (FDA) 2001 [16]. 
Selectivity, lower limit of quantification (LLOQ), calibration curve, intra- and inter-day 
accuracy and precision as well as absolute recovery, stability, matrix effects and dilution 
integrity of loperamide, elacridar and tariquidar were evaluated. The influence of hemolyzed 
plasma was also investigated. 
 
4.2.5.1 Selectivity 
 
The selectivity of the method was determined by analyzing six different batches of rat blank 
plasma or tissue homogenates. Samples were prepared as previously described with and 
without addition of both IS. Absence of interference and selectivity should be ensured at the 
LLOQ of loperamide, elacridar and tariquidar and at the working concentrations of each IS. 
 
4.2.5.2 Lower limit of quantification (LLOQ) and calibration curve 
 
To determine the linearity of the assay, six-point calibration curves, a blank sample (whether 
plasma or tissue homogenates), which was not used for linear regression and three sets of 
QCS were analyzed on each of the three validation days. The calibration curves were 
evaluated by linear regression based on the peak area ratio (analyte peak area/IS peak area) (y) 
versus the nominal concentration (x) of each CS. The slopes, intercepts and correlation 
coefficients of the corresponding individual curves were then calculated. The acceptance 
criterion for each back-calculated standard concentration was ± 15% from the nominal 
concentration except for the lowest concentration, where the deviation should not exceed 
20%. 
The LLOQ was defined as the lowest concentration of standard on the calibration curve where 
the analyte peak should be reproducible with both an accuracy and a precision less or equal to 
20%. 
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4.2.5.3 Accuracy and precision 
 
The intra- and inter-day accuracy and precision were evaluated by determining the 
concentrations of loperamide, elacridar and tariquidar in five replicates of each QCS. The 
accuracy was calculated as the ratio of the experimental and the nominal concentrations: 
Accuracy (%) = (experimental concentration/nominal concentration) x 100.  Precision was 
calculated as the coefficient of variation (CV) of the experimental concentrations: CV (%) = 
(standard deviation/mean) x 100. The criteria for acceptability of the data included accuracy 
within ± 15% from the nominal values and precision within ± 15%, except for the LLOQ 
where the accuracy and precision should not exceed 20%. 
 
4.2.5.4 Absolute recovery  
 
Absolute recovery of loperamide, elacridar and tariquidar through the sample preparation 
procedures was investigated by comparing the responses of spiked extracted samples with 
post-extracted spiked samples. Absolute recovery (%) = mean peak area of the analyte in 
spiked and extracted rat sample/mean peak area of the analyte added to post-extracted blank 
rat sample) x 100. Absolute recovery of loperamide, elacridar and tariquidar was evaluated in 
six replicates at three different concentrations and the recovery of IS was determined in a 
similar way except that it was evaluated only at the working concentrations. A 100% recovery 
of each analyte and IS was not required, but the recovery should be consistent, precise and 
reproducible.  
 
4.2.5.5 Stability studies 
 
The stability of loperamide, elacridar and tariquidar and the stability of their IS in rat plasma 
or tissue homogenates was assessed by analyzing five QCS at two concentrations (low and 
high) exposed to different storage times and temperatures. The results were then compared 
with those of freshly prepared QCS. The freeze-thaw stability was assessed after three freeze-
thaw cycles; in each cycle, the samples were frozen at -20°C for 24 hours and thawed to room 
temperature. The short-term stability was determined after incubation of the samples at room 
temperature for 8 hours. The long-term stability was evaluated after storage of the samples at 
-20°C for 2 and 40 days. The post-preparative stability was investigated after storage at 20°C 
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(autosampler temperature) for 24 and 48 hours. The stability of the stock solutions of 
loperamide, elacridar, tariquidar and their respective IS was evaluated after storage at room 
temperature for 6 hours. 
 
4.2.5.6 Matrix effect 
 
The assessment of the absolute matrix effect of loperamide, elacridar and tariquidar and their 
IS was carried out according to the method proposed by Matuszewski [17]. The responses of 
post-extracted spiked samples were compared to the responses of the same concentrations of 
analytes in the mobile phase. Matrix factor = peak area ratio of the analyte added to post-
extracted blank rat sample/peak area ratio of the analyte in the mobile phase. The matrix 
effect was evaluated in six replicates at three different concentrations. A matrix factor greater 
than 1 suggests analyte ion enhancement and a value lower than 1 indicates ion suppression 
due to matrix components. A value equal to 1 suggests no matrix effects. The variability of 
the matrix factor as measured by the CV should be less than 15%.  
 
4.2.5.7 Influence of hemolyzed plasma 
 
The influence of hemolyzed plasma on the quantification of loperamide, elacridar and 
tariquidar was determined by measuring five replicates of spiked QCS at 8 and 800 ng/mL in 
hemolyzed rat plasma. These five replicates were analyzed in the same run with QCS at 8 and 
800 ng/mL in non-hemolyzed rat plasma. The hemolyzed rat plasma was processed as 
previously described for non-hemolyzed rat plasma. Accuracy should be within ± 15% of the 
nominal values and precision should be less than or equal to 15%. 
 
4.2.5.8 Applicability of the analytical method 
 
The applicability of the previously described method was tested for the quantitation of 
loperamide, elacridar and tariquidar during the pharmacokinetic and tissue studies. Briefly, 
Sprague Dawley male rats were randomized into nine groups of twelve animals each. The 
different groups received intravenous loperamide alone at 0.5 mg/kg or in co-administration 
with intravenous elacridar and/or tariquidar. Elacridar and tariquidar were studied as free 
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drugs at 0.5 and 1.0 mg/kg and co-encapsulated in four types of liposomes at a total dose of 
1.0 mg/kg of P-gp modulators.  
In the pharmacokinetic study, blood was collected from rat tail vein 1, 6, 12 and 24 hours 
after every administration. Plasma was obtained by centrifugation of the blood at 2500 g for 5 
min and stored frozen at -20°C until analysis Three rats were used at each time point (n=3). 
In the tissue distribution study, animals were sacrificed at 1, 6, 12 and 24 hours after deep 
anesthesia with sodium pentobarbital (50 mg/kg; intraperitoneal), cardiac perfusion with 
saline and exsanguination. After sacrifice, the whole brain, liver and kidneys were 
immediately frozen at -20°C until analysis analysis. Three rats were used at each time point 
(n=3). See chapter 5. 
 
4.3 Results and discussion 
 
4.3.1 Method development 
 
Based on structural similarities, solubility, recovery efficiency and previous successful data 
[11, 13], ketoconazole showed satisfactory results as IS for loperamide, as did chlorpromazine 
for elacridar and tariquidar (Fig. 1 and 2).  
 
 
 
 
 
 
 
 
 
Figure 1. Chemical structures of loperamide and ketoconazole (IS). 
 
 
 
Loperamide 
C29H33ClN2O2 (477.05) 
 
Ketoconazole  
C26H28Cl2N4O4 (531.44)  
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Figure 2. Chemical structures of elacridar, tariquidar and chlorpromazine (IS). 
 
The main challenge during the method development was the chromatographic separation of 
loperamide, elacridar, tariquidar and their respective IS. Among the various common C18 
columns tested, the Zorbax Eclipse XDB-C18 (2.1 x 150 mm, 5.0 µm) at 50°C was the 
stationary phase with the best sensitivity and resolution. To achieve complete 
chromatographic resolution for each compound, several elution conditions using acetonitrile, 
methanol, buffers with a pH range between 4.0 and 6.0 and a flow rate between 0.2 and 0.5 
mL/min were tested. Moreover, varying the pH of the ammonium acetate buffer was the most 
critical factor because lower pH (4.0 – 5.0) worsened the resolution. Isocratic elution of 
ammonium acetate (pH 5.5; 10 mM)-methanol-acetonitrile (37.5:40.0:22.5 v/v/v) at 0.4 
mL/min was the most suitable mobile phase for the best resolution and least peak tailing of 
each compound. 
To optimize ESI conditions for loperamide, elacridar, tariquidar and for their IS, full scans 
were carried out in both positive and negative SIM modes. Positive mode was chosen over 
negative mode because of its improved signal to noise ratio (S/N) for extracted samples. 
Elacridar  
C34H33N3O5 (563.64)  
 
Tariquidar  
C38H38N4O6 (646.73)  
 
Chlorpromazine 
C17H19ClN2S (318.86) 
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4.3.2 Validation procedure 
 
4.3.2.1 Selectivity 
 
Six samples of plasma, brain, liver and kidneys from six healthy rats receiving no medication 
were extracted and analyzed to discard potential interference from endogenous substances. 
Based on the analysis of drug-free rat plasma, brain, liver and kidneys, endogenous matrix 
components did not interfere with the analytes or with their IS at their respective retention 
times and over the concentration range described herein. Figure 3 shows representative 
chromatograms obtained from rat blank plasma (A), and rat plasma obtained 6 h after 
simultaneous administration of loperamide, elacridar, and tariquidar, at 0.5 mg/kg, each (B). 
 
 
Figure 3. Representative chromatograms for rat blank plasma (A) and plasma sample from a  rat obtained 6 h 
after simultaneous administration of loperamide, elacridar and tariquidar at 0.5 mg/kg, each (B). 
 
4.3.2.2 Lower limit of quantification (LLOQ) and calibration curve 
 
Linear regression of the peak area ratios versus concentrations was fitted over the 
concentration range of 5.0 ng/mL – 1000 ng/mL for loperamide, elacridar and tariquidar in 
plasma and tissues. The mean linear regression equation of the calibration curves and the 
correlation coefficients generated during the validation are summarized in table 1.  
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Table 1: Loperamide, elacridar and tariquidar calibration curve parameters (n=3). 
Tissue Analyte Slope Intercept r2 
Plasma 
Loperamide 0.0306 ± 0.0028 0.0162 ± 0.0023 
≥ 0.9990 Elacridar 0.0105 ± 0.0005 0.0062 ± 0.0014 
Tariquidar 0.0065 ± 0.0011 0.0031 ± 0.0013 
Brain 
Loperamide 0.0267 ± 0.0015 0.0206 ± 0.0056 
≥ 0.9990 Elacridar 0.0108 ± 0.0004 0.0020 ± 0.0009 
Tariquidar 0.0066 ± 0.0018 0.0028 ± 0.0013 
Liver 
Loperamide 0.0307 ± 0.0046 0.0123 ± 0.0027 
≥ 0.9990 Elacridar 0.0129 ± 0.0014 0.0078 ± 0.0025 
Tariquidar 0.0077 ± 0.0018 0.0033 ± 0.0004 
Kidney 
Loperamide 0.0312 ± 0.0029 0.0069 ± 0.0027 
≥ 0.9990 Elacridar 0.0108 ± 0.0002 0.0050 ± 0.0015 
Tariquidar 0.0085 ± 0.0013 0.0037 ± 0.0018 
 
 
The inter-day accuracy of the back-calculated calibration standards in plasma and tissues 
ranged from 93.87 % to 102.39 % for loperamide, from 94.51 % to 105.57 % for elacridar and 
from 96.29 % to 104.41 % for tariquidar. The inter-day precision in plasma and tissues ranged 
from 0.33 % to 8.53 % for loperamide, from 0.24 % to 5.37 % for elacridar and from 0.22 % 
to 7.24 % for tariquidar. These results met the acceptance criteria of no more than 15% 
deviation of standards from nominal concentrations. 
 
Using 100 µL of rat plasma or tissue homogenates, the LLOQ defined as the lowest 
concentration of standard on the calibration curves, was 5.0 ng/mL for loperamide, elacridar 
and tariquidar in plasma, brain, liver and kidneys, which were adequate for the 
pharmacokinetic and tissue distribution studies. The inter-day accuracy and precision obtained 
at the LLOQ are shown in table 2. In all the cases, these values were were within the 
acceptance criteria of no more than 20% deviation for concentrations at the LLOQ. 
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Table 2: Inter-day accuracy and precision for loperamide, elacridar and tariquidar at their LLOQ in rat plasma, 
brain, liver and kidneys (n=3). 
 
 
Numerous methods for quantitation of loperamide in human plasma and biological 
homogenates were developed and have approached the pg/mL scale for the LLOQ, 
unfortunately these LC-MS and LC-MS/MS methods used a volume of at least 500 µL [9-12]. 
The same disadvantage was met with the method of Kemper et al. for the quantitation of 
elacridar using HPLC with fluorescence detection. In that study, the LLOQ was 5.7 ng/mL for 
200 µL of human plasma and 23.0 ng/mL for 50 µL of murine plasma [13]. Hence, the 
method proposed in this paper was amenable to the preclinical and simultaneous 
pharmacokinetic and biodistribution studies of loperamide, elacridar and tariquidar because 
only small volumes of blood can be collected in murine models. 
 
4.3.2.3 Accuracy and precision 
 
Intra- and inter-day accuracy and precision for loperamide, elacridar and tariquidar were 
assessed by extracting and analyzing five replicates of each of the three QCS in each of the 
three validation days. Tables 3 and 4 summarize intra- and inter-day accuracy and precision 
for loperamide and elacridar. These values were within the acceptance criteria of no more 
than ±15% deviation for concentrations above the LLOQ. 
Tissue 
Loperamide Elacridar Tariquidar 
Accuracy 
 (%) 
Precision 
 (%) 
Accuracy 
(%) 
Precision 
(%) 
Accuracy 
(%) 
Precision 
(%) 
Plasma 95.64 3.32 95.32 4.16 99.88 3.30 
Brain 93.87 4.39 95.46 3.47 103.98 7.24 
Liver 102.39 4.05 97.26 4.89 102.44 4.20 
Kidney 98.61 5.97 105.57 4.16 101.51 2.68 
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Table 3: Intra-day precision and accuracy for loperamide, elacridar and tariquidar quantitation in rat plasma, 
brain, liver and kidneys (n=5). 
 
 
 
Tissue 
Nominal  
concentration  
(ng/mL) 
Day 
Loperamide Elacridar Tariquidar 
Accuracy 
(%) 
Precision 
(%) 
Accuracy 
(%) 
Precision 
(%) 
Accuracy 
(%) 
Precision 
(%) 
Plasma 
8 
Day 1 100.98 3.98 99.31 2.93 104.55 5.25 
Day 2 101.83 1.01 104.22 4.13 100.12 4.21 
Day 3 104.33 1.72 100.45 5.29 102.76 3.79 
80 
Day 1 101.99 3.42 101.92 2.50 103.10 2.46 
Day 2 103.23 2.04 99.87 3.68 100.90 3.24 
Day 3 100.52 2.23 100.02 3.92 102.24 4.06 
800 
Day 1 103.25 4.89 99.90 2.88 100.97 2.04 
Day 2 100.95 1.42 99.58 2.80 99.89 4.51 
Day 3 99.08 1.63 100.95 2.38 101.47 1.68 
Brain 
8 
Day 1 99.26 6.46 108.03 2.27 100.00 3.70 
Day 2 107.81 8.28 99.43 3.93 111.92 4.77 
Day 3 102.29 2.25 102.29 4.60 100.76 6.78 
80 
Day 1 102.88 4.83 105.47 2.48 101.58 3.15 
Day 2 102.10 2.88 91.11 3.66 100.83 2.85 
Day 3 101.80 1.80 99.75 2.73 99.18 2.28 
800 
Day 1 103.36 5.03 102.87 2.87 99.66 4.49 
Day 2 102.66 3.35 90.41 2.80 102.41 2.73 
Day 3 101.74 1.71 99.56 0.39 97.07 1.56 
Liver 
8 
Day 1 99.66 5.85 99.65 1.67 98.03 2.38 
Day 2 101.21 2.42 100.78 5.73 106.62 2.08 
Day 3 99.23 5.94 94.73 4.33 103.88 7.39 
80 
Day 1 100.88 4.28 96.20 2.64 101.41 3.04 
Day 2 98.31 3.85 98.99 3.38 103.05 3.49 
Day 3 97.81 6.69 96.33 6.70 103.79 5.07 
800 
Day 1 97.55 2.57 96.89 1.32 100.69 3.53 
Day 2 99.00 2.92 96.35 4.14 99.05 1.23 
Day 3 99.56 1.90 98.09 4.00 100.97 5.51 
Kidney 
8 
Day 1 98.51 8.74 102.64 6.51 101.45 5.19 
Day 2 103.05 5.07 101.76 3.51 108.62 2.53 
Day 3 102.35 1.63 101.63 3.08 100.05 4.98 
80 
Day 1 101.38 4.15 99.95 5.75 100.82 4.71 
Day 2 102.26 2.45 100.50 1.82 105.51 2.84 
Day 3 101.00 3.48 103.02 0.72 103.96 3.43 
800 
Day 1 101.71 3.68 95.46 2.87 100.30 1.55 
Day 2 101.71 1.79 99.35 2.40 102.94 3.34 
Day 3 99.84 4.33 105.59 1.71 102.44 5.29 
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Table 4: Inter-day precision and accuracy for loperamide, elacridar and tariquidar quantitation in rat plasma, 
brain, liver and kidneys (n=15). 
Tissue 
Nominal 
concentration 
(ng/mL) 
Loperamide Elacridar Tariquidar 
Accuracy 
(%) 
Precision 
(%) 
Accuracy 
(%) 
Precision 
(%) 
Accuracy 
(%) 
Precision 
(%) 
Plasma 
8 102.38 2.24 101.33 4.11 102.48 4.42 
80 101.91 2.56 100.60 3.36 102.08 3.25 
800 101.10 2.65 100.15 2.69 100.78 2.74 
Brain 
8 103.12 5.66 103.25 3.76 104.23 5.08 
80 102.26 3.17 98.78 2.96 100.53 2.76 
800 102.58 3.33 97.61 2.02 99.71 2.93 
Liver 
8 100.03 4.74 98.39 3.91 102.84 3.95 
80 99.00 4.94 97.17 4.24 102.75 3.87 
800 98.70 2.46 97.11 3.15 100.24 3.42 
Kidney 
8 101.30 5.15 102.01 4.37 103.37 4.23 
80 101.55 3.36 101.16 2.77 103.43 3.66 
800 101.09 3.27 100.13 2.33 101.89 3.39 
 
4.3.2.4 Absolute recovery  
 
In our study, the use of tert-butyl methyl ether alone for the recovery of elacridar and 
chlorpromazine suggested by Kemper et al. [13] yielded poor recovery values for 
chlorpromazine (chapter 4). However, a mixture of tert-butyl methyl ether and acetonitrile, 
one of the most effective protein precipitants [18], resulted in satisfactory recovery values not 
only for chlorpromazine but also for the other analytes. The mean absolute recovery values 
for each analyte are shown in table 5.  
 
Table 5:  Absolute recovery for loperamide, elacridar, tariquidar and their IS in rat plasma, brain, liver and 
kidneys (n = 15). 
Tissue Loperamide Ketoconazole Elacridar Tariquidar Chlorpromazine 
Plasma 93.19 ± 1.92 92.54 ± 1.47 93.35 ± 3.10 91.64 ± 4.70 91.89 ± 5.20 
Brain 91.07 ± 2.10 90.16 ± 3.71 91.51 ± 0.92 92.41 ± 7.39 92.87 ± 3.45 
Liver 86.43 ± 2.61 88.57 ± 4.23 88.65 ± 3.66 89.28 ± 4.70 87.67 ± 1.26 
Kidney 87.05 ± 4.47 90.97 ± 4.00 85.43 ± 4.03 89.26 ± 3.12 90.38 ± 6.04 
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Previously, Yu et al. reported extraction recovery values for plasma loperamide and 
ketoconazole of 88.4% and 85.6%, respectively, when tert-butyl methyl ether alone was used. 
In addition, Kemper et al. reported extraction recovery values for plasma elacridar and 
chlorpromazine of 86.0% and 91.0%, respectively, when tert-butyl methyl ether alone was 
again used [11, 13]. In this study sample preparation procedure using acetonitrile and tert-
butyl methyl ether (1:1) demonstrated satisfactory and similar recovery values for the analytes 
not only in rat plasma but also in brain, liver and kidneys.   
 
4.3.2.5 Stability studies 
 
The results of the stability tests (Table 6) proved that the analytes of interest were stable 
during sample storage, sample preparation and chromatographic analysis. Furthermore, 
loperamide, elacridar, tariquidar and IS stock solutions proved to be stable at room 
temperature for up to 6 hours. 
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Table 6: Stability of loperamide, elacridar and tariquidar in rat plasma, brain, liver and kidneys (n = 5). 
Tissue 
Loperamide 
Stability test 
LQCS HQCS 
Accuracy (% ) Precision (%) Accuracy (% ) Precision (%) 
Plasma 
Freeze-thaw 3 cycles 103.62 5.32 102.35 3.42 
Short-term 12 hours 99.59 3.21 97.96 2.01 
Long-term 40 days 100.28 5.01 100.25 1.05 
Post-preparative 24 hours 104.01 2.26 101.99 3.24 
Brain 
Freeze-thaw 3 cycles 100.25 7.31 97.63 4.14 
Short-term 12 hours 101.67 2.07 100.86 4.40 
Long-term 40 days 98.62 5.39 101.35 3.65 
Post-preparative 24 hours 104.26 6.04 99.00 2.11 
Liver 
Freeze-thaw 3 cycles 102.36 5.25 99.48 2.69 
Short-term 12 hours 103.58 4.83 98.30 3.01 
Long-term 40 days 100.84 4.00 100.14 3.55 
Post-preparative 24 hours 105.25 5.32 101.27 2.36 
Kidney 
Freeze-thaw 3 cycles 101.52 6.36 97.25 2.07 
Short-term 12 hours 100.20 5.12 99.43 3.76 
Long-term 40 days 102.28 4.23 99.28 2.88 
Post-preparative 24 hours 104.89 4.86 101.21 3.11 
Stock sol. 6 hours 105.51 2.18 102.39 3.23 
Tissue 
Elacridar 
Stability test 
LQCS HQCS 
Accuracy (% ) Precision (%) Accuracy (% ) Precision (%) 
Plasma 
Freeze-thaw 3 cycles 100.26 5.29 101.29 2.56 
Short-term 12 hours 101.54 4.63 102.64 6.01 
Long-term 40 days 99.86 4.16 100.23 3.28 
Post-preparative 24 hours 102.31 2.36 103.68 4.67 
Brain 
Freeze-thaw 3 cycles 107.22 3.45 105.24 3.53 
Short-term 12 hours 104.06 2.69 102.15 5.94 
Long-term 40 days 102.97 6.95 99.68 2.31 
Post-preparative 24 hours 108.93 4.21 103.15 1.98 
Liver 
Freeze-thaw 3 cycles 99.58 7.28 100.26 1.21 
Short-term 12 hours 95.32 3.25 99.21 3.64 
Long-term 40 days 100.52 4.84 94.02 4.09 
Post-preparative 24 hours 102.33 5.30 101.56 0.84 
Kidney 
Freeze-thaw 3 cycles 99.48 3.97 100.28 2.86 
Short-term 12 hours 100.01 4.28 99.63 2.03 
Long-term 40 days 97.10 6.24 96.34 0.42 
Post-preparative 24 hours 101.26 3.64 102.59 2.17 
Stock sol. 6 hours 107.53 1.02 103.54 0.31 
Tissue 
Tariquidar 
Stability test 
LQCS HQCS 
Accuracy (% ) Precision (%) Accuracy (% ) Precision (%) 
Plasma 
Freeze-thaw 3 cycles 102.36 5.61 100.59 3.01 
Short-term 12 hours 100.65 2.36 101.63 2.51 
Long-term 40 days 101.89 4.97 100.88 0.84 
Post-preparative 24 hours 103.57 5.30 103.42 0.62 
Brain 
Freeze-thaw 3 cycles 104.56 8.01 97.59 2.62 
Short-term 12 hours 103.27 5.69 101.73 4.86 
Long-term 40 days 100.51 6.24 99.08 2.07 
Post-preparative 24 hours 106.35 2.85 102.51 0.11 
Liver 
Freeze-thaw 3 cycles 106.68 3.64 100.83 2.04 
Short-term 12 hours 100.37 4.59 99.65 1.86 
Long-term 40 days 97.64 5.66 99.57 3.15 
Post-preparative 24 hours 108.29 5.42 105.24 2.98 
Kidney 
Freeze-thaw 3 cycles 104.21 5.04 101.00 2.36 
Short-term 12 hours 102.62 2.39 99.53 4.85 
Long-term 40 days 103.73 5.43 100.48 3.49 
Post-preparative 24 hours 107.40 4.00 103.69 0.88 
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Stock sol. 6 hours 104.99 2.67 102.87 1.35 
4.3.2.6 Matrix effect 
 
Using the method proposed by Matuszewski [17], the matrix factors obtained for loperamide, 
elacridar and tariquidar are shown in table 7. These values indicated the absence of matrix 
effects is surely due to favorable protein precipitation by acetonitrile [18] and the ability of 
tert-butyl methyl ether to exclude phospholipids found in the matrices [19]. This synergism 
has already been exploited and approved by Bristol-Myers Squibb [20]. In this last document 
the ratio of acetonitrile to tert-butyl methyl ether was 1:3 to ensure elimination of irregular 
emulsions between aqueous and organic interfaces and to modulate the polarity of the 
extraction solvents. In our study, an adjustment of the ratio to 1:1 was made to achieve 
desired recovery values.  
 
Table 7: Matrix effects evaluation for loperamide, elacridar and tariquidar in rat plasma, brain, liver and kidneys 
(n = 18). 
 
Tissue Loperamide Elacridar Tariquidar 
Plasma 104.25  104.31 103.36 
Brain 108.35 102.60 106.52 
Liver 96.73 91.45 94.90 
Kidney 97.83 95.43 92.52 
 
4.3.2.7 Influence of hemolyzed plasma 
 
As depicted in table 8, no influence of hemolyzed rat plasma on the accuracy and precision of 
the method was observed. 
 
Table 8: Influence of hemolyzed plasma on the quantitation of loperamide, elacridar and tariquidar (n = 3). 
 
 
Nominal 
concentration 
(ng/mL) 
Loperamide Elacridar Tariquidar 
Accuracy 
(%) 
Precision 
(%) 
Accuracy 
(%) 
Precision 
(%) 
Accuracy 
(%) 
Precision 
(%) 
8 94.54 1.95 95.6 0.75 99.78 2.04 
800 97.98 0.92 101.4 2.34 101.76 0.99 
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4.3.2.8 Applicability of the analytical method  
 
The aforementioned method was successfully applied to the pharmacokinetic and tissue 
distribution studies of loperamide, elacridar and tariquidar (see: Co-administration of P-gp 
modulators on loperamide pharmacokinetics and brain distribution). The samples which were 
initially above the upper limit of quantification (ULOQ), were analyzed after dilution along 
with QCS treated with the same dilution factor.  
 
4.4 Conclusion 
 
To date, no published method is available for the simultaneous determination of loperamide, 
elacridar and tariquidar in a biological matrix. Therefore, a sensitive, accurate and precise LC-
MS method for the simultaneous determination of the three analytes in rat plasma, brain, liver 
and kidneys using structurally close IS was developed and validated. The method involved 
sample preparation using acetonitrile and tert-butyl methyl ether (1:1), which allowed 
quantitation of loperamide, elacridar and tariquidar with high absolute recovery and without 
interference of matrix components. The advantages of this method include easy sample 
preparation, small sample volumes, high selectivity and a fast run time. This method 
represents a meaningful tool for in vivo pharmacokinetic and tissue distribution studies.  
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5 CO-ADMINISTRATION OF P-GLYCOPROTEIN MODULATORS ON 
LOPERAMIDE PHARMACOKINETICS AND BRAIN DISTRIBUTION 
 
Abstract 
 
The efflux transporter P-glycoprotein, expressed at high levels at the blood-brain barrier, 
exerts a profound effect on the disposition of various therapeutic compounds in the brain. A 
rapid and efficient modulation of this efflux transporter could enhance the distribution of its 
substrates and thereby improve central nervous system pharmacotherapies. This study 
explored the impact of the intravenous co-administration of two P-glycoprotein modulators, 
tariquidar and elacridar, on the pharmacokinetics and brain distribution of loperamide, a P-
glycoprotein substrate probe, in rats. After one hour post-dosing, tariquidar and elacridar, both 
at a dose of 1.0 mg/kg, increased loperamide levels in the brain by 2.3- and 3.5-fold, 
respectively. However, the concurrent administration of both P-glycoprotein modulators, each 
at a dose of 0.5 mg/kg, increased loperamide levels in the brain by 5.8-fold and resulted in the 
most pronounced opioid-induced clinical signs. This phenomenon may be the result of a 
combined non-competitive modulation by tariquidar and elacridar. Besides, the simultaneous 
administration of elacridar and tariquidar did not significantly modify the pharmacokinetic 
parameters of loperamide. This observation potentially allows the concurrent use of low but 
therapeutic doses of P-gp modulators to achieve full inhibitory effects.  
 
Keywords: P-glycoprotein, blood-brain barrier, P-gp modulators, co-administration, synergy.  
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5.1 Introduction 
 
Since its discovery in 1976 [1], P-glycoprotein (P-gp) has been the most extensively studied 
ATP-binding cassette (ABC)-dependent efflux transporter. This protein is often regarded as a 
model to understand the biochemical mechanism of some ABC transport proteins. Two 
factors make P-gp the most critical efflux transporter: (1) its broad substrate specificity which 
results in multidrug resistance (MDR) [2] and (2) the prominent expression of P-gp in most 
excretory and barrier-function tissues [3]. The relevant expression of P-gp at the blood brain 
barrier (BBB) exerts a profound effect on the brain distribution of HIV protease inhibitors, 
anticancer drugs, opioids, some psychotropics and other drugs, which leads to the failure of 
various clinical treatments for brain diseases [3-5]. The inhibition of P-gp-mediated efflux 
could enhance the distribution of these substrates into the brain and therefore improve central 
nervous system (CNS) pharmacotherapies.  
The identification of some P-gp substrates that also had the ability to block the P-gp-mediated 
efflux led to the synthesis of their analogs in order to minimize effects not related to their 
inhibition of P-gp-mediated efflux. Unfortunately, these compounds, known as first- and 
second-generation P-gp modulators, caused undesirable pharmacokinetic profiles due to their 
non-specificity towards the P-gp [6]. With the purpose of avoiding these limitations, third-
generation P-gp modulators have been developed. To be therapeutically effective, these 
compounds should be non-competitive and sufficiently potent to achieve inhibitory effects at 
non-toxic plasma concentrations and sufficiently selective for P-gp to minimize effects on 
overall drug pharmacokinetics [7]. In vivo studies demonstrated that elacridar and tariquidar, 
third-generation P-gp modulators, significantly increased the brain distribution of several P-gp 
substrates without pharmacokinetic interactions [8, 9]. In contrast, recent studies promote the 
use of significantly high doses of these P-gp modulators to efficiently modulate the P-gp-
mediated efflux at the BBB [10]. However, when co-administered with P-gp substrates, these 
doses may be associated with pharmacokinetic interactions and toxic profiles, thus limiting 
the use of these agents. This escalating doses approach could reflect the same drawbacks of 
the first- and second-generation P-gp modulators. 
Unnecessary exposure to P-gp modulators could be minimized and potential drug-related side 
effects might be reduced if, instead of using one P-gp modulator at a high dose, a combination 
of P-gp modulators with different drug binding sites were used at lower and safe doses. 
Martin et al. described the presence of at least four distinct interaction sites on P-gp and the 
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binding of tariquidar to site II (a transport and regulatory site) and elacridar to site IV (an 
exclusive regulatory site) [11]. In the presence of a P-gp substrate, elacridar and tariquidar, 
complex allosteric communication between the binding sites may result in synergistic 
interactions, thus improving the pharmacokinetics and pharmacodynamics of the P-gp 
substrate. The goal of this work was to evaluate the concomitant administration of tariquidar 
and elacridar and the subsequent impact on the pharmacokinetics and brain distribution of 
loperamide in rats after simultaneous intravenous (I.V) administration of the three 
compounds. After effective modulation of the P-gp activity by elacridar and/or tariquidar, 
loperamide, a µ-opioid agonist without central effects, can become a drug that produces 
substantial antinociception. 
 
5.2 Materials and Methods 
 
5.2.1 Materials 
 
Loperamide hydrochloride and tetraglycol were obtained from Sigma Aldrich (France), 
elacridar was synthesized by the Laboratory of Pharmaceutical Chemistry at the University of 
Bonn in Germany and tariquidar was purchased from API Services Inc. (USA). Polyethylene 
glycol 600 (PEG600) was obtained from Interchimie (France). Trisodium citrate solution was 
purchased from BD Vacutainer®80. 
Ketoconazole (internal standard for loperamide) and chlorpromazine hydrochloride (internal 
standard for elacridar and tariquidar), tert-Butyl methyl ether (t-BME), analytical grade 
ammonium acetate and glacial acetic acid were obtained from Sigma Aldrich (France). HPLC 
grade methanol (MeOH) and acetonitrile (ACN) were purchased from Carlo Erba (France). 
Ultrapure water was freshly obtained before use from a Purelab Prima 7/15/20 - Purelab Ultra 
Mk 2 from Elga (France).  
 
5.2.2 Animals 
 
Behavioral observation, pharmacokinetic and brain distribution studies were conducted in 
male Sprague Dawley rats (Janvier, France). All animal experiments were carried out in 
accordance with the recommendations in the Guide for the Care and Use of Laboratory 
Animals (Institute of Laboratory Animal Resources, National Research Council, National 
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Academy of Sciences, USA). All the animals were allowed to acclimate for one week and 
were seven weeks old (230 – 280 g) at the time of the experiment. The animals were 
maintained under a 12-h light/dark cycle and a temperature-controlled environment. Food and 
water were provided ad libitum. The studies were approved by the Institutional Animal Care 
and Use Committee of the University of Franche-Comte. 
 
5.2.3 Drug solutions  
 
The drug solutions were prepared on the day of the experiment. Elacridar was dissolved in 
tetraglycol at an initial concentration of 20 mg/mL. Loperamide and tariquidar were dissolved 
separately in a mixture of saline and PEG600 (3:1) at concentrations of 2 mg/mL. For each 
treatment, loperamide, elacridar and tariquidar solutions were diluted with saline and PEG600 
(3:1). All the solutions were completely transparent indicating the full solubility of 
loperamide and both P-gp modulators in the vehicle (Appendices 1 and 2). 
 
5.2.4 Study design  
 
This study was carried out using a rat model, which is a promising model to predict P-gp- 
based drug-drug interactions at the human BBB [12]. The choice of loperamide as a P-gp 
substrate and its dose was based on its opiate-like behavior, which provides an efficient means 
with which to ascertain the blockage of the P-gp [13]. Because the reported half-maximum 
effective dose (ED50) for tariquidar and elacridar in rats [14] were lethal in co-administration 
with loperamide in our pilot study, the doses of the P-gp modulators were reduced to 0.5 or 
1.0 mg/kg. 
The animals were randomly divided into five experimental groups, each of which received 
loperamide at a dose of 0.5 mg/kg. The co-administration of P-gp modulators was carried out 
as follows: Group I, elacridar 1.0 mg/kg; group II, tariquidar 1.0 mg/kg; group III, elacridar 
1.0 mg/kg plus tariquidar 1.0 mg/kg; group IV, elacridar 0.5 mg/kg plus tariquidar 0.5 mg/kg 
and group V (control group), no P-gp modulator. The different treatments were administered 
via the jugular vein by a single I.V bolus. Groups I, II and III were used to study the influence 
of the co-administration of elacridar and tariquidar on their own plasma and brain distribution. 
Groups I, II, IV and V were used to evaluate the influence of the concurrent administration of 
elacridar and tariquidar on the pharmacokinetics and brain distribution of loperamide. 
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Prior to the pharmacokinetic and tissue distribution studies, all the animals were observed for 
one hour to determine the clinical signs induced by central opiate effects of loperamide.  
Observations were limited to two to three rats at a time to maximize visibility (n=12). The 
clinical signs were established according to previous data [15, 16] and our pilot study. The 
degrees of the clinical signs were scored on a 0 to 3 scale according to the intensity of each 
clinical sign, where 0 = none, 1 = mild, 2 = moderate and 3 = severe (Table 3). Rats that 
displayed a score of 1 or higher on three or more signs were considered to display opioid-
induced behavior.  
In the pharmacokinetic study, blood (̴ 0.25 mL) was serially sampled from the tail vein at 1, 6, 
12 and 24 hours after administration of the different treatments. The blood was collected in 
tubes containing trisodium citrate solution. The plasma was obtained by centrifugation of the 
blood at 2500 x g for 5 minutes and stored frozen at -20°C until analysis. Three rats were used 
at each time point (n=3). 
In the tissue distribution study, animals were sacrificed at 1, 6, 12 and 24 hours after 
administration of the different treatments, following deep anesthesia with sodium 
pentobarbital (50 mg/kg; intraperitoneal), cardiac perfusion with saline and exsanguination. 
After sacrifice, the whole brain was immediately frozen at -20°C until analysis. Three rats 
were used at each time point (n=3). 
The blood and brains were first sampled at 1 hour post-dosing because according to the 
literature, loperamide reaches a pseudoequilibrium between the brain and the plasma at this 
time [12]. The subsequent time points up to 24 hours were selected to determine possible 
drug-drug interactions and a possible extension of the P-gp modulation at the BBB.  
 
5.2.5 Analysis of loperamide, elacridar and tariquidar by Liquid 
Chromatography-Mass Spectrometry (LC-MS) 
 
Loperamide, elacridar and tariquidar in plasma and brain samples were determined by an LC-
MS method that has been validated for specificity, calibration curve, lower limit of 
quantification (LLOQ), accuracy, precision, and recovery according to the FDA guidance for 
bioanalytical method validation [17]. Ketoconazole was used as internal standard for 
loperamide and chlorpromazine for elacridar and tariquidar. 
The chromatographic analyses were carried out on a Shimadzu High Performance Liquid 
Chromatography/Mass Spectrometer LCMS-2010EV equipped with a LC-20AD solvent 
delivery system. The analytes were well separated on a Zorbax Eclipse XDB-C18 2.1 x 150 
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mm, 5.0-µm column from Agilent Technologies at 50°C using a Millipore Waters oven. The 
mobile phase, consisting of 10 mM ammonium acetate (pH 5.5):MeOH:ACN (37.5:40:22.5 
v/v/v), was delivered in isocratic mode at 0.4 mL/min. An autosampler 360 from Kontrons 
Instruments was set at 20 µL. The compounds were quantitated using positive electrospray 
ionization (ESI) in an octupole quadrupole mass analyzer with single ion monitoring (SIM) 
mode at m/z 477 for loperamide, m/z 531 for ketoconazole, m/z 564 for elacridar, m/z 647 for 
tariquidar and m/z 319 for chlorpromazine. Nitrogen was used as the nebulizing gas at 1.5 
L/min. The curved desolvation line (CDL) and heat block temperatures were set at 250°C and 
300°C, respectively. The detector voltage was 1.5 KV, the interface voltage was -3.5 KV and 
the CDL voltage was 15.0 V. 
Frozen brain samples were thawed and homogenized with one volume of water using a Janke 
& Kunkel T45 Ultra-turrax and a Fischer Scientific Vibra-cell homogenizer. Prior to 
chromatographic analysis, 25 µL of the internal standard solution containing ketoconazole 
and chlorpromazine hydrochloride were added to 100 µL of each plasma or homogenate 
sample to yield final concentrations of 100 ng/mL and 25 ng/mL, respectively. After 
deproteinization by addition of 800 µL of a mixture of ACN and t-BME (1:1), the samples 
were vortexed for 3 minutes and centrifuged at 5000 x g for 10 minutes. The upper organic 
layer was decanted and evaporated to dryness and the residue was reconstituted in 100 µL of 
mobile phase. A volume of 20 µL was injected onto the analytical column.  
 
5.2.6 Pharmacokinetic calculations 
 
The pharmacokinetic parameters were calculated by non-compartmental analysis using 
Kinetica™ version 4.0 (Inna Phase Corp., 2001). The area under the concentration-time 
curves (AUC) values was determined using the trapezoidal rule. The half-lives of elimination 
(t1/2) were calculated as ln(2)/K, where K represents the terminal elimination rate constant 
obtained from the slopes of the semilogarithmic plots of the concentration-time profile. The 
mean residence time (MRT) was estimated from AUMC/AUC, where AUMC is the partial 
area under the moment curve. The plasma clearance (CL) was calculated as dose/AUCinf, 
where AUCinf is the AUC from time zero to infinity. The apparent volume of the plasma 
compartment (Vdss) was calculated from dose x MRT/AUCinf. The brain-to-plasma partition 
coefficient (Kp) was calculated as AUCinf-brain/AUCinf-plasma.  
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5.2.7 Statistical Analysis 
 
The statistical analysis was carried out using SigmaStat 3.5 software. Analyses of statistical 
significance between two groups were examined by Student's t-test and between many groups 
by one-way analysis of variance (ANOVA) with the Holm-Sidak post-hoc test. A P < 0.05 
was considered to be significant. Moreover, the variance of the AUCinf in each treatment 
group was estimated according to the Bailer method [18, 19], which is based on the variability 
of the concentrations at each sampling time. A Z-test was used for pairwise comparison of 
AUCs. A P < 0.05 was considered to be significant. 
 
5.3 Results 
 
5.3.1 Analysis of loperamide, elacridar and tariquidar by Liquid 
Chromatography-Mass Spectrometry (LC-MS) 
 
Based on structural similarities, solubility, recovery efficiency and previous successful data 
[20, 21], ketoconazole was a satisfactory internal standard for loperamide, as chlorpromazine 
was for elacridar and tariquidar. The developed LC-MS method described in this manuscript 
was linear over the concentration range 5.0 ng/mL – 1000 ng/mL for all the three analytes, 
loperamide, elacridar and tariquidar (r2 ≥ 0.9990). Using 100 µL of rat plasma or tissue 
homogenate, the validated lower limit of quantification (LLOQ) for each compound was the 
lowest concentration of standard on the calibration curves, 5.0 ng/mL. Intra- and inter-day 
accuracy and precision were within 15% for the three analytes. The specificity of the method 
was confirmed by the absence of interferences from endogenous compounds. In this study, the 
sample preparation procedure using ACN and t-BME (1:1) demonstrated absolute recovery 
values from rat plasma and brain samples higher than 90%, for loperamide, ketoconazole, 
elacridar, tariquidar and chlorpromazine. Furthermore, stability tests demonstrated that the 
analytes were stable under the storage conditions. The current validated method (chapter 4) 
was then used for the simultaneous quantitation of loperamide, elacridar and tariquidar in 
plasma and brain samples. 
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5.3.2 Influence of the co-administration of elacridar and tariquidar on their 
plasma and brain levels 
 
At a first stage, the groups which received elacridar at 1.0 mg/kg and/or tariquidar at 1.0 
mg/kg (groups I, II and III) were used to compare whether the concurrent administration of 
both P-gp modulators influenced their own plasma and brain distributions (Fig 1 and 2). 
No modification in the plasma AUCinf of elacridar alone or co-administered with tariquidar 
(31.9 ± 2.7 vs 32.2 ± 3.4 nmol.h/mL) and in the plasma AUCinf of tariquidar alone or co-
administered with elacridar (37.8 ± 1.9 vs 37.0 ± 2.8 nmol.h/mL) were observed (Table 1). 
These values indicate that the co-administration of these P-gp modulators at 1.0 mg/kg each 
had no observable effects on each other plasma concentrations.  
The elacridar AUCinf for the brain remained unchanged after concurrent administration with 
tariquidar (3.1 ± 0.1 vs 3.6 ± 0.4 nmol.h/g). Vice versa, the tariquidar AUCinf for the brain 
increased from 0.8 ± 0.1 to 1.6 ± 0.1 nmol.h/g (2.0-fold) in the presence of elacridar (Table 
1). This increase was associated with a 2-fold higher Kp for tariquidar. These findings suggest 
that when both P-gp modulators are co-administered, elacridar could interfere with the active 
transport of tariquidar at the BBB.  
 
Table1. Area under the concentration-time curves (AUCinf) and Kp of elacridar and tariquidar 
 
Pharmacokinetic 
parameters 
Elacridar 1.0 mg/kg 
(1773.05 nmol/kg) 
Elacridar 1.0 mg/kg 
(+ Tariquidar 1.0 mg/kg) 
Tariquidar 1.0 mg/kg 
(1545.60 nmol/kg) 
Tariquidar 1.0 mg/kg 
(+ Elacridar 1.0 mg/kg) 
Mean S.D. Mean S.D. Mean S.D. Mean S.D. 
AUCinf-plasma 
(nmol.h/mL) 
31.9 2.7 32.2 3.4 37.8 1.9 37.0 2.8 
AUCinf-brain 
(nmol.h/g) 
3.1 0.1 3.6 0.4 0.8 0.1 1.6* 0.1 
Kp 0.098 0.011 0.115 0.021 0.022 0.003 0.043# 0.007 
 
* Bailler method: Significantly different compared to the group which only received one P-gp modulator, 
whether elacridar at 1.0 mg/kg or tariquidar at 1.0 mg/kg  
# Student's t-test: Significantly different compared to the group which only received one P-gp modulator, 
whether elacridar at 1.0 mg/kg or tariquidar at 1.0 mg/kg  
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Figure 1: Brain concentrations (left axis) and plasma concentrations (right axis) of elacridar after intravenous 
administration of elacridar alone at 1.0 mg/kg (white bars/empty squares) or concurrently administered with 
tariquidar at 1.0 mg/kg (gray bars/full squares). Concentrations are expressed as mean ± standard deviation. 
Concentrations are expressed as mean ± standard deviation. Bars represent the standard deviation. n = 3. 
# Student’s t-test: Significantly different compared to the group which received elacridar at 1.0 mg/kg alone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Brain concentrations (left axis) and plasma concentrations (right axis) of tariquidar after intravenous 
administration of tariquidar alone at 1.0 mg/kg (white bars/empty triangles) or concurrently administered with 
elacridar at 1.0 mg/kg (gray bars/full triangles). Concentrations are expressed as mean ± standard deviation. Bars 
represent the standard deviation. n = 3. 
# Student’s t-test: Significantly different compared to the group which received tariquidar at 1.0 mg/kg alone. 
 
 
 
# 
# 
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5.3.3 Influence of the co-administration of elacridar and tariquidar on 
loperamide plasma levels 
 
To evaluate the effects of the co-administration of both P-gp modulators on loperamide 
pharmacokinetics, the groups which received a total dose of 1.0 mg/kg of P-gp modulators 
(groups I, II, and IV) were compared. Group V served as a control.  
In rats receiving 0.5 mg/kg loperamide alone, the concentration of loperamide in plasma 
(Cmax) after 1 hour (Tmax) was approximately 4.0 %/mL of the administered dose, which 
reflects a rapid metabolism of loperamide during this first hour (Fig. 3, Table 2). The mean 
elimination half-life of a single loperamide administration in this study was 3.6 ± 0.3 hours 
and it was not significantly altered in presence of elacridar and/or tariquidar. Likewise, the 
AUC, MRT, CL and Vdss were not significantly different in any of the treatments using one or 
two P-gp modulators. These results confirmed that neither elacridar nor tariquidar altered the 
pharmacokinetic parameters of loperamide.  
 
 
Table 2. Pharmacokinetic parameter of loperamide 
 
 
# ANOVA: Significantly different compared to the group which received no P-gp modulator. 
## ANOVA: Significantly different compared to the group which received elacridar or tariquidar at 1.0 mg/kg. 
 
 
 
Pharmacokinetic 
parameters 
No P-gp modulator Tariquidar 1.0 mg/kg Elacridar 1.0 mg/kg 
Elacridar 0.5 mg/kg + 
Tariquidar 0.5 mg/kg 
Mean S.D. Mean S.D. Mean S.D. Mean S.D. 
Tmax (h) 1.0 --- 1.0 --- 1.0 --- 1.0 --- 
Cmax  
(ng/mL) 
5052 800 5371 660 5855 626 5756 252 
AUCinf  
(ng.h/mL) 
28900 4554 34365  4800 34409 4306 30627  3492 
t1/2 (h) 3.6  0.3 3.9 0.5 4.9  0.7 4.2  0.2 
MRT (h) 5.0 0.4 5.5 0.3 5.9 0.8 5.0  0.5 
Cl  
(mL/h /Kg) 
4.4 0.7 3.7 0.5 3.4 0.5 4.2 0.5 
Vd  
(mL/Kg) 
22.1 2.6 20.6 3.5 21.7 3.7 20.8 1.0 
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5.3.4 Influence of the co-administration of elacridar and tariquidar on 
loperamide concentrations in the CNS 
 
To evaluate the effects of the co-administration of both P-gp modulators on the brain 
distribution of loperamide, the groups which received a total dose of 1.0 mg/kg of P-gp 
modulators (groups I, II, and IV) were compared. Group V served as a control.  
Previous studies [13, 22] showed that low doses of P-gp modulators and loperamide were 
taken up into the brain. In agreement with these results, in the present study, these doses 
demonstrated sufficient degree of P-gp inhibition at the BBB (Table 3). Immediately after 
administration, a few animals from the loperamide-treated groups which received tariquidar at 
1.0 mg/kg or elacridar at 1.0 mg/kg showed lethargy, piloerection and shallow breathing. 
However, these animals were able to respond if handled, and by 15 minutes post-treatment 
they recovered normal activity. According to our clinical score, 1.0 mg/kg of tariquidar (total 
score = 13) and 1.0 mg/kg of elacridar (total score = 26) slightly promoted the central effects 
of loperamide. More than 50% of the animals from the group that received loperamide co-
administered with elacridar and tariquidar, each at 0.5 mg/kg not only immediately exhibited 
the same clinical signs but also demonstrated whole body tetany and eye protrusion. In 
addition, two of the 12 animals of this group showed the Straub reaction which is 
characterized by the rigidity of the tail, held in an S-shaped curve across the back of the 
animal [23]. These animals recovered normal activity approximately 30 minutes later. These 
clinical signs indicate that the co-administration of the two P-gp modulators (total score = 
102) at a total dose of 1.0 mg/kg significantly potentiated the opioid brain effects of 
loperamide. 
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Table 3. Opioid-induced clinical signs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/n = number of rats displaying these clinical signs/number of rats per group. (n=12). 
The degrees of the clinical signs are scored as 0 = none, 1 = mild, 2 = moderate and 3 = severe. 
Values shown in the degree columns are the mean degree score for each symptom.  
Total score = total sum of N x degree 
Rats that displayed a score of 1 or higher on 3 or more signs were considered to display opioid-induced behavior. 
Clinical signs  
(1 hour post-dose) 
No P-gp modulator Elacridar 1.0 mg/kg Tariquidar 1.0 mg/kg  
Elacridar 0.5 mg/kg + 
Tariquidar 0.5 mg/kg  
N/n degree N/n degree N/n degree N/n degree 
CNS : 
 
 
 
 
 
 
 
 
   Lethargy 0/12 0 6/12 2 4/12 2 9/12 3 
Whole body tetany 0/12 0 0/12 0 0/12 0 9/12 2 
Straub tail 0/12 0 0/12 0 0/12 0 2/12 3 
Piloerection 0/12 0 4/12 1 3/12 1 7/12 2 
Pulmonary : 
 
 
 
 
 
 
 
 
Shallow breathing 0/12 0 5/12 2 2/12 1 9/12 3 
Eyes : 
 
 
 
 
 
 
 
 
Eye protrusion 0/12 0  0/12 0 0/12 0 5/12 2 
Total score 0 26 13 102 
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The administration of loperamide alone resulted in very low levels (10.53 ± 0.51 ng/g) in the 
brain after 1 hour (Fig. 3). However, the co-administration of the P-gp modulators 
significantly increased the concentration of loperamide in the brain at this time point. 
Tariquidar and elacridar, each at 1.0 mg/kg increased loperamide levels in the brain by 2- 
(22.48 ± 2.93 ng/g) and 3-fold (33.84 ± 3.95 ng/g), respectively. However, the concurrent 
administration of both P-gp modulators at half doses increased the concentration of 
loperamide in the brain by 5-fold (47.26 ± 6.09 ng/g). After 6 hours, loperamide was 
undetectable in brains from animals that had not received either P-gp modulator and close to 
10.0 ng/g in the other three groups. After 12 and 24 hours, loperamide was not detectable in 
any group. The differences in the loperamide AUCinf for the brains and the Kp values were 
even more marked than the effects at the individual times (Table 4).  All these results suggest 
a greater inhibition of the P-gp-mediated efflux by elacridar than by tariquidar and a possible 
synergistic effect of both P-gp modulators when they are co-administered. 
 
Table 4. Brain distribution of loperamide 
 
 
 
 
*Bailer method: Significantly different compared to the group which received no P-gp modulator. 
**Bailer method: Significantly different compared the group which received elacridar or tariquidar at 1.0 mg/kg.   
#ANOVA: Significantly different compared to the group which received no P-gp modulator. 
##ANOVA: Significantly different compared to the group which received elacridar or tariquidar at 1.0 mg/kg. 
 
Pharmacokinetic 
parameters 
No P-gp modulator Tariquidar 1.0 mg/kg Elacridar 1.0 mg/kg 
Elacridar 0.5 mg/kg + 
Tariquidar 0.5 mg/kg 
Mean S.D. Mean S.D. Mean S.D. Mean S.D. 
AUCinf  
(ng.h/g) 
10.5 0.5 124.5* 20.1 142.3* 15.8 
160.5* 
** 
16.2 
Kp 0.0004 0.0001 0.0037# 0.0009 0.0042# 0.0004 
0.0061# 
## 
0.0002 
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Figure 3 : Brain concentrations (left axis) and plasma concentrations (right axis) of loperamide after intravenous 
administration of loperamide alone at 0.5 mg/kg (white bars/rhombus) or concurrently administered with 
tariquidar at 1.0 mg/kg (light gray bars/triangles), or with elacridar at 1.0 mg/kg (dark gray bars/squares) or with 
tariquidar at 0.5 mg/kg plus elacridar at 0.5 mg/kg (black bars/circles).  Bars represent the standard deviation. n 
= 3. 
#ANOVA: Significantly different compared to the concentration of loperamide in the brain (ng/g) from the group 
which received no P-gp modulator. 
##ANOVA: Significantly different compared to the concentration of loperamide in the brain (ng/g) from the 
group which received elacridar or tariquidar at 1.0 mg/kg. 
 
 
5.4 Discussion 
 
Given that the use of relatively high doses of the third-generation P-gp modulators [24] may 
be limited by the same drawbacks of the first- and second-generation P-gp modulators, this 
study evaluated the potential of combining the administration of two P-gp modulators to see 
the influence on the efflux activity of the P-gp at the BBB.  
The co-administration of elacridar and tariquidar did not significantly increase the plasma 
concentrations of each agent relative to the values obtained for administration of the single 
agents. Their respective AUCs suggest that at the doses used in the current work, neither P-gp 
modulator interferes with the elimination pathway of the other. The Kp obtained for 
individual doses of elacridar and tariquidar are low due to the low concentrations of either P-
gp modulator in the brain. These results contrast with prior studies that showed that the levels 
of tariquidar and elacridar were much higher in the brain than in the plasma [14, 25], but those 
experiments utilized between 3.0- and 15-fold higher doses of P-gp modulators compared to 
# 
# 
# ## 
 
# 
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the current study. These differences were properly explained before [22, 26],  where murine 
models revealed that at higher doses of elacridar, a higher distribution of the P-gp modulator 
was attained in the brain. For instance, at 1 hour post-injection, the B/P ratio of elacridar 
increased from  ̴ 0.4 at 0.5 mg/kg to  ̴ 5.2 at 2.5 mg/kg [26]. This dose-dependent distribution 
relationship was also observed for tariquidar [27]. A supplementary explanation for the low 
brain distribution of elacridar and tariquidar in this study is based on the pharmacokinetic 
behavior of these compounds at low doses. At nanomolar doses, both P-gp modulators are 
actively transported not only by the P-gp but also by the breast cancer resistance protein 
(BCRP) at the BBB [27]. Thus, the amount transported by these two proteins would be higher 
than the amount that arrives to the brain by passive diffusion, resulting in increased plasma 
concentrations and decreased brain concentrations of these compounds. Nevertheless, when 
the two compounds are co-administered, elacridar may reduce or delay the active transport of 
tariquidar by both proteins [28], thus significantly increasing the Kp of tariquidar. An 
important issue to consider when comparing the distribution of low doses of P-gp modulators 
in the brain is the species differences in P-gp transport activity, which appear to be substrate-
dependent [29]. It was found that several chemical entities which were P-gp substrates in mice 
were also P-gp substrates in rats, but the brain distribution of these compounds is not always 
the same in both species. In one clear example, while the Kp of N-desmethyl-venlafaxine was 
the same in mice and rats, the Kp of risperidone was 2.36-fold higher in mice than in rats [30]. 
These data can also account for the higher brain distribution of relative low doses of P-gp 
modulators in mice compared to our rat model. 
To evaluate the effects of the co-administration of both P-gp modulators at a total dose of 1.0 
mg/kg on P-gp activity, loperamide was chosen as a P-gp substrate probe. The mean half-life 
of loperamide was 3.6 ± 0.3 h, which is different from a previous study [15], where less than 
1.0 %/mL of the intravenous administered dose of loperamide was monitored at 5 minutes 
post-dosing. This difference can be attributed to the low solubility of loperamide in the 
vehicle used in that study. However, our Kp values of loperamide are more in agreement with 
another study, where the Kp(0-1h) of the µ-opioid agonist was 0.006 [13]. In the current 
investigation, the half-life as well as the AUC, MRT, CL and Vdss were not significantly 
modified when loperamide was co-administered with elacridar or tariquidar or both P-gp 
modulators at a total dose of 1.0 mg/kg. The lack of alterations in the pharmacokinetic 
parameters of loperamide in the different groups confirms the minimal modulation on the 
cytochrome P4503A4 by elacridar and tariquidar [9]. This cytochrome plays a predominant 
role in the metabolism of loperamide [31, 32]. Previously, different models showed that even 
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higher doses of tariquidar and elacridar did not significantly change the pharmacokinetics of 
the P-gp substrates [8, 9].  
Therefore, the increase of loperamide levels in the brain could not be explained by the modest 
increase of loperamide in plasma. Instead, it was likely due to the efficient modulation of the 
P-gp at the BBB by tariquidar and elacridar. The clinical signs noticed in the observation 
phase are in line with the opiate effects [23] when loperamide at an oral dose of 10 mg/kg was 
administered to Mdr1a knockout rats (SAGE Mdr1a) [15], a standard for the complete 
blockage of the P-gp at the BBB. These observations suggest an important and extremely 
rapid distribution of the P-gp modulators in the brain and an immediate modulation of the P-
gp at the BBB. After one hour of administration, tariquidar or elacridar, each at 1.0 mg/kg, 
increased loperamide levels in the brain by 2.3- and 3.5-fold, respectively, thus showing that 
even at relatively low doses, elacridar is more potent than tariquidar. These results are 
consistent with precedent studies [9, 14], where the authors used BBB mice and rat models to 
show that the ED50 of elacridar is between 2- and 3-fold lower than the ED50 of tariquidar. 
Nevertheless, the most significant finding in this investigation was that the concurrent 
administration of both P-gp modulators at half doses increased the concentration of 
loperamide in the brain by 5-fold. A suitable explanation for this lies on the non-competitive 
activity of tariquidar and elacridar towards the P-gp, which means that both P-gp modulators 
can independently and simultaneously bind the P-gp on distinct drug binding sites [11]. 
Equilibrium and kinetic radioligand binding assays allowed to determine the presence of at 
least four distinct drug interaction sites on P-gp. Sites I, II and III were classified as sites for 
transport because they interacted with P-gp substrates such as vinblastine, paclitaxel, 
rhodamine 123 and Hoechst 33342. Site II could also interact with some P-gp modulators 
such as tariquidar. In contrast, site IV was classified as a regulatory site because only P-gp 
modulators such as elacridar could interact with this site [11]. Although site IV could 
allosterically communicate in a negative heterotropic manner with the site II, the dissociation 
rate of [3H]XR9576, an analog of tariquidar, was significantly slower than that of the P-gp 
substrate [3H]vinblastine [33]. Thus, despite the active transport, it appears that both P-gp 
modulators were able to bind the P-gp at their corresponding drug binding sites and the 
complex allosteric communication resulted in a possible synergistic interaction. Nevertheless, 
the dose-limiting opioid effects of loperamide preclude assessing this strategy with higher 
doses of loperamide co-administered with higher doses of the P-gp modulators. Taking into 
account that synergism can be different at different dose levels [34]; these preliminary 
synergistic effects should be further confirmed using radiolabelled [3H or 14C] loperamide 
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associated to higher doses of P-gp modulators. Moreover, many other P-gp substrates with 
different therapeutic effects and several doses of elacridar and tariquidar remain to be 
explored and extrapolated to different species to define the synergistic interaction between 
both P-gp modulators. The synergistic phenomenon observed herein resulted in strong 
pharmacodynamic effects by loperamide, a potent CNS agent. However, this approach could 
be restricted in infectious or cancer diseases, where high brain concentrations of the 
therapeutic agents are needed and a synergism at high effect levels is more relevant than at 
low effect levels [34]. Other P-gp modulators can also be used for these studies, provided that 
the steric hindrance of one does not affect the binding of the other. 
Since this preliminary study support the synergistic modulation of P-gp using low doses of 
elacridar and tariquidar, this approach may represent a potential step forward to avoid the use 
of high, nearly toxic doses of P-gp modulators without significant pharmacokinetics 
interactions. Furthermore, because the distribution and the permanence of these P-gp 
modulators in the brain are dose-dependent, the rapid decrease of the P-gp modulators in the 
brain as observed in this work represents an advantage. Our approach could avoid the entry of 
harmful compounds after a long-lasting P-gp inhibition at the BBB. 
 
104 
 
References 
 
[1] R.L. Juliano, V. Ling, A surface glycoprotein modulating drug permeability in Chinese 
hamster ovary cell mutants, Biochim Biophys Acta, 455 (1976) 152-162. 
[2] S.V. Ambudkar, S. Dey, C.A. Hrycyna, M. Ramachandra, I. Pastan, M.M. Gottesman, 
Biochemical, cellular, and pharmacological aspects of the multidrug transporter, Annu Rev 
Pharmacol Toxicol, 39 (1999) 361-398. 
[3] W. Loscher, H. Potschka, Role of drug efflux transporters in the brain for drug disposition 
and treatment of brain diseases, Prog Neurobiol, 76 (2005) 22-76. 
[4] K. Linnet, T.B. Ejsing, A review on the impact of P-glycoprotein on the penetration of 
drugs into the brain. Focus on psychotropic drugs, Eur Neuropsychopharmacol, 18 (2008) 
157-169. 
[5] L. Varatharajan, S.A. Thomas, The transport of anti-HIV drugs across blood-CNS 
interfaces: summary of current knowledge and recommendations for further research, 
Antiviral Res, 82 (2009) A99-109. 
[6] G. Ecker, P. Chiba, Structure-activity-relationship studies on modulators of the multidrug 
transporter P-glycoprotein--an overview, Wien Klin Wochenschr, 107 (1995) 681-686. 
[7] B.D. Anderson, M.J. May, S. Jordan, L. Song, M.J. Roberts, M. Leggas, Dependence of 
nelfinavir brain uptake on dose and tissue concentrations of the selective P-glycoprotein 
inhibitor zosuquidar in rats, Drug Metab Dispos, 34 (2006) 653-659. 
[8] M. Hubensack, C. Muller, P. Hocherl, S. Fellner, T. Spruss, G. Bernhardt, A. Buschauer, 
Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in 
nude mice, J Cancer Res Clin Oncol, 134 (2008) 597-607. 
[9] E.F. Choo, D. Kurnik, M. Muszkat, T. Ohkubo, S.D. Shay, J.N. Higginbotham, H. 
Glaeser, R.B. Kim, A.J. Wood, G.R. Wilkinson, Differential in vivo sensitivity to inhibition 
of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier, J Pharmacol Exp 
Ther, 317 (2006) 1012-1018. 
[10] M. Bauer, M. Zeitlinger, D. Todorut, M. Bohmdorfer, M. Muller, O. Langer, W. Jager, 
Pharmacokinetics of Single Ascending Doses of the P-Glycoprotein Inhibitor Tariquidar in 
Healthy Subjects, Pharmacology, 91 (2013) 12-19. 
[11] C. Martin, G. Berridge, C.F. Higgins, P. Mistry, P. Charlton, R. Callaghan, 
Communication between multiple drug binding sites on P-glycoprotein, Mol Pharmacol, 58 
(2000) 624-632. 
105 
 
[12] P. Hsiao, J.D. Unadkat, P-glycoprotein-based loperamide-cyclosporine drug interaction 
at the rat blood-brain barrier: prediction from in vitro studies and extrapolation to humans, 
Mol Pharm, 9 (2012) 629-633. 
[13] I.A. Elkiweri, Y.L. Zhang, U. Christians, K.Y. Ng, M.C. Tissot van Patot, T.K. 
Henthorn, Competitive substrates for P-glycoprotein and organic anion protein transporters 
differentially reduce blood organ transport of fentanyl and loperamide: pharmacokinetics and 
pharmacodynamics in Sprague-Dawley rats, Anesth Analg, 108 (2009) 149-159. 
[14] C. Kuntner, J.P. Bankstahl, M. Bankstahl, J. Stanek, T. Wanek, G. Stundner, R. Karch, 
R. Brauner, M. Meier, X. Ding, M. Muller, W. Loscher, O. Langer, Dose-response assessment 
of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat 
blood-brain barrier using (R)-[(11)C]verapamil PET, Eur J Nucl Med Mol Imaging, 37 (2010) 
942-953. 
[15] M.J. Zamek-Gliszczynski, D.W. Bedwell, J.Q. Bao, J.W. Higgins, Characterization of 
SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, 
sulfasalazine, and carboxydichlorofluorescein pharmacokinetics, Drug Metab Dispos, 40 
(2012) 1825-1833. 
[16] A. Pinelli, S. Trivulzio, Quantitative evaluation of opioid withdrawal signs in rats 
repeatedly treated with morphine and injected with naloxone, in the absence or presence of 
the antiabstinence agent clonidine, J Pharmacol Toxicol Methods, 38 (1997) 117-131. 
[17] F.D.A.U.S.D.o.H.a.H. Services., Guidance for Industry: Bioanalytical Method 
Validation, (2001). 
[18] A.J. Bailer, Testing for the equality of area under the curves when using destructive 
measurement techniques, J Pharmacokinet Biopharm, 16 (1988) 303-309. 
[19] J. Yuan, Estimation of variance for AUC in animal studies, J Pharm Sci, 82 (1993) 761-
763. 
[20] J.H. Yu, H.J. Kim, S. Lee, S.J. Hwang, W. Kim, C.J. Moon, LC-MS determination and 
bioavailability study of loperamide hydrochloride after oral administration of loperamide 
capsule in human volunteers, J Pharm Biomed Anal, 36 (2004) 421-427. 
[21] E.M. Kemper, B. Jansen, K.R. Brouwer, J.H. Schellens, J.H. Beijnen, O. van Tellingen, 
Bioanalysis and preliminary pharmacokinetics of the acridonecarboxamide derivative 
GF120918 in plasma of mice and humans by ion-pairing reversed-phase high-performance 
liquid chromatography with fluorescence detection, J Chromatogr B Biomed Sci Appl, 759 
(2001) 135-143. 
[22] K. Kawamura, T. Yamasaki, F. Konno, J. Yui, A. Hatori, K. Yanamoto, H. Wakizaka, 
M. Takei, Y. Kimura, T. Fukumura, M.R. Zhang, Evaluation of limiting brain penetration 
related to P-glycoprotein and breast cancer resistance protein using [(11)C]GF120918 by PET 
in mice, Mol Imaging Biol, 13 (2011) 152-160. 
106 
 
[23] D.L. Bilbey, H. Salem, M.H. Grossman, The anatomical basis of the straub phenomenon, 
Br J Pharmacol Chemother, 15 (1960) 540-543. 
[24] N.N. Salama, E.J. Kelly, T. Bui, R.J. Ho, The impact of pharmacologic and genetic 
knockout of P-glycoprotein on nelfinavir levels in the brain and other tissues in mice, J Pharm 
Sci, 94 (2005) 1216-1225. 
[25] J.P. Bankstahl, C. Kuntner, A. Abrahim, R. Karch, J. Stanek, T. Wanek, W. Wadsak, K. 
Kletter, M. Muller, W. Loscher, O. Langer, Tariquidar-induced P-glycoprotein inhibition at 
the rat blood-brain barrier studied with (R)-11C-verapamil and PET, J Nucl Med, 49 (2008) 
1328-1335. 
[26] R. Sane, S. Agarwal, R.K. Mittapalli, W.F. Elmquist, Saturable active efflux by p-
glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear 
distribution of elacridar to the central nervous system, J Pharmacol Exp Ther, 345 (2013) 111-
124. 
[27] J.P. Bankstahl, M. Bankstahl, K. Romermann, T. Wanek, J. Stanek, A.D. Windhorst, M. 
Fedrowitz, T. Erker, M. Muller, W. Loscher, O. Langer, C. Kuntner, Tariquidar and elacridar 
are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a 
small-animal positron emission tomography and in vitro study, Drug Metab Dispos, 41 (2013) 
754-762. 
[28] P. Kannan, K.R. Brimacombe, W.C. Kreisl, J.S. Liow, S.S. Zoghbi, S. Telu, Y. Zhang, 
V.W. Pike, C. Halldin, M.M. Gottesman, R.B. Innis, M.D. Hall, Lysosomal trapping of a 
radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET, Proc 
Natl Acad Sci U S A, 108 (2011) 2593-2598. 
[29] J.H. Lin, M. Yamazaki, Role of P-glycoprotein in pharmacokinetics: clinical 
implications, Clin Pharmacokinet, 42 (2003) 59-98. 
[30] C. Bundgaard, C.J. Jensen, M. Garmer, Species comparison of in vivo P-glycoprotein-
mediated brain efflux using mdr1a-deficient rats and mice, Drug Metab Dispos, 40 (2011) 
461-466. 
[31] K.A. Kim, J. Chung, D.H. Jung, J.Y. Park, Identification of cytochrome P450 isoforms 
involved in the metabolism of loperamide in human liver microsomes, Eur J Clin Pharmacol, 
60 (2004) 575-581. 
[32] A.S. Kalgutkar, H.T. Nguyen, Identification of an N-methyl-4-phenylpyridinium-like 
metabolite of the antidiarrheal agent loperamide in human liver microsomes: underlying 
reason(s) for the lack of neurotoxicity despite the bioactivation event, Drug Metab Dispos, 32 
(2004) 943-952. 
[33] C. Martin, G. Berridge, P. Mistry, C. Higgins, P. Charlton, R. Callaghan, The molecular 
interaction of the high affinity reversal agent XR9576 with P-glycoprotein, Br J Pharmacol, 
128 (1999) 403-411. 
107 
 
[34] T.C. Chou, Theoretical basis, experimental design, and computerized simulation of 
synergism and antagonism in drug combination studies, Pharmacol Rev, 58 (2006) 621-681. 
 
 
 
 
 
 
 
  
108 
 
6 LIPOSOMES CO-LOADED WITH ELACRIDAR AND TARIQUIDAR TO 
MODULATE THE P-GLYCOPROTEIN AT THE BLOOD-BRAIN BARRIER 
 
Abstract 
 
The present study aimed to prepare four liposomal formulations co-loaded with elacridar and 
tariquidar to overcome the P-glycoprotein-mediated efflux at the blood-brain barrier. Their 
pharmacokinetics and brain distribution as well as their impact on the P-glycoprotein 
substrate, loperamide, were compared to the co-administration of free elacridar plus free 
tariquidar. After intravenous administration in rats, elacridar and tariquidar in conventional 
and poly(ethylene glycol)-COOH-coated liposomes were rapidly cleared from the 
bloodstream. Their low levels in the brain did not improve the brain distribution of 
loperamide. Elacridar and tariquidar in poly(ethylene glycol)-OCH3-coated liposomes 
exhibited 4.1 and 1.9 longer half-lives and 4.8- and 6.1-fold higher brain distribution than free 
elacridar and free tariquidar, respectively. This resulted in 2.1-fold higher levels of 
loperamide in the brain. The conjugation of OX26 F(ab’)2 fragments to poly(ethylene glycol)-
OCH3-coated liposomes increased the brain uptake of elacridar and tariquidar  by 9.8- and 
11.8-fold respectively. Consequently, the brain levels of loperamide increased by 4.4-fold. 
Moreover, the pharmacokinetic parameters and the tissue distribution of loperamide were not 
modified by the OX26 F(ab’)2 immunoliposomes. Thus, this formulation represents a 
promising tool to modulate the P-glycoprotein-mediated efflux at the blood-brain barrier and 
improve the brain uptake of any P-glycoprotein substrate which is intended to treat central 
nervous system diseases. 
 
Keywords: P-glycoprotein, blood-brain barrier, immunoliposomes, co-encapsulation, P-
glycoprotein modulators. 
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6.1 Introduction 
 
Drug uptake into the brain depends on a variety of factors, including the blood-brain barrier 
(BBB) and the expression of drug efflux transporters at this barrier. These transporters, 
specially the P-glycoprotein (P-gp), efficiently removes various drugs from the central 
nervous system (CNS), limiting their brain uptake [1, 2]. Therefore the overcoming of the P-
gp at the BBB has become an imperative for the treatment of brain diseases.  
The development of third-generation P-gp modulators, which directly inhibit the transport of 
P-gp substrates, has been a promising approach to circumvent the P-gp activity [3]. Recent 
studies based on two third-generation P-gp modulators, elacridar and tariquidar [4, 5], suggest 
high doses of these compounds to efficiently modulate the P-gp at the BBB [6]. However, 
when co-administered with P-gp substrates, these high doses may be associated with 
pharmacokinetic interactions and toxic profiles, thus limiting the use of these compounds. 
Another non-invasive strategy emphasizes the potential of drug delivery systems (DDSs). 
This approach is based on the encapsulation of drugs, which masks them from the biological 
environment and avoid a direct interaction with the P-gp [7]. Among them, liposomes have 
been the most studied due to their composition, which makes them biocompatible, 
biodegradable and less toxic [8]. The incorporation of PEG-lipid derivatives within the bilayer 
of conventional liposomes prolongs considerably the liposomal half-life by steric stabilization 
and reduces the reticuloendothelial system (RES) uptake [9]. Nevertheless, an increased 
liposomal drug accumulation in the brain could be achieved with targeted liposomes. This 
involves the coupling of targeting moieties such as monoclonal antibodies (MAb) or their 
fragments (Fab’, F(ab’)2) at the distal ends of the PEG chains [10]. These immunoliposomes 
are then able to target the brain using the biochemical transport systems at the BBB; among 
them the transferrin transcytosis system [11]. The transferrin receptor (TfR) is over-expressed 
on the brain capillary endothealial cells (BCECs) and is widely used for drug targeting to the 
BBB [12]. The most successful studied TfR-targeted monoclonal antibody is OX26 [13, 14], 
which does not bind the TfR on the transferrin binding site but uses another epitope [15]. 
Since the whole OX26 antibody activates the Fc receptor-mediated phagocytosis and the 
classical pathway of the complement system [16], the coupling of the Fab’ fragments instead 
of the whole antibody was used as an alternative to prolong the vascular residence time of the 
DDSs [17]. However, at the same density, the targeting across the BBB using OX26 
nanocarriers demonstrated to be more efficient than that achieved with OX26 
Fab’nanocarriers [17]. We hypothesize that by maintaining the two binding sites of the 
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antibody, F(ab’)2 fragments, the brain targeting might be in the same rate that the observed 
with the whole antibody but avoiding the activation of the immune system. 
In this light, we aimed to develop OX26 F(ab’)2 immunoliposomes to simultaneously increase 
the delivery of elacridar and tariquidar across the BBB. For this purpose, it was necessary to 
find the right balance between the vascular stability of the DDS and an effective but transient 
modulation of the P-gp at the BBB. To select the formulation that fits better the 
aforementioned properties for further development of immunoliposomes, three types of 
liposomes co-loaded with elacridar and tariquidar were assessed: Conventional, PEGylated 
with DSPE-PEG2000-COOH and PEGylated with DSPE-PEG2000-OCH3 liposomes. The rapid 
opsonization of conventional liposomes led to their destabilization and the leakage of 
elacridar and tariquidar which was not enough to modulate the P-gp at the BBB. It was 
expected that in DSPE-PEG2000-COOH liposomes, the negative surface charge of the 
carboxylic acid could counterbalanced the long circulating properties conferred by PEG to 
facilitate an effective but short P-gp modulation. However, the low brain uptake of elacridar 
and tariquidar indicated that these negatively charged liposomes were cleared from the 
bloodstream before than they could release both P-gp modulators. In contrast, DSPE-PEG2000-
OCH3 liposomes significantly increased the plasma concentrations of elacridar and tariquidar 
as well as their brain distribution in comparison to the free form of both P-gp modulators. 
Hence immunoliposomal development was carried out with DSPE-PEG2000-OCH3. As steric 
hindrance of the PEG chains may interfere with the antibody moieties recognition by the 
targeted tissue, we proposed the functionalization of liposomes with two PEG chain lengths, 
DSPE-PEG2000-OCH3 and DSPE-PEG5000-COOH. While DSPE-PEG2000-OCH3 confers long 
circulating properties, DSPE-PEG5000-COOH was used as linker to graft the OX26 moieties. 
The brain distribution of free loperamide concurrently administered with these DDSs was 
determined, as an in vivo probe of full blockage of the P-gp the BBB. Results were compared 
with the concurrent administration of both free P-gp modulators associated with free 
loperamide.  
 
6.2 Materials and Methods 
 
6.2.1 Materials 
 
Loperamide hydrochloride was obtained from Sigma Aldrich (France), elacridar was 
synthesized by the Laboratory of Pharmaceutical Chemistry, University of Bonn, Germany 
111 
 
and tariquidar was purchased from API Services Inc. (USA). 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethyleneglycol)-2000] (ammonium salt) (DSPE-PEG2000), 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[carboxy(polyethyleneglycol)-2000] (ammonium salt) 
(DSPE-PEG2000-COOH), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[carboxy(polyethyleneglycol)-5000] (ammonium salt) (DSPE-PEG5000-COOH) were supplied 
by Coger (France). OX26 and the micro BCATM protein assay kit were purchased from 
Fischer Thermo Scientific (France). N-(3-dimethylaminopropyl)-N’ethyl-carbodiimide 
hydrochloride (EDC), N-hydroxysulfosuccinimide (sulfo-NHS) and 2-(N-
morpholino)ethanesulfonic acid (MES), ketoconazole (internal standard for loperamide) and 
chlorpromazine hydrochloride (internal standard for elacridar and tariquidar), tert-Butyl 
methyl ether (t-BME), analytical grade ammonium acetate and glacial acetic acid were 
obtained from Sigma Aldrich (France). Glycine was purchased from Fluka (France) and 
Trisodium citrate solution was from BD Vacutainer®80. Polyethylene glycol 600 (PEG600) 
was obtained from Interchimie (France). HPLC grade methanol and acetonitrile were 
purchased from Carlo Erba (France). Ultrapure water was freshly obtained before use from a 
Purelab Prima 7/15/20 - Purelab Ultra Mk 2 from Elga (France). All the other reagents were 
purchased from Sigma Aldrich (France). 
 
6.2.2 Preparation of OX26 F(ab’)2 fragments 
 
OX26 F(ab’)2 fragments generation and subsequent purification was carried out using the 
Thermo Scientific Pierce F(ab’)2 preparation kit according to the manufacturer procedure. 
Briefly, 2.75 mL of the antibody at a concentration of 1 mg/mL in 20 mM sodium acetate, pH 
4.4 was added to the equilibrated immobilized pepsin. The mixture was incubated at 37°C for 
4 hours with gentle shaking. The F(ab’)2 fragments were then separated from undigested 
antibody and Fc fragments by affinity chromatography with immobilized protein A column  
with the manufacturer IgG elution buffer, pH 2.8. Finally, centrifugation at 1000 x g using 
Ultra 30 K centrifugal filters was performed to remove the small Fc fragments.   
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6.2.3 Preparation of liposomes 
 
In this study, four types of liposomes co-loaded with elacridar and tariquidar were prepared: 
Conventional liposomes (EL-TAR-CL), PEGylated with DSPE-PEG2000-COOH (EL-TAR-
COOHL), PEGylated with DSPE-PEG2000-OCH3 long circulating liposomes (EL-TAR-LCL) 
and OX26 F(ab’)2 immunoliposomes (EL-TAR-IL). The four types of liposomes were 
prepared by thin film hydration method followed by sonication [18]. Briefly, DMPC alone or 
along with DSPE-PEG2000COOH, or DSPE-PEG2000-OCH3 or DSPE-PEG2000-OCH3 and 
DSPE-PEG5000-COOH (Table 1) were weighted and dissolved in chloroform. In all the cases, 
tariquidar and elacridar were added to chloroform along with lipids. Combined amount of 
equimolar quantities of tariquidar and elacridar was kept at 10.0% (w/w) final lipids. The 
organic solvent was removed under a nitrogen stream to form a thin film, which was 
subjected to freeze-drying (Heto Lyolab 3000) overnight to remove any trace of the organic 
phase. The dried lipid film was then hydrated at 40°C with phosphate buffer solution (PBS) 
pH 7.4, or with MES buffer in the case of immunoliposomes, to obtain a final phospholipid 
concentration of 10 µmol/mL. The hydration was followed by a 15 minutes bath sonication 
above 40°C to produce multilamellar vesicles (MLV). After a rest of 10 minutes to overcome 
any structural defects, the MLV suspension was sized by sonication at 40°C for 15 minutes 
using a 13 mm diameter probe sonicator (Bandelin Sonoplus) at 150 watts. The resulting 
small unilamellar vesicles (SUV) were finally centrifuged for 10 minutes at 10 000 x g to 
remove the titanium particles originating from the probe.  
Immunoliposomes were prepared by coupling OX26 F(ab’)2 fragments at the distal carboxylic 
groups of the linker lipid, DSPE-PEG5000COOH. The coupling procedure involved a 
carbodiimide reaction [19]. Briefly, 50 mM EDC and 100 mM Sulfo-NHS were mixed with 8 
mL of liposomes at 10 µmol/mL in 100 mM MES buffer, pH 5.2. The mixture was incubated 
with gentle shaking and then dialyzed (100 kDa cut-off) for 15 minutes against PBS pH 7.4 at 
room temperature to remove the reagents in excess and free DSPE-PEG5000COOH. This last 
step was repeated three times more to complete one hour of dialysis. After dialysis, the pH of 
activated liposomes was adjusted to 7.4 with a sodium hydroxide solution. Then, 1.38 mg of 
the OX26 F(ab’)2 fragments were added to activated liposomes which were incubated at room 
temperature for two hours and thereafter at 4°C overnight. The reaction was stopped by 
addition of glycine 50 mM followed by 30 min-incubation. The immunoliposomes were then 
stored in the dark at 4°C and used within 24 hrs.  
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6.2.4 Characterization of liposomes 
 
6.2.4.1 Liposomes size and zeta potential 
 
The size of diluted 1/10 (with PBS pH 7.4) liposomes was measured by dynamic light 
scattering using the NanoZS (Malvern Instrument, France). Zeta potential was measured by 
the same instrument. 
 
6.2.4.2 Drugs loading efficiency 
 
150 µL of each liposome formulation was sampled and lysed with 450µL of acetonitrile. The 
mixture was centrifugated at 10 000 x g for 5 minutes to precipitate acetonitrile insoluble 
compounds. The supernatant containing elacridar and tariquidar was diluted with the mobile 
phase to determine the drug loading efficiency (DLE) of liposomes. The analytical method is 
described in “Analysis of loperamide, elacridar and tariquidar by Liquid Chromatography-
Mass Spectrometry (LS-MS)”. At these conditions a calibration curve was constructed for 
tariquidar and elacridar using five calibrations standards of 0.5, 0.75, 1.0, 2.5 and 5.0 µg/mL. 
DLE (%) = (amount of drug in liposomes/amount of drug initially added) x 100. 
 
6.2.5 Animals 
 
Pharmacokinetic and tissue distribution studies were conducted in male Sprague Dawley rats 
(Janvier, France). All animal experiments were carried out in accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals (Institute of 
Laboratory Animal Resources, National Research Council, National Academy of Sciences, 
USA). All the animals were allowed to acclimate for one week and were seven weeks old 
(230 – 280 g) at the time of the experiment. The animals were maintained under a 12-h 
light/dark cycle and a temperature-controlled environment. Food and water were provided ad 
libitum. The studies were approved by the Institutional Animal Care and Use Committee of 
the University of Franche-Comte. 
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6.2.6 Study design  
 
The animals were randomly divided into four experimental groups. The different treatments 
were administered via the jugular vein by IV bolus. Each group received first a liposomal 
formulation whether EL-TAR-CL, EL-TAR-COOHL, EL-TAR-LCL or EL-TAR-IL. In all 
the groups the total administered dose of combined P-gp modulators was 1.0 mg/kg. Given 
the drugs loading efficiencies, the ratio of tariquidar:elacridar was 1:1 for the first three 
groups and 2:1 for the group receiving EL-TAR-IL. After one minute, all the groups received 
free loperamide at a dose of 0.5 mg/kg, previously dissolved and diluted in a mixture of saline 
and PEG600 (3:1). Prior to the pharmacokinetic and tissue distribution studies, all the animals 
were observed for one hour to determine the clinical signs induced by central opiate effects of 
loperamide.  Observations were limited to two or three rats at a time to maximize visibility 
(n=12). The CNS (lethargy, whole body tetany, Straub tail and piloerection), respiratory 
(shallow breathing) and ocular (eye protrusion) clinical signs were established according to 
our previous study. The degrees of the clinical signs were scored as 0 = none, 1 = mild, 2 = 
moderate and 3 = severe. The degree score for the CNS, respiratory or ocular clinical signs 
was calculated as: N x D, where N is the number of rats displaying the clinical signs and D is 
the degree score for each symptom.  The total score (TS) was calculated as: Σ (N x D).  
In the pharmacokinetic study, blood was serially sampled from the tail vein at 1, 6, 12 and 24 
hours after the administration of the different treatments. The blood was collected in tubes 
containing trisodium citrate solution. The plasma was obtained by centrifugation of the blood 
at 2500 g for 5 min and stored frozen at -20°C until analysis. Three rats were used at each 
time point (n=3). 
In the tissue distribution study, animals were sacrificed at 1, 6, 12 and 24 hours after 
administration of the different treatments, following deep anesthesia with sodium 
pentobarbital (50 mg/kg; intraperitoneal), exsanguination and cardiac perfusion with saline. 
At sacrifice, the whole brain, liver and kidneys were immediately frozen at -20°C until 
analysis. Three rats were used at each time point (n=3). 
The results from our previously published study, where animals underwent free loperamide at 
0.5 mg/kg concurrently with free elacridar at 0.5 mg/kg plus free tariquidar at 0.5 mg/kg (Free 
EL-TAR) were used for comparison in the pharmacokinetics and tissue distribution studies. 
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6.2.7 Analysis of loperamide, elacridar and tariquidar by Liquid 
Chromatography-Mass Spectrometry (LS-MS) 
 
Loperamide, elacridar and tariquidar in plasma, brain, kidney and liver samples were 
determined by a LC-MS method that has been validated for specificity, calibration curve, 
lower limit of quantification (LLOQ), accuracy, precision, and recovery according to the FDA 
guidance for bioanalytical method validation [20]. 
The chromatographic analyses were carried out on a Shimadzu High Performance Liquid 
Chromatography/Mass Spectrometer LCMS-2010EV, equipped with a LC-20AD solvent 
delivery system. The analytes were well separated on a Zorbax Eclipse XDB-C18 2.1 x 150 
mm, 5.0 µm column from Agilent Technologies at 50°C using a Millipore Waters oven. The 
mobile phase consisting of 10 mM ammonium acetate pH 5.5:MeOH:ACN (37.5:40:22.5 
v/v/v) was delivered in isocratic mode at 0.4 mL/min. An autosampler 360 from Kontrons 
Instruments was set at 20 µL. The compounds were quantitated using positive electrospray 
ionization (ESI) in an octapole quadrupole mass analyzer with single ion monitoring (SIM) 
mode at m/z 477 for loperamide, m/z 531 for ketoconazole, m/z 564 for elacridar, m/z 647 for 
tariquidar and m/z 319 for chlorpromazine. Nitrogen was used as the nebulizing gas at 1.5 
L/min. The curved desolvation line (CDL) and heat block temperatures were set at 250°C and 
300°C, respectively. The detector voltage was 1.5 KV, the interface voltage was -3.5 KV and 
the CDL voltage was 15.0 V. 
Frozen brain, liver and kidney samples were thawed and homogenized with one volume of 
water using a Janke & Kunkel T45 Ultra-turrax and a Fischer Scientific Vibra-cell 
homogenizer. Stability tests demonstrated that the analytes were stable under the storage 
conditions, during the extraction process, and for at least three freeze/thaw cycles. Prior to 
chromatographic analysis, 25 µL of the internal standard solution containing ketoconazole 
and chlorpromazine hydrochloride were added to 100 µL of each plasma or homogenate 
samples to yield final concentrations of 100 ng/mL and 25 ng/mL respectively. After 
deproteinization by addition of 800 µL of a mixture of acetonitrile and tert-butyl methyl ether 
(1:1), the samples were vortexed for 3 minutes and centrifuged at 5000 x g for 10 minutes. 
The upper organic layer was decanted and evaporated to dryness and the residue was 
reconstituted in 100 µL of mobile phase. A volume of 20 µL was injected onto the analytical 
column.  
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6.2.8 Pharmacokinetic calculations 
 
The pharmacokinetic parameters were calculated by non-compartmental analysis using 
Kinetica™ version 4.0 (Inna Phase Corp., 2001). The area under the concentration-time 
curves (AUC) values was determined using the trapezoidal rule. The half-lives of elimination 
(t1/2) were calculated as ln(2)/K, where K represents the terminal elimination rate constant 
obtained from the slopes of the semilogarithmic plots of the concentration-time profile. The 
plasma clearance (CL) was calculated as dose/AUCinf, where AUCinf is the AUC from time 
zero to infinity. The brain-to-plasma partition coefficient (Kp) was calculated as AUCinf-
brain/AUCinf-plasma.  
 
6.2.9 Statistical Analysis 
 
The statistical analysis was carried out using SigmaStat 3.5 software. Analyses of statistical 
significance between two groups were examined by Student's t-test and between many groups 
by one-way analysis of variance (ANOVA) with the Holm-Sidak post-hoc test. A P < 0.05 
was considered to be significant. Moreover, the variance of the AUCinf in each treatment 
group was estimated according to the Bailer method [21, 22], which is based on the variability 
of the concentrations at each sampling time. A Z-test was used for pairwise comparison of 
AUCs. A P < 0.05 was considered to be significant. 
 
6.3 Results 
 
6.3.1 Characterization of liposomal formulations 
 
The average particle diameters of the liposomal formulations vary from 102.6 ± 2.3 to 135.8 ± 
0.8 nm (Table 1). The size increase of EL-TAR-COOHL and EL-TAR-LCL compared to EL-
TAR-CL liposomes is due to the inclusion of DSPE-PEG2000-COOH and DSPE-PEG2000-
OCH3, respectively, which is in accordance with the 5 nm thickness of PEG2000 and its 
possible extension up to 15 nm [10]. The highest size of EL-TAR-IL is surely caused by the 
presence of DSPE-PEG5000-COOH and OX26 F(ab’)2 fragments. This value is consistent with 
the size increase of 8 nm that DSPE-PEG5000 shows over DSPE-PEG2000 [23] and with the size 
increase between 7 and 20 nm caused by the OX26 F(ab’)2 coupling [24]. 
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The zeta potential of EL-TAR-CL, EL-TAR-LCL and EL-TAR-IL (after OX26 F(ab’)2 
coupling) was nearly neutral but the presence of DSPE-PEG2000-COOH in EL-TAR-COOHL 
or DSPE-PEG5000-COOH in EL-TAR-IL (before OX26 F(ab’)2 coupling) switched to a 
negative surface charge.  
 
 
Table 1. Composition, size and zeta potential of elacridar-tariquidar liposomal formulations (n = 3) 
 
 
 
6.3.2 Drugs loading and antibody-liposomes coupling efficiencies  
 
The average loading for both, elacridar and tariquidar, was largely higher than 60.0% in the 
EL-TAR-CL, EL-TAR-COOHL and EL-TAR-LCL formulations (Table 2). The use of MES 
buffer pH 5.2 in the hydration step for the preparation of EL-TAR-IL boosted a high elacridar 
loading which reached 81.3 ± 4.3 %. However, decreased loading efficiencies were observed 
for elacridar and tariquidar after the dialysis step, 72.7 ± 3.6 % and 34.7 ± 1.9 %, respectively.  
 
 
Table 2. Drugs loading efficiencies (n = 3) 
Liposomal 
formulation 
Composition Molar ratio 
Mean particle 
diameter (nm) 
Zeta potential 
(mV) 
EL-TAR-CL DMPC 100 102.6 ± 2.3 1.7 ± 0.8 
EL-TAR-COOHL DPMC:DSPE-PEG2000-COOH 100:7.5 111.7 ± 3.9 -9.3 ± 1.6 
EL-TAR-LCL DMPC:DSPE-PEG2000-OCH3 100:7.5 109.4 ± 4.7 1.9 ± 1.2 
EL-TAR-IL before OX26 
F(ab’)2 coupling 
DMPC:DSPE-PEG2000-OCH3:DSPE-PEG5000- COOH 100:6.25:1.25 124.5 ± 0.7 -4.4 ± 0.4 
EL-TAR-IL after 
OX26 F(ab’)2 coupling 
DMPC:DSPE-PEG2000-OCH3:DSPE-PEG5000- COOH 100:6.25:1.25 135.8 ± 0.8 -1.2 ± 0.1 
Liposomal  
formulation 
Elacridar loading  
efficiency (%) 
Tariquidar loading  
efficiency (%) 
EL-TAR-CL  64.3 ± 3.3 62.2 ± 0.9 
EL-TAR-COOHL 69.9 ± 3.2 71.5 ± 4.0 
EL-TAR-LCL  63.6 ± 0.5 67.6 ± 1.5 
EL-TAR-IL (before OX26 
F(ab’)2 coupling) 
81.3 ± 4.3 55.6 ± 5.0 
EL-TAR-IL (after OX26  
F(ab’)2coupling) 
72.7 ± 3.6 34.7 ± 1.9 
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6.3.3 Pharmacokinetics of elacridar and tariquidar co-loaded in different 
types of liposomes 
 
Both, elacridar and tariquidar, as free drugs were rapidly eliminated from the plasma. Their 
half-lives were 3.1 ± 0.2 and 5.8 ± 0.7 h, respectively (Table 3). Even though these values 
were not modified when both compounds were co-loaded in EL-TAR-CL and EL-TAR-
COOHL, the AUCinf were importantly decreased and the clearance values increased. EL-
TAR-LCL significantly increased the plasma concentrations of elacridar and tariquidar up to 
12 hours. Hence, the half-lives of elacridar and tariquidar increased to 12.6 ± 2.8 and 11.0 ± 
1.8 hours, respectively. These values indicate longer retention of these liposomes in the blood 
stream as well as an adequate retention of these two compounds in the liposomes. The effect 
of PEG-conjugation was partially reversed by conjugation to OX26 F(ab’)2 fragments. Hence, 
the AUCinf of elacridar and tariquidar in EL-TAR-IL were reduced by 1.6- and 1.5-fold, 
respectively, in comparison with the values obtained in EL-TAR-LCL.  
 
 
Table 3. Pharmacokinetic parameters of elacridar and tariquidar 
 
 
# ANOVA: Significantly different compared to the group which received free elacridar plus 
free tariquidar 
## ANOVA: Significantly different compared to the group which received EL-TAR-LCL 
 
 
 
 
Formulation 
Elacridar Tariquidar 
AUCinf (% 
dose.h/mL) 
t1/2 (h) 
CL 
(mL/h /Kg) 
AUCinf (% 
dose.h/mL) 
t1/2 (h) 
CL 
(mL/h /Kg) 
Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. 
Free EL-TAR 9.8 0.7 3.1 0.2 10.3 0.7 11.9 1.7 5.8 0.7 8.6 1.2 
EL-TAR-CL 4.5# 0.4 3.7 0.1 22.4# 1.9 6.0# 0.7 5.5 0.3 16.8# 1.9 
EL-TAR-COOHL 6.5 0.7 3.9 0.5 15.6# 1.8 4.0# 0.6 6.3 1.1 25.2# 3.3 
EL-TAR-LCL 43.5# 1.6 12.6# 2.8 2.3# 0.1 39.0# 6.1 11.0# 1.8 2.6# 0.4 
EL-TAR-IL 27.9# ##  4.8 10.7# 1.2 3.7# ## 0.7 26.5# ## 1.2 9.3# 2.2 3.8# ## 0.2 
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6.3.4 Brain distribution of elacridar and tariquidar co-loaded in different 
types of liposomes 
 
Figures 1 and 2 show a pronounced difference in the brain distribution of both P-gp 
modulators after their IV administration as free drugs and co-loaded in liposomal 
formulations. At 1 hour post-dosing, only 0.24 ± 0.06 % of the injected dose (ID)/g of free 
elacridar was monitored in the brain. While EL-TAR-CL did not improve the brain uptake of 
elacridar, EL-TAR-COOHL decreased by 4-fold (0.06 ± 0.01 % ID/g) the brain distribution 
of the P-gp modulator. However, when elacridar was co-loaded in EL-TAR-LCL and EL-
TAR-IL, its distribution increased by 4.8- (1.14 ± 0.42 % ID/g) and 9.6-fold (2.30 ± 0.22 % 
ID/g), respectively. At 6 hours post-dosing, elacridar in COOHL was not detected but still 
significant high concentrations of the P-gp modulator co-loaded in EL-TAR-LCL (0.13 ± 0.03 
% ID/g) and EL-TAR-IL (0.26 ± 0.10 % ID/g) were achieved in comparison to free elacridar 
(0.03 ± 0.01% ID/g). At 12 hours, elacridar, as a free compound and in EL-TAR-CL was not 
detectable but approximately 0.08 % ID/g could be detected for elacridar in EL-TAR-LCL 
and in EL-TAR-IL. Free tariquidar also showed low brain uptake, only 0.09 ± 0.01% ID/g at 
1 hour. Its distribution was not improved with EL-TAR-CL and decreased by 3.0-fold (0.03 ± 
0.06 % ID/g) with EL-TAR-COOHL. Nevertheless, the brain uptake of tariquidar increased 
by 6.1- (0.55 ± 0.06 % ID/g) and 11.8-fold (1.11 ± 0.19 % ID/g) when it was co-loaded in EL-
TAR-LCL and EL-TAR-IL, respectively. At 6 hours post-dosing, tariquidar in COOHL was 
not detected but still significant high concentrations of the P-gp inhibitor co-loaded in EL-
TAR-LCL (0.06 ± 0.01 % ID/g) and EL-TAR-IL (0.13 ± 0.04 % ID/g) were observed in 
comparison to free tariquidar (0.09 ± 0.01% ID/g). Unlike elacridar, tariquidar co-loaded in 
EL-TAR-LCL and EL-TAR-IL could not be detectable at the brain at 12 hours post-dosing. 
These observations are also reflected in the AUCinf for the brain of each P-gp modulator 
(Table 4). However, the Kp values (Table 4) suggest that a significant higher exposure to both 
P-gp modulators was only achieved with EL-TAR-IL. This is in agreement with the brain 
uptake of elacridar and tariquidar in EL-TAR-IL at 6 hours post-dosing, which is in the same 
range that the one obtained for free elacridar plus free tariquidar at 1 hour post-dosing. The 
significant higher Kp values obtained with EL-TAR-CL in comparison with the free form of 
the P-gp modulators are merely due to the low plasma concentrations of these compounds. 
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Figure 1: Brain concentrations of elacridar (mean ± S.D.) after intravenous administration of free elacridar (plus 
free tariquidar) (white), in ELA-TAR-CL (light grey), in ELA-TAR-COOHL (dark grey), in ELA-TAR-LCL 
(black), or in ELA-TAR-IL (striped). In all the cases the treatments were concurrently administered with 
loperamide at 0.5 mg/kg. Bars represent the standard deviation. n = 3. 
#  ANOVA: Significantly different compared to the group which received free elacridar. 
## Student’s t-test: Significantly different compared to the group which received EL-TAR-LCL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Brain concentrations of tariquidar (mean ± S.D.) after intravenous administration of free tariquidar 
(plus free elacridar) (white), in ELA-TAR-CL (light grey), in ELA-TAR-COOHL (dark grey), in ELA-TAR-
LCL (black), or in ELA-TAR-IL (striped). In all the cases the treatments were concurrently administered with 
loperamide at 0.5 mg/kg. Bars represent the standard deviation. n = 3. 
# ANOVA: Significantly different compared to the group which received free elacridar. 
## ## Student’s t-test: Significantly different compared to the group which received EL-TAR-LCL. 
 
# 
# ## 
# 
# 
# 
# ## 
# 
# 
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Table 4. Brain distribution of elacridar and tariquidar 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Bailler method: Significantly different to the group which received free elacridar plus free tariquidar. 
** Bailler method: Significantly different compared to the group which received EL-TAR-LCL. 
# ANOVA: Significantly different compared to the group which received free elacridar plus free tariquidar. 
## ANOVA: Significantly different compared to the group which received EL-TAR-LCL. 
 
 
6.3.5 Tissues distribution of elacridar and tariquidar co-loaded in different 
types of liposomes 
 
Liver and kidneys distribution of elacridar and tariquidar are shown in Table 5. In liver, the 
AUCinf of elacridar and tariquidar co-loaded in EL-TAR-CL and EL-TAR-COOHL confirmed 
that these formulations were rapidly removed from the circulation by the RES and 
significantly accumulated in this organ. In agreement with their extended half-lives, elacridar 
and tariquidar in EL-TAR-LCL showed 2.4- and 1.6-fold lower AUCinf values compared to 
the free form of each P-gp modulators, respectively. As the conjugation of OX26 F(ab’)2 
fragments to long circulating liposomes partially reversed the stealth effects, a partial increase 
in AUCinf of elacridar and tariquidar co-loaded in EL-TAR-IL were found in relation to EL-
TAR-LCL. However, these values were still lower compared to the values obtained with free 
elacridar and free tariquidar.  
In kidneys, the distribution of both P-gp modulators in EL-TAR-CL, EL-TAR-LCL and EL-
TAR-IL was similar to the distribution of the free drugs. Surprisingly, the distribution of 
elacridar in EL-TAR-COOHL was 1.8-fold lower than the value obtained with free elacridar.  
 
 Elacridar Tariquidar 
 AUCinf (% dose.h/g) Kp AUCinf (% dose.h/g) Kp 
 Mean S.D. Mean S.D. Mean S.D. Mean S.D. 
Free EL-TAR 0.79 0.12 0.08 0.02 0.29 0.06 0.03 0.01 
EL-TAR-CL 1.18 0.28 0.26# 0.05 0.50 0.09 0.09# 0.02 
EL-TAR-COOHL 0.06 0.01 0.01# 0.002 0.03 0.01 0.01 0.001 
EL-TAR-LCL 4.15* 0.72 0.10 0.02 1.83* 0.14 0.05 0.01 
EL-TAR-IL 8.16* **  0.93 0.30# ## 0.05 3.70* ** 0.81 0.14# ## 0.03 
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Table 5. Area under the concentration time curves (AUCinf) (mean ± S.D) of elacridar and tariquidar (% 
dose.h/g) 
 
 Elacridar Tariquidar 
 Liver Kidney Liver Kidney 
 Mean S.D. Mean S.D. Mean S.D. Mean S.D. 
Free EL-TAR 15.2 1.0 4.1 0.4 7.8 0.3 3.1 0.1 
EL-TAR-CL 25.0# 2.8 4.2 0.2 24.4# 4.6 3.9 0.2 
EL-TAR-COOHL 21.4# 3.1 2.3# 0.1 29.0# 9.3 3.2 0.3 
EL-TAR-LCL 6.4# 1.1 3.4 0.3 4.9 0.5 2.5 0.5 
EL-TAR-IL 9.5# ## 1.1 4.8 0.5 6.2 1.4 3.6 0.4 
 
# ANOVA: Significantly different compared to the group which received free elacridar plus free tariquidar 
## ANOVA: Significantly different compared to the group which received EL-TAR-LCL 
 
 
6.3.6 Effects of elacridar and tariquidar co-loaded in different types of 
liposomes on the brain distribution of free loperamide 
 
Elacridar and tariquidar under their free or liposomal form potentiated the opioid-like 
behavior produced by loperamide. The animals presented mainly lethargy, piloerection and 
shallow breathing. Only few animals from the groups treated with Free-EL-TAR and EL-
TAR-IL showed whole body tetany, the Straub reaction [25] and eyes protrusion. However 
there were significant differences in the latency, intensity and duration of these clinical signs 
(Fig 3).  While the animals treated with Free-EL-TAR (TS = 102), EL-TAR-CL (TS = 11) 
and EL-TAR-COOHL (TS = 5) showed the aforementioned clinical signs immediately or 5 
minutes after treatment, the animals which received EL-TAR-LCL (TS = 22) and EL-TAR-IL 
(TS = 90) did it only 30 minutes post-dosing. In contrast, the persistence of the opioid-like 
behavior for Free-EL-TAR, EL-TAR-LCL and EL-TAR-IL was the same (30 minutes) and 
longer than those for EL-TAR-CL (10 minutes) and EL-TAR-COOHL (5 minutes).  
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Figure 3: Mean degree score for CNS, respiratory and ocular clinical signs induced by loperamide after 
concurrent intravenous with free elacridar plus free tariquidar (white), ELA-TAR-CL (light grey), ELA-TAR-
COOHL (dark grey), ELA-TAR-LCL (black), or ELA-TAR-IL (striped). n = 12. 
 
 
Despite the concurrent administration of free elacridar plus free tariquidar, at 1 hour post-
dosing, loperamide only reached a brain uptake of 0.038 ± 0.005 % ID/g (Fig. 4). Whereas the 
simultaneous administration of EL-TAR-CL and EL-TAR-COOHL did not improve the brain 
uptake of loperamide; EL-TAR-LCL and EL-TAR-IL at 1 hour increased the loperamide 
brain distribution by 2.1- (0.077 ± 0.006 % ID/g) and 4.4-fold (0.162 ± 0.010 % ID/g), 
respectively. EL-TAR-LCL and EL-TAR-IL significantly succeed in avoiding the P-gp-
mediated efflux of loperamide also at 6 hours. At this time point, EL-TAR-LCL and EL-
TAR-IL increased the loperamide brain uptake by 2.1 (0.015 ± 0.004 % ID/g) and 6.0-fold 
(0.042 ± 0.003 % ID/g), respectively as compared to that with free elacridar plus free 
tariquidar (0.007 ± 0.001 % ID/g). Importantly, the brain uptake of loperamide achieved with 
EL-TAR-IL at 6 hours post-dosing is in the same range that the value obtained with free 
elacridar plus free tariquidar at 1 hour post-dosing. After 12 hours post-dosing, loperamide 
was not detected in any of the different groups. The differences in the loperamide AUCinf for 
the brains and the Kp values were even more marked than the effects at the individual times 
(Table 6).  
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Figure 4: Brain concentrations (left axis) and plasma concentrations (right axis) of loperamide (mean ± S.D.) 
after intravenous co-administration with free elacridar plus free tariquidar (white/ rhombus), ELA-TAR-CL 
(light grey/square), ELA-TAR-COOHL (dark grey/triangle), ELA-TAR-LCL (black/cross), or ELA-TAR-IL 
(striped/circle). Bars represent the standard deviation. n = 3. 
# ANOVA: Significantly different compared to the group which received loperamide at 0.5 mg/kg concurrently 
with free elacridar plus free tariquidar. 
## Student’s t-test: Significantly different compared to the group which received loperamide at 0.5 mg/kg 
concurrently with EL-TAR-LCL. 
 
 
 
Table 6. Brain distribution of loperamide in co-administration with free and liposomal elacridar plus tariquidar 
 
 AUCinf (% dose.h/g) Kp 
 Mean S.D. Mean S.D. 
Free EL-TAR 0.15 0.01 0.006 0.0003 
EL-TAR-CL 0.21* 0.02 0.009 0.0014 
EL-TAR-COOHL 0.02* 0.01 0.001# 0.0005 
EL-TAR-LCL 0.31* 0.04 0.013# 0.0023 
EL-TAR-IL 0.77*** 0.04 0.035# ## 0.0039 
 
 
* Bailler method: Significantly different to the group which received free loperamide concurrently with free 
elacridar plus free tariquidar 
** Bailler method: Significantly different compared to the group which received free loperamide concurrently 
with EL-TAR-LCL. 
# ANOVA: Significantly different compared to the group which received free loperamide concurrently with free 
elacridar plus free tariquidar 
## ANOVA: Significantly different compared to the group which received free loperamide concurrently with EL-
TAR-LCL 
 
 
# 
# 
# ## 
# ## 
# 
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6.3.7 Effects of elacridar and tariquidar co-loaded in different types of 
liposomes on the pharmacokinetics, liver and kidneys distribution of 
free loperamide 
 
Previously, we have shown that the pharmacokinetics of loperamide alone at a dose of 0.5 
mg/kg was not significantly modified when it was concurrently administered with free 
elacridar plus free tariquidar at a total dose of 1.0 mg/kg. The present study reveals that both 
P-gp inhibitors at the same total dose co-loaded in EL-TAR-CL, EL-TAR-LCL and EL-TAR-
IL neither changed the pharmacokinetics of loperamide (Fig. 4). Nonetheless, compared to the 
concurrent administration of both free P-gp inhibitors, the simultaneous administration of EL-
TAR-COOHL significantly decreased the AUCinf (24.32 ± 2.94 to 14.80 ± 1.77 %dose.h) and 
increased the clearance (4.17 ± 0.47 to 6.85 ± 0.77 mL/h/kg) of loperamide. Besides, related 
to the co-administration of free P-gp modulators, EL-TAR-COOHL significantly decreased 
the loperamide AUCinf for the liver (2.55 ± 0.26 to 1.79 ± 0.20 %dose/h).  
  
6.4 Discussion 
 
Recently, we have shown that while tariquidar and elacridar, both at 1.0 mg/kg, increased 
loperamide levels in the brain by 2.3- and 3.5-fold respectively, the concurrent administration 
of both P-gp modulators at a total dose of 1.0 mg/kg, increased loperamide levels in the brain 
by 5.8-fold. Hence, this study aims to assess the pharmacokinetics and brain distribution of 
the same total dose of elacridar and tariquidar co-loaded in OX26 F(ab’)2 immunoliposomes. 
To select the framework for immunoliposomal development, conventional, PEGylated COOH 
and PEGylated OCH3 liposomes were previously evaluated. A special emphasis was given to 
the brain uptake of loperamide, as an in vivo probe of full and simultaneous blockage of the P-
gp by both, elacridar and tariquidar.  
There were big differences in the pharmacokinetics and tissue distribution of elacridar and 
tariquidar co-loaded in liposomal formulations compared to the free form of both P-gp 
modulators. Elacridar and tariquidar in conventional liposomes did preferentially accumulate 
to a high degree in liver. This behavior is well known and is a consequence of their clearance 
by macrophages of the RES which can occur when the DDS is directly injected into the blood 
circulation [26]. The coating of liposomes by a PEG shell is probably one of the most efficient 
ways to avoid this detrimental liver and/or non-specific accumulation [9]. The most accepted 
hypothesis for this phenomenon is the ability of PEG to create a hydrophilic protective layer 
that repel the adsorption of plasma proteins onto the surface of liposomes (opsonization) via 
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steric repulsion, thereby avoiding the consequent uptake by the macrophages of the RES [9, 
27]. However, this ability depends on the PEG chain length and density [9]. DSPE-PEG2000 at 
a density up to 10 mol % incorporated into various DDSs demonstrated to efficiently prevent 
the aggregation and enhance the permanence of various DDSs in the bloodstream [28, 29]. 
However, the effect of DSPE-PEG2000 on the pharmacokinetics and biodistribution of the 
DDSs can be also counterbalanced by the charge of the particle since negatively charged 
liposomes showed increased RES uptake [30]. In our study, two types of PEG molecules were 
used, DSPE-PEG2000-COOH for PEGylated-COOH liposomes and DSPE-PEG2000-OCH3 for 
PEGylated-OCH3 long circulating liposomes. As expected by their zeta potential, the 
influence of each PEG on the liposomes distribution was different. PEGylated-COOH 
liposomes did not improve the permanence of the P-gp modulators in the bloodstream and 
accumulated in the liver in the same rate than conventional liposomes. In contrast, PEGylated-
OCH3 long circulating liposomes significantly increased the plasma concentrations of 
elacridar and tariquidar, lengthening their half-lives in comparison to the free drugs, 
conventional or PEGylated-COOH liposomes. Simultaneously, the clearance values as well as 
the liver accumulation of both P-gp modulators decreased using PEGylated-OCH3 long 
circulating liposomes. These results confirm that negatively charged liposomes have shorter 
half-lives in the blood than do neutral liposomes [9]. Previous studies showed that the fast 
clearance of 200 nm negatively-charged phosphatidic acid liposomes can be reversed by PE-
PEG5000 but not by PE-PEG750 and that negatively-charged phosphatidyl serine liposomes 
cannot be reversed by either PE-PEG5000 or PE-PEG750 [30]. In contrast, the functionalization 
of 8 nm particles with PEG2000-COOH prevented their accumulation in the liver, spleen and 
lungs [31]. Given the above points, we confirm then that the harmoniously tune of size, 
surface charge and surface chemistry will determine the fate and behavior of these 
nanocarriers in vivo. In general, a size of around 100 nm, a neutral surface charge and steric 
stabilization reduce the RES clearance, improve the pharmacokinetics and augur an increase 
in the targeted tissue uptake [5, 9]. Moreover, if PEGylation is required to ensure the stay of 
the nanocarriers in the bloodstream, their distribution not only depends on the PEG chain 
length and density but also on the nature of its end group. The selection of this end group 
could be also determining when co-administering PEGylated liposomes with a free drug. As 
observed herein, an alteration in loperamide distribution was caused by the COOH terminal 
groups of the negatively charged liposomes. Although, in our study the placement of OX26 
F(ab’)2 at the distal end of PEG partially reversed the effect of PEGylation, the vascular 
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residence time achieved with the immunoliposomes was sufficient for contact with the target 
tissue.  
The brain uptake of both P-gp modulators co-loaded in conventional liposomes may arise 
from the brain uptake of free elacridar and free tariquidar released to the bloodstream after 
dissolution of these liposomes in peripheral tissues. A similar pattern was observed for 
negatively charged COOH liposomes. In fact, the rapid clearance and the lowest brain uptake 
of elacridar and tariquidar  indicate that these nanocarriers activated the complement system 
via the classical pathway [9] before than they could release both P-gp modulators. 
Conversely, PEGylation with OCH3 end groups had a positive impact on the therapeutic 
delivery of elacridar and tariquidar to the brain. Early investigations demonstrated that PEG 
coated neutral charged nanocarriers had no effect on the brain uptake of encapsulated drugs 
[32]. However, since neutral PEG slows down the first-pass metabolism, it may increase the 
chance of around 150 nm sized nanocarriers to deliver the encapsulated drugs across the BBB 
[33]. In the same way, it was demonstrated that nanoparticles coated with PEG were able to 
penetrate the BBB and reach the maximum in brain at 1 hour post-injection [34]. 
Additionally, nanocarriers as large as 114 nm in diameter and densely coated with PEG are 
able to spread rapidly within the brain tissue [35]. Thus, the limited contribution of passive 
targeting seen with our PEGylated-OCH3 long circulating liposomes could be further 
improved if they are coated with a high density of a longer PEG molecule, for example with 
DSPE-PEG5000-OCH3. These data favored then further development of long circulating 
immunoliposomes. These DDSs were armed with an approximately 100 nm size, neutral zeta 
potential and sterically stabilized properties, prolonging thus their systemic circulation. 
Moreover, these immunoliposomes were provided of an elevated permeability to the brain 
through the conjugation of OX 26 F(ab’)2 fragments. OX26 is an appropriate vector that 
previously exhibited specific brain targeting using liposomes [13], lipid [17] and polymer 
nanoparticles [36]. Therefore, the greatest brain uptake of immunoliposomal elacridar and 
tariquidar is well explained by the Pardridge pharmacokinetic rule. This rule states that the 
brain uptake of a drug is a dual function of the plasma AUC of the drug and the permeability 
of the same drug against brain tissue [37]. Lately, a microemulsion containing elacridar was 
also prepared to improve the bioavailability and brain distribution of the P-gp modulator [38]. 
In spite of the 3.0-fold higher Kp value obtained with this DDS in comparison to free elacridar 
[38], its elimination half-life was not improved, thus limiting the brain uptake of elacridar 
according to the Pardridge pharmacokinetic rule. 
128 
 
Even though the brain distribution of both free P-gp modulators is dose-dependent [38, 39], 
herein the low doses of free elacridar plus free tariquidar caused an important and extremely 
rapid modulation of the P-gp at the BBB. This phenomenon could be unmanageable leading 
to toxic profiles with lethal results. Nevertheless, the opioid-induced behavior and the 4.4- (at 
1 hour) and 6.1-fold (at 6 hours) higher brain uptake of loperamide achieved by the 
immunoliposomes indicates that the brain distribution of both P-gp modulators could be 
delayed and prolonged up to 6 hours. This could avoid an abrupt entry of the P-gp substrate 
into the brain and subsequent acute toxicities. However the increase in the brain uptake of 
loperamide was not in the same range than the brain uptake of both immunoliposomal P-gp 
modulators. This phenomenon could be the result of the minimal interaction of these 
immunoliposomes with the pharmacokinetics of loperamide and the consequent rapid 
elimination of the µ-opioid agonist from the bloodstream. Although tariquidar loading 
efficiency remains to be improved, this immunoliposomal formulation represent a promising 
tool to modulate the P-gp at the BBB and allow the brain uptake of loperamide or any other P-
gp substrate without major pharmacokinetic interactions. 
 
In brief, by integrating two P-gp overcoming strategies, namely, P-gp direct modulation with 
elacridar and tariquidar and the use of an advanced DDS, an efficient modulation of the P-gp 
at the BBB can be obtained. Particular attention should be given to the development of the 
nanocarrier. As seen, the size, the surface charge as well as the length and the end group of 
the PEG chain should be carefully tuned to successfully modulate the pharmacokinetics and 
tissue distribution of the encapsulated drugs. Moreover, the coupling of an appropriate 
targeting vector such as OX26 F(ab’)2 fragments and its number density are factors that could 
ensure an effective transport of the encapsulated drugs across the BBB. More detailed in vivo 
pharmacokinetics, biodistribution, pharmacodynamics, and toxicology studies could 
maximize the efficacy of this approach.  
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7 SEQUESTRATION OF P-GLYCOPROTEIN INHIBITORS BY NOCARRIERS 
 
Abstract 
 
The crucial tissue localization of P-glycoprotein suggests its important physiological role in 
the protection of susceptible organs, where it pumps out of the cells an unlimited number of 
P-glycoprotein substrates from therapeutic drugs to pesticides. Thus prolonged periods of P-
glycoprotein inactivity caused by over-doses of P-glycoprotein inhibitors could result in 
detrimental or even lethal outcomes. This study evaluated then the ability of three 
nanocarriers to sequester two potent P-glycoprotein inhibitors, elacridar and tariquidar. The 
transport of rhodamine 123, a P-glycoprotein substrate, across Caco-2 cells was used as a 
probe of functional activity of P-glycoprotein. Among the various concentrations of P-
glycoprotein inhibitors (0.1 – 2.0 µM), elacridar at 0.5 µM and tariquidar at 1.00 µM 
abolished any significant directionality in the transport of rhodamine 123. None of the 
nanocarriers succeed in impairing the P-gp inhibitory activity of elacridar at 0.5 µM. In 
contrast, liposomes made of DMPC and cholesterol were able to partially impair the P-
glycoprotein inhibitory activity of tariquidar 1.0 µM increasing the efflux of rhodamine 123 
from 26.77 ± 1.90 % to 51.15 ± 4.49 %. Further investigations and improvements could make 
this formulation a bio-detoxifying agent to deal with toxic profiles caused by over-doses of 
tariquidar.  
 
Keywords: Reversal of P-glycoprotein inhibitors, DMPC:Chol liposomes, bio-detoxifying 
agents and Caco-2 monolayers. 
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7.1 Introduction 
 
P-glycoprotein (P-gp), the product of the multidrug resistance gene, is a membrane-bound 
ATP-dependent efflux transporter [1]. Its strategic localization at the BBB impedes the 
diffusion of several therapeutic compounds into the brain by actively returning them to the 
bloodstream [2]. Hence, various studies suggest the use of high doses of potent P-gp 
inhibitors such as elacridar and tariquidar to overcome the P-gp mediated efflux at the BBB 
[3, 4]. However, it is irrefutable that the main physiological role of the P-gp at the BBB is to 
protect the brain from a variety of xenobiotics and some endogenous metabolites that could 
penetrate the BBB without any limitation [5]. Thus, a transient P-gp inhibition at the BBB by 
elacridar or tariquidar could enhance the brain uptake of the therapeutic compounds but could 
avoid the later uptake and damage caused by xenobiotics that are also P-gp substrates. Then, it 
is highly desired to develop an approach to re-induce the P-gp-mediated efflux after 
prolonged periods of inactivity that could be caused by high doses of elacridar and tariquidar. 
One strategy to re-induce the P-gp mediated efflux involves the use of drugs, namely 
dexamethasone, rifampicin, doxorubicin, daunorubicin, vinblastine and the the herbal 
antidepressant St John’s wort, which demonstrated to be P-gp inducers [6]. Nevertheless, their 
pharmacological effects not related to the P-gp re-induction could lead to significant systemic 
side effects. In contrast, a more suitable strategy would be to administer empty nanocarriers 
like nanoemulsions or liposomes that can extract the P-gp modulators from the bloodstream 
and brain avoiding a long exposure and a long-lasting P-gp inhibition [7]. Nanoemulsions are 
systems of nano-sized oil droplets dispersed and stabilized by one or more emulsifiers in a 
continuous aqueous phase (oil-in-water) [7, 8]. Liposomes are spherical vesicles made of one 
or more concentric phospholipid bilayer membranes that delimit the internal hydrophilic core 
from the external aqueous compartment [7, 8]. The structural characteristics of nanoemulsions 
and liposomes allow them to circulate in a hydrophilic environment while capturing a broad 
range of lipophilic compounds through partition or adsorption mechanisms [8, 9]. Since 
elacridar and tariquidar are mainly lipophilic compounds, their extraction or sequestration 
using the aforementioned nanocarriers could represent an alternative to achieve a transient P-
gp inhibition at the BBB. Alternatively, α-tocopherol, which is commonly used as antioxydant 
in the pharmaceutical formulations, demonstrated its ability to re-induce the P-gp mediated 
efflux. Using the P-gp over-expressing MDR cell line, H69/LX4, Anderson et al. showed that 
α-tocopherol was able to antagonize the P-gp inhibitory activity of elacridar [10].  
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The Caco-2 cell line, derived from human colorectal adenocarcinoma, is widely accepted as a 
potent in vitro model that expresses endogenously high levels of P-gp [11]. Therefore, Caco-2 
monolayers are a well-suited tool to assess interactions between empty nanocarriers and P-gp 
modulators. 
In this regard, the purpose of this study was to examine the potential of three nanocarriers to 
sequester elacridar and tariquidar. Sequestration by liposomes, and nanoemulsions containing 
or not α-tocopherol was studied in an in vitro model of Caco-2 cells using rhodamine 123 as 
P-gp substrate probe. 
 
7.2 Materials and methods  
 
7.2.1 Reagents 
 
Dulbecco’s modified Eagle’s medium (DMEM), Hanks’ balanced salt solution 1X (HBSS), 
Dulbecco’s phosphate-buffered saline 1X (DPBS), fetal bovine serum (FBS), non-essential 
amino acids and penicillin streptomycin antibiotics were purchased from Gibco® Life 
Technologies (France). 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), D-(+)-
glucose and rhodamine 123 were obtained from Sigma Aldrich (France). Elacridar was 
synthesized at the Laboratory of Pharmaceutical Chemistry, University of Bonn (Germany) 
and tariquidar was purchased from API Services Inc. (USA). 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC) was supplied by Thermo Fischer Scientific (France) and cholesterol 
(Chol) and α-tocopherol by Sigma Aldrich (France). Miglyol® 812 was obtained from Condea 
(France) and soy lecithin from Unither Pharmaceuticals (France). HTS Transwell®-24 well 
permeable supports with 0.4µm pore polycarbonate membrane and 6.5mm inserts were 
obtained from Corning (France). All other test compounds were obtained from Sigma Aldrich 
(France). 
 
7.2.2 Caco-2 cell culture 
 
Caco-2 cells were seeded onto 24-well polycarbonate filter membranes at a density of 30 000 
cells/cm2. The cells were grown in culture medium consisting of DMEM supplemented with 
15% FBS, 1% non-essential amino acids, 100 U/mL penicillin and 100 µg/mL streptomycin.  
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The culture medium was replaced every two days and the cells were maintained at 37 °C, 
95% relative humidity and 5% CO2. Permeability studies were conducted with monolayers 
cultured for 21 days at passage numbers 21 - 28. Physiologically and morphologically well-
developed Caco-2 cell monolayers with transepithelial electrical resistance (TEER) values 
greater than 400 Ω cm2 were used for the transport studies. 
 
7.2.3 Selection of the P-gp inhibitors doses to be reversed  
 
The transport buffer (TB) used for the bi-directional studies was HBSS containing 10 mM 
HEPES and 25 mM D-(+)-glucose. Stock solutions of elacridar, tariquidar and rhodamine 123 
were prepared in 100% DMSO at 10 mM and successively diluted in transport buffer. The 
concentrations of the P-gp inhibitors were in the range of 0.1 to 2.0 µM and the concentration 
of rhodamine 123 in all the studies was 5µM. The pH of apical and basolateral sides was 7.4. 
Prior to the studies, each monolayer was washed twice with HBSS and TEER was measured 
to ensure the integrity of the monolayers. The P-gp inhibition studies were initiated by adding 
the buffer containing the different concentrations of elacridar or tariquidar to apical and 
basolateral sides (to maintain the P-gp inhibitors concentrations constant during the studies) 
[12]. Blank transport buffer was added to monolayers used as control. The monolayers were 
then incubated at 37°C for 30 minutes. After the incubation period, buffer containing elacridar 
or tariquidar was removed and apical and basolateral sides were washed twice with HBSS.  
Rhodamine 123 was added to the apical side for the apical to basolateral transport (A-B) or to 
the basolateral side for the basolateral to apical transport (B-A). The transwell was again 
incubated at 37°C for 2 hours. Samples were taken from both, apical and basolateral sides at 
the end of the 2 hours incubation and concentrations of rhodamine 123 were analyzed using 
an EnVisionT Xcite Multilabel Reader Perkin Elmer. 
The apparent permeability coefficients (Papp) across Caco-2 cell monolayers in both A-B (Papp 
A-B) and B-A (Papp B-A) directions were calculated as: 
 
Papp = (dA/dt) x (1/S x C0) 
 
where, (dA/dt) is the flux of rhodamine 123 across the monolayer, S, the surface area of the 
filter membrane and C0, the initial concentration in the donor compartment. The Papp values 
are expressed as cm/s.  
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The efflux ratio (ER) of rhodamine 123 in the presence and absence of the P-gp inhibitors was 
calculated as:  
ER = Papp B-A/ Papp A-B 
 
with Papp B−A and Papp A−B as the mean permeability coefficients obtained for the B-A direction 
and A-B direction, respectively. 
 
7.2.4 Time-dependent reversal of the P-gp inhibitory activity of elacridar 
and tariquidar 
 
The transport medium and the study procedures listed in the previous section were used to 
study reversal of P-gp modulators. Caco-2 monolayers were exposed to elacridar 0.25 and 
0.50 µM or tariquidar 0.50 and 1.00 µM on both sides, apical and basolateral at 37°C for 30 
minutes. After removal of P-gp inhibitors, the monolayers were washed twice with HBSS and 
incubated with fresh medium for additional 0, 2, 6, 10, 24 and 48 hours. The P-gp activity was 
then assessed by measuring the efflux transport (B-A) of rhodamine 123 5 µM after 2 hours of 
incubation. The apparent permeability was calculated as percentage of the control, which is 
the total P-gp mediated efflux of rhodamine 123 (14.16 x 10-6 cm/s) (table 1). 
 
7.2.5 Effect of nanocarriers on P-glycoprotein inhibitory activity of 
elacridar and tariquidar 
 
The transport medium and the study procedures from the previous sections were also used in 
this stage. The studies were started by adding the buffer containing elacridar 0.25 and 0.50 
µM or tariquidar 0.50 and 1.00 µM to both sides, apical and basolateral. After incubation at 
37°C for 30 minutes, the P-gp inhibitors were removed and the monolayers were washed 
twice with HBSS and incubated with the different formulations for 2 hours. Blank transport 
buffer was added to monolayers used as control. The monolayers were then washed twice 
with DPBS and rhodamine 123 5µM was added to the basolateral side to evaluate the efflux 
transport (B-A). After 2 hours of incubation, samples were taken from both, apical and 
basolateral sides and concentrations of rhodamine 123 were analyzed. The apparent 
permeability was calculated as percentage of the control, which is the total P-gp mediated 
efflux of rhodamine 123 (14.16 x 10-6 cm/s) (table 1). 
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7.2.6 Preparation of nanocarriers 
 
Liposomes were prepared by thin film hydratation method followed by sonication. Briefly, 
DMPC and cholesterol were weighed and dissolved in chloroform at a molar ratio of 80:20 
(Table 2). The organic solvent was removed under a nitrogen stream to form a thin film, 
which was subjected to freeze-drying (Heto Lyolab 3000) overnight to remove any trace of 
the organic phase. The dried lipid film was then hydrated at 40°C with transport buffer (TB), 
pH 7.4 to obtain a final phospholipid concentration of 10 µmol/mL. The hydration was 
followed by a 15 minutes bath sonication at 40°C to produce multilamellar vesicles (MLV). 
After a rest of 10 minutes to overcome any structural defects, the MLV suspension was sized 
by sonication at 40°C for 15 minutes using a 13 mm diameter probe sonicator (Bandelin 
Sonoplus) at 150 watts. The resulting small unilamellar vesicles (SUV) were finally 
centrifuged for 10 minutes at 10 000 g to remove the titanium dust originating from the probe.  
For the preparation of nanoemulsions (Table 2), the lipid phase composed of miglyol and soy 
lecithin in the absence or presence of α-tocopherol and the aqueous phase composed by 
transport buffer (TB), pH 7.4 were heated up to 40°C, separately. The lipid phase was injected 
into the aqueous phase under high shear mixing (Janke & Kunkel T45 Ultra-turrax). The 
mixing was carried out for 3 minutes three times. 
 
7.2.7 Size measurements  
 
The size of diluted (with PBS pH 7.4) nanocarriers was measured by dynamic light scattering 
using the NanoZS (Malvern Instrument, France).  
 
7.2.8 Statistical Analysis 
 
All the data are presented as mean ± S.D from six monolayers. The statistical analysis was 
carried out with the software SigmaStat 3.5. All analyses of statistical significance were 
examined by the one way analysis of variance (ANOVA) with the Holm-Sidak post hoc test. 
In all cases, P < 0.05 was considered to be significant. 
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7.3 Results  
 
7.3.1 Selection of the P-gp inhibitors doses to be reversed  
 
The permeability of rhodamine 123 at a concentration of 5.0 µM was measured in two 
directions, A-B and B-A, in the absence of elacridar and tariquidar. In agreement with the 
literature [13], the transport rate of rhodamine 123 for B-A direction was significantly higher 
than the rate for the A-B direction, yielding an ER value of 9.44 (Table 1). In general, for the 
Caco-2 monolayer, an ER higher than 1.5 indicates the contribution of P-gp mediated efflux 
[14]. Our results confirmed then the P-gp-mediated efflux of the P-gp substrate probe across 
Caco-2 monolayers and validated the in vitro model for further studies. Various 
concentrations of elacridar and tariquidar (0.1 – 2.0 µM) were assessed to identify those doses 
at which rhodamine 123 does not undergo P-gp efflux. The addition of elacridar and 
tariquidar at concentrations higher than 0.5 µM and 1.0 µM, respectively, abolished any 
significant directionality in transport rate (Table 1).  
 
Table 1: Effect of elacridar and tariquidar on the transport of rhodamine 123 across Caco-2 cell monolayers. 
Drug 
Concentration 
(µM) 
Papp A – B 
(x10-6 cm/s) 
Papp B – A 
(x10-6 cm/s) 
ER P-gp substrate 
Rhodamine 123 5.00 14.16 ± 0.73 1.50 ± 0.30 9.44 Yes 
+ Elacridar 
0.10 9.40 ± 0.25 1.59 ± 0.47 5.91 Yes 
0.25 5.41 ± 0.52 1.75 ± 0.11 3.09 Yes 
0.50 3.07 ± 0.22 2.07 ± 0.21 1.48 --- 
1.00 2.78 ± 0.19 2.39 ± 0.32 1.16 --- 
2.00 2.14 ± 0.16 3.06 ± 0.16 0.70 --- 
+ Tariquidar 
0.10 11.85 ± 0.43 1.52 ± 0.21 7.80 Yes 
0.25 9.96 ± 0.37 1.60 ± 0.31 6.22 Yes 
0.50 6.30 ± 0.33 1.88 ± 0.14 3.35 Yes 
1.00 3.16 ± 0.20 2.12 ± 0.45 1.49 --- 
2.00 2.76 ± 0.25 2.31 ± 0.18 1.19 --- 
 
Data are presented as mean ± S.D from six monolayers. Involvement of a P-gp mediated efflux mechanism is 
suggested if the efflux ratio (B-A/A-B) is greater than 1.5. 
 
Although elacridar at 0.25 µM and tariquidar at 0.5 µM did not shown full P-gp inhibitory 
activity, we supposed that their reversal could be easily achieved. Thus, elacridar at 0.25 and 
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0.5 µM and tariquidar at 0.5 and 1.0 µM were chosen to assess the reversal of the P-gp 
inhibitory activity within 48 hours and after contact with the colloidal particulates. 
 
7.3.2 Time-dependent reversal of the P-gp inhibitory activity of elacridar 
and tariquidar 
 
This set of experiments examined whether the effects of elacridar and tariquidar in Caco-2 
cells are reversed within 48 hours (Appendix 4). As seen in figure 1, approximately 50 % of 
the total P-gp efflux function was restored between 2 and 6 hours after treatment with 
elacridar at 0.25 or 0.50 µM. These monolayers recovered 97.2 ± 4.4 % and 97.3 ± 4.0 % of 
the P-gp efflux function 24 and 48 hours after treatment with elacridar 0.25 and 0.5 µM, 
respectively. Figure 2 shows the reversal of tariquidar 0.5 and 1.0 µM. Approximately 50% of 
P-gp efflux activity was restored between 2 and 6 hours after treatment with tariquidar 0.5 µM 
and between 10 and 24 hours after treatment with tariquidar 1.0 µM. P-gp recovered 99.0 ± 
2.9 % and 97.8 ± 3.9 % of its activity only after 48 hours of treatment with tariquidar 0.5 and 
1.0 µM, respectively. These results suggest that while elacridar at a concentration of 0.5 µM 
efficiently impedes the P-gp mediated efflux of rhodamine 123, tariquidar at the same 
concentration acts as a weak P-gp inhibitor. Nevertheless, after 6 hours, both P-gp inhibitors 
at the same concentration of 0.5 µM displayed the same reversal pattern. 
 
 
Figure 1. Apparent permeability of rhodamine 123 (mean ± S.D) – time profiles after pre-treatment of Caco-2 
monolayers with elacridar at 0.25 µM (rhombus) and 0.50 µM (square). Bars represent the S.D. n = 6. 
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Figure 2: Apparent permeability of rhodamine 123 (mean ± S.D) – time profiles after pre-treatment of Caco-2 
monolayers with tariquidar at 0.50 µM (rhombus) and 1.00 µM (square). Bars represent the S.D. n = 6. 
 
Given the prolonged and late reversal of the P-gp inhibitory activity caused by elacridar and 
tariquidar, sequestration of both P-gp inhibitors using colloidal particulates was studied 
immediately after the treatment with both P-gp inhibitors. 
 
7.3.3 Effect of nanocarriers on P-glycoprotein inhibitory activity of 
elacridar and tariquidar 
 
In this stage, we tested the effects of three nanocarriers (Table 2) on the P-gp inhibitory 
activity of elacridar and tariquidar.  
  
Table 2: Composition and size of the colloidal particulates systems 
Formulation Composition 
Mean particle 
diameter (nm) 
DMPC:Chol-L DMPC:Cholesterol (80:20 molar ratio) liposomes 201 ± 6.9 
M-Ne  miglyol 812:soy lecithin:TB (1:1:40 % w/w) nanoemulsion 232 ± 3.6 
AT-Ne α-tocopherol:miglyol 812:soy lecithin:TB (0.5:1:1:40 % w/w) nanoemulsion 267 ± 8.5 
Data are presented as mean ± S.D from three formulations. 
 
After incubation with the corresponding nanocarriers, any significant change in the TEER 
values was observed, this confirms that these colloidal systems do not damage Caco-2 
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monolayers. Figure 3 shows the impact of the three nanocarriers on the P-gp inhitory activity 
of elacridar, at 0.25 and 0.50 µM. According to the statistical test, the α-tocopherol 
nanoemulsion significantly increased the P-gp mediated efflux of monolayers pre-treated with 
elacridar 0.25 µM. In other words, the total P-gp efflux function increased from 43.62 ± 3.18 
to 58.99 ± 3.15 %. However, this reversal effect cannot be validated. First, because at this 
concentration of elacridar, rhodamine 123 still undergoes P-gp efflux and second, because the 
α-tocopherol nanoemulsion failed in reverse the P-gp inhibitory activity of elacridar 0.50 µM. 
Unfortunately, none of the other nanocarriers were able to impair the P-gp inhibitory activity 
of elacridar 0.25 and 0.5 µM (Appendix 5).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3:  Apparent permeability of rhodamine 123 (mean ± S.D) after pre-treatment of Caco-2 monolayers with 
elacridar at 0.25 µM or 0.50 µM followed by transport buffer (white), DMPC:Chol-L (light gray), M-Ne (dark 
gray) and AT-Ne (black). Bars represent the S.D. n = 6. 
*Significantly different compared to the Papp of Caco-2 monolayers treated with elacridar for 30 minutes and 
blank buffer for two hours. 
 
 
Figure 4 depicts the effects of DMPC:Chol liposomes, M-Ne and AT-Ne formulations on the 
P-gp inhibitory activity tariquidar 0.5 and 1.0 µM. Among the nanocarriers, it was the 
liposomal formulation, which was able to partially impair the P-gp inhibitory activity of 
tariquidar 0.5 µM increasing the P-gp efflux function from 47.93 ± 2.32 % to 72.27 ± 3.69 %. 
The reversal ability of this formulation was certified when monolayers were also pre-treated 
with tariquidar 1.0 µM. In this case, the P-gp mediated efflux increased from 26.77 ± 1.90 % 
to 51.15 ± 4.49 %. The increase of 25 % of the P-gp efflux function regardless the 
concentrations of tariquidar, 0.5 or 1.0 µM suggest that the sequestration of tariquidar by the 
* 
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liposomal formulation reached its saturation plateau region. However, none of the other 
formulations succeeded in imparining the effects of tariquidar, whether at 0.5 or at 1.0 µM 
(Appendix 5).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4:  Apparent permeability of rhodamine 123 (mean ± S.D) after pre-treatment of Caco-2 monolayers with 
tariquidar at 0.50 µM or 1.00 µM followed by transport buffer (white), DMPC:Chol-L (light gray), M-Ne (dark 
gray) and AT-Ne (black). Bars represent the S.D. n = 6. 
*Significantly different compared to the Papp of Caco-2 monolayers treated with tariquidar for 30 minutes and 
blank buffer for two hours. 
 
 
7.4 Discussion 
 
Direct modulation of the P-gp-mediated efflux using potent P-gp inhibitors is a logical 
strategy to improve brain uptake of an unlimited number of P-gp substrates. Recent 
investigations suggest the use of high doses of P-gp modulators, namely elacridar and 
tariquidar, to efficiently overcome the P-gp efflux at the BBB [4, 15]. However, we cannot 
sidestep that these large doses could result in a long-lasting P-gp inhibition with subsequent 
toxic or even lethal outcomes. Hence, it would be prudent to set a strategy to rapidly treat 
overdoses with the aforementioned P-gp inhibitors. The detoxification strategy studied herein 
is based on the premise that sequestration of elacridar or tariquidar by empty nanocarriers 
would serve to re-induce the P-gp-mediated efflux in a Caco-2 cell model.  
* 
* 
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The validation studies carried out to confirm the functionality of the in vitro model, indicated 
that the typical P-gp substrate rhodamine 123 [16], crosses the Caco-2 cell layer with an 
efflux ratio of 9.44. Since for the Caco-2 monolayer an ER higher than 1.5 suggests the 
contribution of P-gp mediated efflux, this data confirmed the suitability of the selected 
experimental conditions for later transport studies. Both P-gp modulators impeded the 
secretion of rhodamine 123 in a concentration-dependent manner but consistent with 
previously reported in vitro [17] and in vivo [18] studies, this experiments also reflects the 
higher potency of elacridar over tariquidar. While elacridar at 0.5 µM inhibited the P-gp-
mediated efflux, tariquidar did it at 1.0 µM. More importantly, the recovery of the P-gp-
mediated efflux by the monolayers reached approximately 100 % only 48 hours after 
treatment with elacridar 0.5 µM or tariquidar 1.0 µM. Because of the late reversal of the P-gp 
inhibitory activity caused by elacridar and tariquidar, the effects of nanocarriers were studied 
immediately after the treatment with both P-gp inhibitors. 
Unfortunately, in our study both nanoemulsions containing or not α-tocopherol were unable to 
reverse the P-gp inhibitory activity of elacridar and tariquidar. Previously, through a P-gp 
over-expressing MDR cell line, H69/LX4, α-tocopherol displayed its capability to antagonize 
not only elacridar but also cyclosporine A and verapamil [10]. The authors suggested that α-
tocopherol prevented the increase in the membrane fluidity, which is associated to P-gp 
inhibition. As our α-tocopherol nanoemulsion did not yield the same results, absence of full 
interactions between α-tocopherol and the cell membrane could be supposed. In other words, 
α-tocopherol could have presented a major affinity for the surfactant than for elacridar or 
tariquidar. Additionally, elacridar and tariquidar may have presented difficulties to partition to 
the droplets of the two “oil-in-water” nanoemulsions.  
In contrast, an increase of 25 % of the P-gp efflux function was achieved with DMPC:Chol 
liposomes, regardless the concentrations of tariquidar, 0.5 or 1.0 µM. This indicates that the 
sequestration of tariquidar by the liposomal formulation might reach its saturation plateau 
region. Over the last years, several observations have highlighted the role of cholesterol on 
the P-gp activity. Most of the studies reported that P-gp ATP-ase activity and the efflux 
transport were inhibited by the absence of cholesterol after its depletion or removal from the 
bilayer membrane and the repletion or addition of cholesterol could stimulate the 
aforementioned activities [19]. Due to the similarity between the liposomal membrane and the 
cell membrane, a direct exchange of lipid components is possible between both of them [20]. 
Then, the transfer of cholesterol from the DMPC:Chol liposomes to the micro-domains where 
P-gp is located [21] could trigger or re-activate the ATP-ase activity and the consequent 
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efflux transport of P-gp substrates. This hypothesis involves the inhibition of the ATP-ase 
activity by tariquidar which was previously demonstrated by Martin et al [22].  
The high lipophilicity of elacridar (clog P = 5.6) and tariquidar (clog P = 6.1) [23] predestine 
their mobility within one lipid bilayer and their transfer between biological interfaces and 
liposomal membranes. It was previously stated that lipophilic drugs, which do not have 
membrane lipid-like structures are not subject to flip-flop [24]. In contrast, once they are 
dissolved in the lipid domain of the membrane, they leave the membrane to the aqueous phase 
(energetic process), where they associate to the acceptor membrane [24]. Applied to our case, 
this diffusion/partition mechanism suggests that tariquidar was inserted only in the outer 
leaflet of the plasma membrane. Then it was able to migrate from the surroundings of the 
micro-domains where P-gp is located [21] to the liposomal membrane. At the same time this 
hypothesis indicates that elacridar was fully buried into the bilayer, from where was harder to 
migrate to the liposomal membrane. If this were the right mechanism, the tariquidar uptake 
efficiency could be further improved by increasing the contact with the acceptor membrane 
(number of particles per unit volume). Assay conditions like the influence of the liposomal 
phospholipid concentration and cholesterol concentration should be also investigated. 
It is evident that much remains to be studied and clarified in order to use nanocarriers, 
specifically liposomes, as bio-detoxifying agents in case of P-gp inhibitors overdoses. 
Nevertheless, the potential of liposomes as reservoirs agents has been widely demonstrated 
with the sequestration of paraoxon, 236Pu-phytate, amitriptyline and haloperidol through 
enzymatic degradation, chelation, partition/electrostatic interactions and pH gradients [7]. 
This last active liposomal loading, where the vesicles with an acidic internal compartment 
possess ion-trapping properties, is usually suggested for the encapsulation of lipophilic weak 
bases such as elacridar and tariquidar [25]. 
The ultimate goal for most detoxifying nanocarriers is drug redistribution. In this light, 
liposomes must be tailored to maximize the P-gp inhibitor-liposomes association so that 
unbound drug molecules in the bloodstream will be sequestered upon intravenous dosing. 
This sequestration then triggers drug molecules in vital organs as the brain to relocate in the 
blood compartment. For this, the liposomal half-life is paramount to ensure their stay in the 
bloodstream long enough for the P-gp modulator to be extracted sufficiently from peripheral 
tissues. Grafting polymers such as DSPE-PEG2000-OCH3 may shield protein binding onto the 
liposomal surface and delay opsonization at least 15 hours [26]. These combined 
characteristics could made liposomes a promising approach in the treatment of P-gp inhibitors 
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overdoses. Moreover, the efficacy and safety of the optimal liposomal formulation should be 
assessed in vitro and in vivo. 
 
7.5 Conclusions 
 
In this study, we used nanotechnology for the extraction of tariquidar and elacridar in a Caco-
2 cell model. A liposomal formulation and two nanoemulsions were tested as bio-detoxifying 
agents of both P-gp inhibitors. Among the three colloidal particulates, only liposomes 
composed of DMPC and cholesterol partially impaired the inhibitory activity of tariquidar. 
Although the mechanism underlying these results is still uncertain, further works aim to 
optimize the characteristics of liposomes to improve their performance as sequestering agent 
of tariquidar and elacridar.  
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8 GENERAL DISCUSSION AND PERSPECTIVES 
 
Up-to-date, the extensive research based on P-gp, an essential component of the BBB, has led 
us to see this efflux transporter from two different standpoints. From a physiological view, P-
gp protects the brain from intoxication by endogenous and exogenous harmful lipophilic 
compounds that otherwise could penetrate the BBB by simple diffusion without any limitation 
[1]. From a therapeutic view, P-gp limits the penetration of several potent drugs into the CNS, 
leading to failure therapies which include HIV protease inhibitors, opioids, antiepileptics, 
antidepressant, antipsychotics and anticancer drugs [2]. Hence, modulation of P-gp represents 
an interesting approach to enhance the brain uptake of a wide variety of drugs. Nevertheless, 
any modulation of the efflux transporter has to consider the potential neurotoxicity of such 
modulation. The ideal approach should inhibit the P-gp at the BBB to let the P-gp substrate 
(therapeutic compound) enter into the brain and then re-induce the P-gp-mediated efflux to 
hamper the entry of harmful compounds. However, in spite of the countless studies the 
effective inhibition of the P-gp at the human BBB is not yet a reality. 
One of the main non-invasive strategies that have been attempted to tackle the P-gp-mediated 
efflux involves the use of chemical entities so-called P-gp modulators. These agents are able 
to transiently and directly inhibit the P-gp-mediated efflux [3]. Elacridar and tariquidar, third-
generation P-gp modulators, significantly increased the brain distribution of several P-gp 
substrates [4-6]. However, the high plasma protein binding of elacridar [7], suggest the use  of 
high doses of the P-gp modulator to saturate the active efflux of P-gp at the BBB [8]. 
Unfortunately, at high doses, elacridar increased the concentrations of  P-gp substrates such as  
nelfinavir in the brain but also in the liver [9]. In the meantime, tariquidar failed to produce 
significant central nervous effects caused by loperamide in healthy patients [10]. This finding 
prompted the assessment of the pharmacokinetics, tolerability and safety of single ascending 
doses of tariquidar in healthy subjects [11].  
“The dose makes the poison”. The contemporary and famous interpretation of Paracelsus, is 
that dose and effect move together in a predictably linear fashion [12]. Otherwise stated, these 
high doses of P-gp modulators by themselves or in co-administration with P-gp substrates 
may predict toxic profiles, thus limiting the use of these agents. The current dilemma is then: 
How do we improve the usage of these compounds? Or do we continue looking for the ideal 
P-gp modulator? Various studies propose the use of natural products, the designs of 
peptidomimetics and dual activity ligands as a fourth-generation of P-gp modulators [13]. In 
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contrast, we aimed to introduce a different strategy to efficiently modulate the P-gp-mediated 
efflux at the BBB using elacridar and tariquidar but avoiding toxic profiles caused by high 
doses of these agents. For this purpose we took advantage of the possible in vivo intravenous 
co-administration of low but therapeutic doses of elacridar and tariquidar, under their free 
form or co-encapsulated in liposomes. The brain distribution of free loperamide was 
determined as an in vivo probe of full inhibition of the P-gp activity at the BBB.  
 
To assess the in vivo pharmacokinetic interactions and biodistribution after concurrent 
administration of loperamide and elacridar and/or tariquidar, a specific and sensitive 
analytical procedure for the simultaneous determination of the three molecules was required. 
However, the extensive literature survey revealed a lack of methods for the simultaneous 
estimation of these three compounds. In this light, we developed and validated (FDA 
guidance for bioanalytical method validation [14]) an LC-MS method for the simultaneous 
quantitation of the three agents in rat plasma, brain, liver and kidneys. Then, we undertook the 
evaluation of the concomitant administration of both P-gp modulators and its effects on 
loperamide in a rat model.  
 
The first obstacle in this part of the project was the limited solubility of both P-gp modulators 
and loperamide in the reported vehicles for IV administration of these compounds.  This poor 
solubility could originate the presence of free particles, which precipitate in the site of 
administration and cause embolization and a trivial exposure to the therapeutic agents [15]. In 
other words, the vehicle selection could strongly influence the pharmacokinetics, 
biodistribution and pharmacodynamics in vivo studies. For instance, reported vehicles 
containing saline [5], dextrose and/or ethanol [4] led to the precipitation of both P-gp 
modulators in our pilot study (Appendix 2). In the same way, a reported mixture of saline and 
0.2 M equivalents of HCl to solubilize loperamide [16], resulted in negligible plasma 
concentrations (less than 1.0 %/mL of the IV dose of loperamide) at 5 minutes post-dosing 
[16]. This could be explained by the precipitation of loperamide in the vehicle as observed in 
our pilot study (Appendix 1). Moreover, the low pH (1.4) of this mixture for injectable 
volumes was considered aggressive to the vein and the surroundings structures and a source 
of subsequent changes in the loperamide plasma concentrations. To optimize the in vivo 
exposure to both P-gp modulators and loperamide and to ensure the dose delivery minimizing 
erroneous results, various vehicles were tested in this study. Among them, tetraglycol yielded 
a total transparent and yellow solution of elacridar, which did not precipitate even after six 
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months. Loperamide and tariquidar were well dissolved separately in a mixture of saline and 
PEG600 (3:1). Subsequent dilutions of both P-gp modulators and loperamide in the mixture of 
saline and PEG600 (3:1) were completely transparent indicating full solubility for an 
appropriate IV administration. Like this, in our study about 4.0 %/mL of the IV dose of 
loperamide was attained at one hour post-dosing. It means that the exposure to loperamide 
solubilized in a mixture of saline and PEG600 (3:1) was significantly higher than that observed 
with a mixture of saline and 0.2 M equivalents of HCl (less than 1.0 %/mL of the IV dose of 
loperamide at 5 minutes post-dosing) [16]. Moreover, the updated literature does not mention 
the modulation of the P-gp-mediated efflux by tetraglycol or PEG600.   
 
The administration of loperamide alone resulted in very low levels (10.53 ± 0.51 ng/g) in the 
brain at one hour post-dosing. However, the co-administration of the P-gp modulators 
significantly increased the concentration of loperamide in the brain at the same time point. 
Tariquidar and elacridar, each at 1.0 mg/kg increased loperamide levels in the brain by 2- 
(22.48 ± 2.93 ng/g) and 3-fold (33.84 ± 3.95 ng/g), respectively. More importantly, the 
concurrent administration of elacridar plus tariquidar, each at 0.5 mg/kg increased the brain 
concentrations of loperamide by 5-fold (47.26 ± 6.09 ng/g). In contrast, the pharmacokinetic 
parameters of loperamide in the P-gp modulators-treated groups remained unchanged in 
comparison to the group which received no P-gp modulator. These findings are consistent 
with the minimal modulation of the cytochrome P4503A4 by elacridar and tariquidar by 
separate or co-administered [4]. Therefore, the increase of loperamide levels in the brain 
could not be explained by a modest increase of loperamide in plasma. Instead, it was likely 
due to the efficient modulation of the P-gp at the BBB by tariquidar and elacridar. The brain 
uptake of P-gp modulators and loperamide suggest a greater inhibition of the P-gp-mediated 
efflux by elacridar than by tariquidar and a possible synergistic effect of both P-gp modulators 
when they are co-administered. The most suitable explanation for this synergistic 
phenomenon is that the low doses of elacridar may inhibit the P-gp and BCRP transport of 
tariquidar at the BBB thereby improving its accessibility to the P-gp. Then, the  simultaneous 
binding of tariquidar (on site II, a transport and regulatory site) and elacridar (on site IV, an 
exclusive regulatory site) [17], significantly hampered the P-gp-mediated efflux of 
loperamide. To our knowledge, this is the first study demonstrating synergistic modulation of 
the P-gp-mediated efflux using third-generation P-gp modulators. However, this type of drug-
drug phenomenon was previously described using first-generation P-gp modulators [18]. In 
those studies, cylosporin A and verapamil showed significant synergism in modulating the P-
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gp mediated efflux of a series of P-gp substrates in human acute lymphocytic leukemia cells 
(CCRF-CEM) [18-20]. Although the mechanisms underlying these observations were not 
explained by the authors, later it was found that cyclosporine A and verapamil bind different 
P-gp binding sites [21]. Moreover, in vitro studies demonstrated that progesterone and 
verapamil are synergistic non-exclusive inhibitors of the ATP-ase activity which is coupled to 
the P-gp-mediated transport [22]. It is clear that the non-P-gp inhibiting effects of these first-
generation P-gp modulators made them obsolete but their aforementioned interactions with P-
gp emphasize the non-competitive modulation of the P-gp-mediated efflux observed in this 
work. 
The dose-limiting opioid effects of loperamide preclude assessing this strategy with higher 
doses of loperamide co-administered with higher doses of elacridar plus tariquidar. Future 
studies may overcome this problem by using radiolabelled [3H or14C] loperamide. In this 
context, many other P-gp substrates with different therapeutic effects and several doses of 
elacridar and tariquidar remain to be explored to define the synergistic interaction between 
both P-gp modulators. Other P-gp modulators can also be used for these studies, provided that 
the steric hindrance of one does not affect the binding of the other. 
The opioid-like clinical signs indicate an important and extremely rapid distribution of the P-
gp modulators in the brain and an immediate modulation of the P-gp at the BBB. In this sense, 
the co-administration of high doses of potent CNS drugs as loperamide (as in our pilot study, 
data not shown) and other P-gp substrates with narrow therapeutic windows could result in 
CNS toxic profiles with lethal results. This issue opens two avenues: The first requires the 
reduction of the P-gp substrate dose, which potentially compromises the therapy via the 
reduced brain accumulation of the P-gp substrate. The second implies the reduction of the P-
gp modulators dose. Since the brain distribution and the permanence of both P-gp modulators 
are dose-dependent [23], a reduction of their doses may increase their transport by the P-gp 
and BCRP at the BBB [23] leading them to the loss of their P-gp inhibitory activity. Thus, 
any of these two avenues fit the purpose. A suitable strategy would involve the maximizing P-
gp inhibitory activity of the low doses of P-gp modulators through their controllable delivery 
across the BBB. These low doses should arrive to the P-gp at the BBB when the concentration 
of the P-gp substrate at the BBB is high enough to produce a therapeutic effect but not toxic 
profiles. To avoid another layer of complexity in this approach, the pharmacokinetics of the 
P-gp substrates should not be altered. 
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In this light, we aimed to develop a nanocarrier to timely increase the delivery of elacridar and 
tariquidar across the BBB. The challenge was then the formulation of liposomes which have 
the right size and structure to entrap elacridar and tariquidar with high efficiency and in such a 
way that they do not leak out. On the other hand, it was important to play on the fluidity of the 
liposomal membrane. A too high liposomal stability is rather disadvantageous than desired. 
Remaining inside of stable liposomes, encapsulated drugs are not delivered to the targeted 
tissue. At that point, it was necessary to find the right balance between stability in the 
bloodstream and a high delivery of both P-gp modulators across the BBB, which must be 
synchronized with the therapeutic concentrations of the P-gp substrate. In order to choose the 
formulation that fits better the aforementioned properties for further development of OX26 
F(ab’)2 immunoliposomes, three types of liposomes co-loaded with elacridar and tariquidar 
were prepared: Conventional, PEGylated with DSPE-PEG2000-COOH and PEGylated with 
DSPE-PEG2000-OCH3 liposomes. For all liposomal formulations, DMPC was used as the main 
frame based on its rapid drug diffusion due to its transition temperature (23.9 °C) [24] and its 
high elacridar and tariquidar loading  compared to EPC, DPPC or DSPC (Appendix 3).  
The rapid absorption of plasma proteins onto the surface of conventional liposomes [25] led 
to their destabilization and the leakage of elacridar and tariquidar which was not enough to 
modulate the P-gp activity at the BBB. It was expected that in liposomes functionalized with 
DSPE-PEG2000-COOH, the negative surface charge of the carboxylic acid could 
counterbalanced the long circulating properties conferred by PEG to facilitate an effective but 
short P-gp modulation. However, the rapid clearance and the lowest brain uptake of elacridar 
and tariquidar indicate that these negatively charged liposomes activated the complement 
system via the classical pathway [25] before than they could release both P-gp modulators. In 
contrast, functionalization of liposomes with DSPE-PEG2000-OCH3 significantly increased the 
plasma concentrations of elacridar and tariquidar as well as their brain distribution in 
comparison to the free form of both P-gp modulators. This is based on the ability of neutral 
PEG chains to avoid the adsorption of plasma proteins onto the liposomal surface [25], thus 
impeding their uptake by resident phagocytes in the liver and spleen. As a result of this 
sterically stabilization, 4.8- and 6.1-fold higher concentrations of elacridar and tariquidar, 
respectively were found in the brain at one hour compared to the concurrent administration of 
both free P-gp modulators. These results confirm recent studies where it was postulated that 
as PEG help to slow down the first-pass metabolism, it increases the chance of around 150 nm 
sized nanocarriers to deliver the encapsulated drug across the BBB [26]. The opioid-induced 
behavior in animals receiving these long-circulating liposomes suggests a release of both P-gp 
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modulators at 30 minutes post-dosing, which was synchronized enough to increase 2.1-fold 
the brain uptake of loperamide.  
Because the grafting of OX26 F(ab’)2 on conventional and PEGylated with DSPE-PEG2000-
COOH liposomes could accelerate and increase their RES uptake limiting their contact with 
the targeted tissue, immunoliposomal development was carried out using liposomes bearing 
DSPE-PEG2000-OCH3. The long residence of these liposomes in the vascular space and the 
delivery of both P-gp modulators across the BBB via the TfR may ensure effective doses of 
these compounds for a full blockage of the P-gp. As previously observed [27], the coupling of 
OX26 partially reversed the effect of neutral PEGylation, however the plasma levels of both 
immunoliposomal P-gp modulators were sufficient for contact with the targeted tissue. Data 
obtained with the immunoliposomes revealed that the release of elacridar and tariquidar also 
begun at 30 minutes post-dosing but the brain accumulation of both compounds at 1 hour 
were ̴ 2-fold higher as compared to long circulating liposomes. In other words, the prolonged 
systemic circulation due to PEG stabilization and the improved permeability due to OX26 
F(ab’)2 grafting led to the most efficient P-gp modulation at the BBB. This in turn, allowed 
the highest brain uptake of loperamide at one hour. Moreover, the total score for the clinical 
signs, indicated that the immunoliposomal-induced brain uptake of loperamide was not as 
abrupt as the one observed immediately after the administration of both free P-gp modulators. 
Such differences indicate that CNS acute toxicities associated with potent P-gp substrates 
could be avoided using this drug delivery system (DDS). Additionally, the lack of 
pharmacokinetic interactions between this DDS and the P-gp substrate used herein augur a 
promising use of these immunoliposomal P-gp modulators.  
There is a clear consensus about the specificity and high brain uptake of OX26 MAb-, Fab’-, 
and F(ab’)2- nanocarriers targeting cerebral tissues. The brain accumulation of 
immunonanocarriers is generally 2-fold higher than the one achieved with long circulating 
nanocarriers (0.04 vs 0.02% of the IV dose/g) at one hour after administration [28]. Although 
our work showed that the brain uptake of immunoliposomal P-gp modulators was 2-fold 
higher than that of long circulating liposomes, the net brain uptake was 2.3 and 1.1 % of the 
IV dose/g for immunoliposomal elacridar and tariquidar, respectively at one hour post-dosing. 
This indicate that a mechanism different to the transcytosis via the TfR came into play in our 
study. We could suppose the association of the antibody to the TfR, a diffusion of both P-gp 
modulators from the liposomes and the subsequent P-gp inhibiton with their extensive 
accumulation in the brain. This hypothesis does not dismiss but join the transcytosis 
mechanism. It means that each P-gp modulator could have been taken up via transcytosis. But 
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at the same time, the high amounts of P-gp modulators in the bloodstream surrounding the 
BBB could have saturated the active efflux of the P-gp and acumulated in the brain. This is in 
agreement with the dose-dependent distribution observed for free elacridar [8] and free 
tariquidar [23].  
In brief, the loading of elacridar and tariquidar in immunoliposomes could result in: (1) Their 
improved solubility. (2) Their prolonged vascular residence time through sterically 
stabilization. (3) Their adequate delivery to the BBB by conjugation of OX26 F(ab’)2 
fragments. (4) Their use at low but therapeutic doses and (5) the synergistic blockage of the P-
gp to allow the brain uptake of any P-gp substrate which is intended to treat CNS diseases. 
However the aforementioned properties depend on the synchronizing therapeutic levels in the 
brain of both P-gp modulators and the P-gp substrate.  
In our study the immunoliposomal-induced brain levels of loperamide at 6 hours were in the 
same range than those observed with free elacridar plus free tariquidar at one hour. This 
suggests possible CNS sub-acute toxic incidents caused by P-gp substrates owning a long 
residual therapeutic activity. Therefore future studies should focus on the latency and residual 
activity of the P-gp substrate co-administered with immunoliposomal elacridar and tariquidar. 
One avenue for P-gp substrates with long residual therapeutic activity would be the partial 
decrease of the vascular residence time of the immunoliposomes co-loaded with elacridar and 
tariquidar. This could be achieved functionalizing liposomes simultaneously with DSPE-
PEG2000-OCH3 and DSPE-PEG2000-COOH at an optimal ratio and coupling the antibody 
through DSPE-PEG5000-COOH. This approach could allow enough contact time between the 
BBB and the immunoliposomes to deliver both P-gp modulators but would shorten the 
liposomal half-life, avoiding thus a long exposure to elacridar and tariquidar. Nonetheless, our 
results suggest that liposomes bearing DSPE-PEG2000-COOH alter the pharmacokinetics of 
loperamide and perhaps that of other P-gp substrates. Hence, the encapsulation of the P-gp 
substrate in a similar DDS could avoid liposomes-drug pharmacokinetic interactions. Possible 
physico-chemically instabilities could be prevented using polymer, lipid, or polymer-lipid 
hybrid nanocarriers, depending on the hydrophobicity of the P-gp substrate. Previous reports 
described the ability of nanoparticles [16], polymersomes [29] and nanocapsules [28] bearing 
OX26 MAb or Fab’ fragments to specifically target cerebral tissues. Then, the use of these 
nanocarriers co-loaded with elacridar plus tariquidar and the desired P-gp substrate could lead 
to improved therapeutic results provided that the delivery of the three agents is synchronized.  
This nanotechnology may be also modulated and adapted to target other receptors localized 
on the BBB such as the insulin receptor. Given that high doses of insulin are required to target 
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the insulin receptor and that an overdose of insulin could cause hypoglycemia, some studies 
promote the use of the murine 83-14 monoclonal antibody to target the insulin receptor with 
successful results [30]. The low-density lipoprotein receptor (LDLR) [31] and the LDLR-
related protein (LRP) [32] at the BBB can bind multiple ligands. Among them, the 
apolipoprotein E covalently attached to loperamide-loaded nanoparticles significantly 
facilitated the transport of loperamide across the BBB via the LDLR and LRP [33].  
 
Remaining to be improved, the decrease in the loading efficiency of both P-gp modulators 
during the immunoliposomal formulation suggested us that if these agents could pass the 
membrane and get outside of the liposomes, the same way back in was not hampered. 
Liposomes were then proposed as a tool to sequester both P-gp modulators in case of 
overdoses. Liposomes made of DMPC and cholesterol had no effect on the P-gp inhibitory 
activity of elacridar. In contrast, they were able to partially impair the P-gp inhibitory activity 
of tariquidar 1.0 µM increasing the P-gp-mediated efflux of rhodamine 123 from 26.77 ± 1.90 
% to 51.15 ± 4.49 % across a Caco-2 cells model. The most plausible explanation for this 
transfer is that tariquidar was inserted only in the outer leaflet of the plasma membrane. Then 
it was able to migrate from the surroundings of the micro-domains where P-gp is located [34], 
to the liposomal membrane. In the meantime, this explanation suppose that elacridar was fully 
buried in the plasma membrane, from where was harder to migrate to the liposomal 
membrane. The use of liposomes as bio-detoxifying agents for elacridar and tariquidar is still 
beginning and has to be elaborated and optimized onward until it can be used for real cases. 
However, further studies should involve the influence of the liposomal composition. Since 
cholesterol has a tendency to stiffen the fatty acid chains in the liposomal membrane [35], an 
increase in the fluidity of the liposomal membrane by regulating the amount of cholesterol 
could result in a greater sequestration of tariquidar.     
To be effective, the liposomes must remain in the bloodstream long enough to sequester the 
P-gp modulator and the liposome-P-gp modulator complex must also remain stable until it is 
removed from the bloodstream. The most successful strategy to increase the liposomal half-
life and stability is by surface modification of the liposomes. Grafting polymers such as 
DSPE-PEG2000-OCH3 may shield protein binding onto the liposomal surface and delay 
opsonization. Furthermore, it cannot be neglected that the ion-trapping properties of 
liposomes towards ionizable compounds (achieved with transmembrane pH gradients) could 
help to sequester weak bases such as tariquidar and elacridar [36]. This dual strategy, surface 
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modification and transmembrane pH gradient, has been previously used to trap and limit the 
toxicity of drugs like doxorubicin [37] and diltiazem [38], which are weak bases. 
Another alternative for the sequestration of tariquidar and elacridar involves the use of lipid 
nanocapsules. These nanocarriers consisting of an oil-filled core with a surrounding polymer 
(PEG) shell could lead to a significant sequestration of both P-gp modulators as observed with 
some other hydrophobic model drugs [39]. 
The small size and long residence time of lipoproteins in the bloodstream as well as their 
ability to transport lipids and hydrophobic molecules have promoted them as potential drug 
delivery systems [40]. The use of lipoproteins from species different to the human one could 
result in the trapping of the P-gp modulator, followed by activation of the RES and the 
elimination of the lipoprotein-P-gp modulator complex from the bloodstream. 
 
In summary, this thesis proposes different approaches for full exploitation of two third-
generation P-gp modulators, elacridar and tariquidar. According to the findings described in 
this manuscript we conclude that: (1) The development of an LC-MS method for the 
simultaneous quantitation of loperamide, elacridar and tariquidar represents a helpful tool for 
in vivo pharmacokinetic and tissue distribution studies using these two P-gp modulators and 
loperamide, as P-gp substrate probe. (2) The co-administration of tariquidar and elacridar at 
low but therapeutic doses does not modify their plasma concentrations or those of the P-gp 
substrate but resulted in the greatest P-gp blockage at the BBB as a result of their non-
competitive modulatory activity. Because of the possible synergism between both P-gp 
modulators, low doses of these agents may improve the effectiveness of CNS 
pharmacotherapies without treatment-related side effects or toxicity. (3) The co-encapsulation 
of elacridar and tariquidar in targeted sterically stabilized immunoliposomes improves the 
half-lives and brain distribution of both compounds. Consequently, the brain uptake of the 
free P-gp substrate is significantly enhanced without any modification of its pharmacokinetics 
or tissue distribution. This formulation represents a step forward to modulate the P-gp at the 
BBB and allow the brain uptake of any P-gp substrate which is intended to treat CNS diseases 
and (4) The partial impairment of the P-gp inhibitory activity of tariquidar by liposomes, 
supports the use of this nanocarrier as a bio-detoxifying approach for the treatment of 
tariquidar overdoses.   
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APPENDICES 
 
 
Appendix 1 
 
Solubility of loperamide in previously reported vehicles (25°C) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 2 
 
 
 Solubility of elacridar and tariquidar in previously reported vehicles (25°C) 
 
 
Vehicle Vehicle pH Loperamide 
Water:Tween 80 (99:1) 7.6 - 
Water:Ethanol (97:3) 7.4 +/- (0.5 mg/mL) 
Saline:0.2M HCl 1.4 - 
Saline:PEG600 (3:1) 7.4 + (2.0 mg/mL) 
Vehicle Vehicle pH Elacridar Tariquidar 
Water:dextrose (97:3) 7.0 - - 
Saline:ethanol (80:20) 7.4 - - 
Tetraglycol 8.5 – 9.0 + (20.0 mg/mL) - 
Saline:PEG600 (3:1) 7.4 + (2.0 mg/mL) + (2.0 mg/mL) 
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Appendix 3 
 
Characterization of elacridar-tariquidar liposomal formulations (n = 3) 
 
 
 
 
 
Liposomal 
composition 
Molar ratio 
Mean particle 
diameter (nm) 
Zeta potential 
(mV) 
Elacridar loading 
efficiency (%) 
Tariquidar loading 
efficiency (%) 
EPC 100 138.2 ± 2.9 0.3 ± 0.2 61.1 ± 2.5 59.6 ± 1.8 
DMPC 100 102.6 ± 2.3 1.7 ± 0.8 64.3 ± 3.3 62.2 ± 0.9 
DPPC 100 291.5 ± 3.6 1.6 ± 0.3 49.1 ± 3.2 46.6 ± 3.7 
DSPC 100 1096.0 ± 10.2 1.9 ± 0.7 28.4 ± 5.8 34.1 ± 4.5 
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Appendix 4 
 
Apparent permeability (A - B) of rhodamine 123 (mean ± S.D) after pre-treatment of Caco-2 
monolayers with elacridar and tariquidar (n = 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 5 
 
Apparent permeability (A - B) of rhodamine 123 (mean ± S.D) after pre-treatment of Caco-2 
monolayers with elacridar and tariquidar by transport buffer (control), DMPC:Chol-L, M-Ne 
and AT-Ne (n = 6). 
 
  
Formulation Elacridar 0.25 µM Elacridar 0.50 µM Tariquidar 0.50 µM Tariquidar 1.0 µM 
Control 6.18 ± 0.55 5.33 ± 0.16 6.79 ± 0.40* 3.79 ± 0.33* 
DMPC:Chol-L 7.03 ± 0.59 6.07 ± 0.62 10.23 ± 0.52 7.24 ± 0.64 
M-Ne 5.76 ± 0.25 5.45 ± 0.50 6.10 ± 0.32 3.56 ± 0.25 
AT-Ne 8.35 ± 0.45* 5.11 ± 0.64 6.40 ± 0.93 4.19 ± 0.60 
 
* Significantly different compared to the Papp of Caco-2 monolayers treated with the P-gp modulator for 30 
minutes and blank buffer (control) for two hours. 
 
Time (hours) Elacridar 0.25 µM Elacridar 0.50 µM Tariquidar 0.50 µM Tariquidar 1.0 µM 
0 5.41 ± 0.63 3.09 ± 0.50 6.30 ± 0.33 3.16 ± 0.55 
2 6.18 ± 0.55 5.33 ± 0.16 6.79 ± 0.40 3.79 ± 0.33 
6 8.17 ± 1.49 7.53 ± 0.61 7.55 ± 0.44 5.44 ± 0.88 
10 11.09 ± 1.05 8.87 ± 0.50 8.95 ± 0.32 6.46 ± 0.16 
24 13.76 ± 0.58 11.35 ± 1.05 11.54 ± 0.90 9.65 ± 0.38 
48 13.89 ± 0.77 13.78 ± 0.56 14.02 ± 0.42 13.56 ± 0.55 
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ABSTRACT 
 
Although the P-glycoprotein (P-gp) represents an obstacle in several central nervous system 
(CNS) pharmacotherapies, the P-gp also protects the brain from intoxication by endogenous and 
exogenous harmful lipophilic compounds that otherwise could penetrate the blood-brain barrier 
(BBB) by simple diffusion. Therefore, any modulation of the efflux transporter has to consider the 
potential neurotoxicity of such modulation. Early studies showed that elacridar and tariquidar, two 
third-generation P-gp modulators, increase the distribution of several P-gp substrates in the brain. 
Unfortunately, recent studies suggest the use of high doses of elacridar and tariquidar to 
efficiently modulate the P-gp at the BBB. Nevertheless, when co-administered with P-gp 
substrates, these high doses may be associated with pharmacokinetic interactions and toxic 
profiles, thus limiting the use of these compounds.  
Hence, this thesis aimed to attain a transient but efficient modulation of the P-gp at the BBB using 
elacridar and tariquidar but avoiding the use of large doses of these compounds. For this purpose 
we took advantage of the possible in vivo intravenous co-administration of low but therapeutic 
doses of elacridar and tariquidar, under their free form or co-encapsulated in liposomes. The brain 
distribution of free loperamide was determined as an in vivo probe of full inhibition of the P-gp 
activity at the BBB.  
The concurrent administration of both free P-gp modulators does not modify their plasma 
concentrations or those of the P-gp substrate but significantly increased the brain uptake of 
loperamide as a result of their non-competitive modulatory activity. Moreover, the co-
encapsulation of elacridar and tariquidar in targeted sterically stabilized immunoliposomes 
improved the half-lives and brain distribution of both compounds. Consequently, the brain uptake 
of free loperamide was significantly enhanced without any modification of its pharmacokinetics 
or tissue distribution. Moreover, the partial impairment of the modulatory activity of tariquidar by 
empty liposomes, supports the use of this nanocarrier as a bio-detoxifying approach for the 
treatment of tariquidar overdoses.   
In summary, this thesis proposes different approaches for full exploitation of elacridar and 
tariquidar. The findings described in this manuscript should open interesting avenues to achieve 
an efficient overcoming of the P-gp at the BBB and succeed CNS pharmacotherapies. 
 
Keywords: P-glycoprotein, blood-brain barrier, elacridar, tariquidar, co-administration, and 
liposomes. 
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RESUME 
 
La présence de la glycoprotéine P (P-gp) dans la barrière hémato-encéphalique (BHE) conduit à 
l’échec de nombreuses thérapies ciblant le système nerveux central (SNC). Cependant la P-gp 
protège aussi le cerveau contre des composés nocifs, essentiellement lipophiles, endogènes et 
exogènes susceptibles de passer la BHE par diffusion simple. Par conséquent, toute inhibition de 
la P-gp qui vise à améliorer la distribution des agents pharmacologiques dans le cerveau doit 
prendre en compte la neurotoxicité potentielle de cette inhibition. Les premiers travaux ont montré 
que l’elacridar et le tariquidar, deux modulateurs de la P-gp de troisième génération, augmentaient 
la distribution dans le cerveau de plusieurs de ses substrats. Malheureusement, d’autres études 
plus récentes, suggèrent l’utilisation de doses élevées de l’elacridar et du tariquidar pour moduler 
efficacement l’activité de la P-gp dans la BHE. Néanmoins, ces doses élevées en co-
administration avec des substrats de la P-gp peuvent être associées à des interactions 
pharmacocinétiques et à des profils toxiques, limitant ainsi l'utilisation de ces inhibiteurs. 
Dans ce contexte, l’objectif principal de cette thèse est d’obtenir une modulation transitoire mais 
efficace de la P-gp dans la BHE par administration intraveineuse de doses faibles mais 
thérapeutiques de l’elacridar et du tariquidar sous leur forme libre ou co-encapsulé dans les 
liposomes. Le lopéramide, substrat de la P-gp, a été également administré sous sa forme libre 
comme une preuve in vivo d’une inhibition efficace de la P-gp dans la BHE. 
L'administration simultanée de ces deux modulateurs de la P-gp n’a pas modifié leurs 
concentrations plasmatiques ou celles du lopéramide, mais a entraîné une importante distribution 
du lopéramide dans le cerveau en raison de leur activité inhibitrice non- compétitive. De plus, la 
co-encapsulation de l’elacridar et du tariquidar dans des immunoliposomes stabilisées 
stériquement a amélioré la demi-vie et la distribution dans le cerveau des ceux deux composés. 
Par conséquent, la distribution dans le cerveau du lopéramide a été considérablement augmentée, 
sans aucune modification de sa pharmacocinétique ou distribution tissulaire. Par ailleurs, la 
diminution partielle de l'activité inhibitrice du tariquidar par des liposomes vides suggère 
l’utilisation de ce nanovecteur comme une approche de bio-détoxification pour le traitement des 
surdoses de tariquidar. En résumé, cette thèse propose différentes approches pour exploiter 
pleinement l’elacridar et le tariquidar. Les résultats décrits dans ce manuscrit devraient ouvrir des 
pistes intéressantes pour atteindre une inhibition efficace de la P-gp dans la BHE et pour réussir 
des thérapies ciblant le système nerveux central. 
 
Mots-clés: Glycoprotéine P, barrière hémato-encéphalique, elacridar, tariquidar, co-
administration, et liposomes. 
